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Thrombosis refers to blood clot formation and when pathological, is the cause of many 
vascular diseases. For example, deep vein thrombosis (DVT), which affects three million 
Americans per year, is the formation of clots in the deep veins of the legs. Current clinical 
treatments include thrombolytic drugs and catheter-based surgical procedures. Both methods 
have significant drawbacks, such as excessive bleeding, invasiveness, and long treatment time. 
Ultrasound has been combined with thrombolytic drugs and/or microbubbles to enhance drug 
delivery. However, these methods are still quite slow and share the drawbacks of thrombolytic 
drugs. 
Histotripsy is a tissue ablation method that mechanically fractionates soft tissue via well-
controlled acoustic cavitation generated by microsecond-long, high-pressure ultrasound pulses. 
The initial feasibility and safety of using histotripsy as a noninvasive, drug-free, and image-
guided thrombolysis technique has been demonstrated both in vitro and in vivo. The in vitro 
studies showed that histotripsy fractionated blood clots into debris smaller than red blood cells at 
a speed an order of magnitude faster than any clinical method. The in vivo studies in a porcine 
deep vein thrombosis model showed histotripsy could restore blood flow and decrease thrombus 
burden with real-time guidance of ultrasound imaging.  
The overriding goal of this dissertation is clinical translation of histotripsy thrombolysis. 
First, an integrated image-guided histotripsy thrombolysis system suitable for clinical DVT 
treatment are designed and constructed. Second, the recently discovered technical innovations, 
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microtripsy and bubble-induced color Doppler (BCD), are investigated for histotripsy 
thrombolysis application to further improve treatment efficacy. Microtripsy is a new histotripsy 
approach and uses an intrinsic threshold mechanism to generate more reproducible and 
predictable cavitation via a single ultrasound pulse, which can minimize vessel damage by 
confining cavitation within vessel lumen and eliminate cavitation on vessel wall. Within 7 
minutes, 2-cm long whole blood clots were recanalized by microtripsy in vitro with flow channel 
opening up to 60%, restored flow up to 500 mL/min and 99.9% of clot debris smaller than 10 
µm. BCD is developed to monitor tissue motion induced by histotripsy pulses and investigated as 
a real-time quantitative feedback for histotripsy thrombolysis. The results show the potential of 
using BCD feedback to quantitatively monitor clot fractionation and accurately predicting its 
completion in real-time. Finally, a comprehensive pre-clinical study in a large animal DVT 
model is conducted to validate the safety and efficacy of this clinically designed system 
incorporating these technical innovations. In 13 out of the 14 treatments, a through channel was 
generated with 50% opening in average, and blood flows were successfully restored or 
significantly improved. The average treatment time was 16.6 minutes per cm-long clot. Only 
mild intravascular hemolysis was induced during microtripsy treatments and no damage was 
observed on vessel walls after two weeks of recovery. It is our hope that this dissertation work 
will establish a foundation for the translation of this noninvasive thrombolysis technology into 















 This dissertation focuses on the research, development and clinical translation of 
noninvasive thrombolysis using histotripsy, which uses focused ultrasound to mechanically 
break down target blood clots in human vascular system via well-controlled acoustic cavitation. 
The dissertation work is conducted in three steps: 1) An integrated, portable histotripsy 
thrombolysis system, consisting of a histotripsy therapy system, an ultrasound imaging system, 
and a motorized positioning system, is designed and constructed for clinical use. 2) Two 
technical innovations, microtripsy and bubble-induced color Doppler, are developed and 
investigated for histotripsy thrombolysis application. 3) A comprehensive pre-clinical study in an 
in vivo porcine DVT model is conducted to validate the safety and efficacy of microtripsy 
thrombolysis using the clinically-designed system. This chapter will first give a brief background 
of thrombosis diseases and current treatments, followed by an introduction of ultrasound-
mediated thrombolysis methods. Histotripsy technology and previous histotripsy thrombolysis 
work are then discussed. Backgrounds of the two technical innovations, microtripsy and bubble-
induced color Doppler, are also covered. Lastly, this chapter is concluded with an outline of this 
dissertation providing an overview of the following chapters. 
1.1 Thrombosis 
 
 Thrombosis is the formation of a blood clot in the cardiovascular system that prevents 
blood from circulating. Arterial thrombosis in the cerebral vasculature leads to ischemic stroke, 
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which is a leading cause of disability and death in the United States [1]. The most common form 
of venous thrombosis is deep vein thrombosis (DVT), which occurs predominantly in the legs 
and can sometimes lead to lethal pulmonary embolism (PE). DVT/PE (also called venous 
thromboembolism) affects over 300,000 people and causes deaths of 60,000 to 100,000 each 
year in the United States [2].  Other common thrombosis diseases include myocardial infarction, 
superficial vein thrombosis, and peripheral artery thrombosis, each of which poses a significant 
clinical problem.  
Anticoagulant medicines are the most common treatment for thrombosis. Severely 
symptomatic patients may require thrombolytic treatments instead of simply taking oral 
anticoagulant drugs. Current thrombolytic treatments include thrombolytic drugs and catheter-
based surgical procedures. Thrombolytic drugs such as tissue plasminogen activator (tPA) 
dissolves the blood clot by breaking down the cross-linked fibrin structures that solidify the clot 
[3]. Systemic administration of thrombolytic drugs has limited effectiveness with long treatment 
time (several hours to days) and is associated with a high risk of major bleeding [4]. Catheter-
based devices are used for localized treatment to the target clot, including catheter-directed 
delivery of thrombolytic drugs [5] and mechanical thrombectomy [6]. Catheter-based procedures 
are more effective than thrombolytic drugs, but they are invasive and carry an increased risk of 
bleeding, vessel damage, and infection [7]. 
1.2 Sonothrombolysis 
 
 Ultrasound has been a promising technique for promoting clot breakdown for several 
decades. Significant efforts have been focused on enhancing the efficacy of thrombolytic drugs 
with low intensity ultrasound [8-11]. Pfaffenberger et al. showed that continuous wave 
ultrasound significantly enhanced rt-PA mediated thrombolysis: in a travelling wave field 
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thrombolysis was augmented by 49.0 ± 14.7% and in a standing wave field by 34.8 ± 7.3%. 
Holland et al. further showed that both pulsed and continuous wave ultrasound enhanced rt-PA 
thrombolysis in a porcine whole blood clot model in vitro. Several clinical trials have been 
conducted for acute ischemic stroke and the results are promising [12-14]. In nine reported 
clinical trials, complete recanalization rates were higher in patients receiving combination of 
transcranial Doppler with tPA 37.2% (95% CI, 26.5%-47.9%) compared with patients treated 
with tPA alone 17.2% (95% CI, 9.5%-24.9%). Ultrasound combined with microbubbles has also 
been demonstrated to successfully break down clot in the presence or absence of thrombolytic 
drugs [15-17]. In a study conducted by Datta et al., a commercial contrast agent, Definity®, was 
used to promote and sustain the nucleation of cavitation during pulsed ultrasound exposure at 
120 kHz to enhance thrombolysis along with tPA and it was showed that stable cavitation 
activity plays an important role in enhancement of thrombolysis [15]. Another study concluded 
that sonothrombolysis using only microbubbles is also effective [17]. High-intensity focused 
ultrasound (HIFU) has been investigated as a stand-alone method for thrombolysis both in vitro 
and in vivo [18-20]. Wright et al. investigated the ability of HIFU for thrombolysis [20]. In their 
in vitro flow bypass experiments, 99.2% clot erosion with 1.1% of debris above 0.5mm in size 
was achieved using HIFU. In their in vivo study where clots were initialized in femoral veins of 
rabbits, partial flow restoration in 6 out of 10 clots was achieved by 1ms pulse with only 1 out of 
10 showing evidence of bleeding. 
1.3 Histotripsy Thrombolysis 
 
Histotripsy is a noninvasive non-thermal tissue ablation technology that mechanically 
fractionates soft tissue through well-controlled acoustic cavitation generated by ultrasound. 
Using high pressure (>10 MPa), microsecond-long ultrasound pulses generated outside human 
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body and focused into target tissue, histotripsy generates a cloud of cavitation microbubbles 
using pre-existing gas nuclei in the tissue within the focal region [21-25]. The rapid expansion 
and collapse of the cavitation bubble clouds induce high strain to the target tissue, which tears 
the cell and the extracellular matrix apart and result in tissue fractionation. Histotripsy can be 
used to create controlled tissue erosion at a fluid-tissue interface [23, 26, 27] or generate 
localized well-demarcated tissue fractionation inside bulk tissue [28-30]. Histotripsy is a 
platform therapeutic ultrasound technology and has potentials for clinical applications where 
noninvasive tissue removal is desired. Previous studies have demonstrated the feasibilities of 
using histotripsy to treat several diseases, such as benign prostatic hyperplasia [31, 32], 
congenital heart disease [23, 33] and liver cancer [30]. 
The feasibility of using histotripsy as a noninvasive, drug-free, and image-guided 
thrombolysis technique has been demonstrated previously. An in vitro study showed that 
histotripsy can completely break down large clots (140-300 mg) within 5 min with none detected 
larger than 100 µm [34] and an in vivo study in a porcine deep vein thrombosis model, showed 
histotripsy therapy can re-establish blood flow and decrease thrombus burden at a speed an order 
of magnitude faster than any current methods [35]. In these studies, multi-cycle (usually ≥ 5 
cycles) ultrasound pulses, often with peak negative pressure below 20 MPa and  peak positive 
pressure above 50 MPa, were used to generate the cavitation bubble cloud via a shock scattering 
mechanism. Individual microbubbles are formed from pre-existing gas nuclei in the tissue in the 
initial 1-2 cycles. The high amplitude positive shock is scattered from these individual bubbles, 
and the inverted shockwave interferes with negative cycles in the incident wave, resulting in very 
high negative pressures and producing a layer of dense bubbles [25]. Using the shock scattering 
approach, the cavitation cloud is less-confined and tends to be generated in contact with vessel 
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wall, resulting in potential vessel damage from histotripsy treatment. Even though no vessel 
penetration was observed in the previous in vivo porcine study, denudation of endothelium was 
found in isolated locations of the vein wall. This damage type is considered reversible, but there 




A new mechanism has been discovered recently to initiate cavitation cloud using an 
ultrasound pulse of ≤ 2 cycles length with very high peak negative pressure, which is enabled by 
the latest breakthrough in transducer amplifier electronics [36]. Cavitation cloud is formed when 
the peak negative pressure directly exceeds a distinctive “intrinsic threshold” of the medium (27 
MPa for blood clots) [24]. Using this intrinsic threshold mechanism, microscopic and precise 
lesions smaller than the diffraction limit (half of the acoustic wavelength) have been generated 
by allowing only a small fraction of the focal region to exceed the intrinsic threshold, hence 
termed “microtripsy” [37]. The location and size of the cavitation cloud generated using the 
intrinsic threshold mechanism is more reproducible and predictable than the shock scattering 
mechanism. Using microtripsy for thrombolysis application, cavitation cloud can be generated 
reliably and entirely within vessel lumen, without contacting the vessel wall and reducing the 
risk of damaging the vein valves or endothelium. The microtripsy approach (both mechanism 
and hardware) and the use of microtripsy for thrombolysis treatment provide a novel innovative 
advantage that is likely to significantly enhance clinical safety of histotripsy thrombolysis. 
1.5 Bubble-induced Color Doppler 
 
Standard ultrasound B-mode imaging is used to visualize cavitation during histotripsy 
treatments, but it is difficult to provide quantitative feedback. A bubble-induced color Doppler 
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(BCD) method has been developed for real-time quantitative monitoring of the progress of bulk 
tissue fractionation by histotripsy [38]. When a cavitation cloud is generated by a histotripsy 
pulse, a substantial motion is induced in the focal zone and observable on color Doppler 
synchronized with the histotripsy pulse. After a brief chaotic motion (within 500 µs) following 
the cloud collapse, a coherent motion was observed first away from the transducer and then 
towards the transducer (lasting for up to 20 ms). The time profile of the resulting velocity of the 
coherent motion expands as target tissue is fractionated and saturate when the target tissue is 
completely liquefied. Similarly, the averaged velocity within a specific time window of the 
coherent motion increases with increasing degree of fractionation, and saturates when the target 
tissue is completely liquefied. The concurrent occurrence of this saturation point and the 
complete fractionation has been observed consistently across different tissue types. The 
surrounding tissue conditions (i.e. vessel/tissue boundaries and tissue-blood interface) are more 
complicated in thrombolysis application than in bulk tissue fractionation, which leads to different 
histotripsy-induced motions and makes BCD monitoring for histotripsy thrombolysis more 
challenging. A specific BCD algorithm needs to be developed for histotripsy thrombolysis to 
detect the BCD saturation point in real-time, as a reliable indication for complete clot 
liquefaction. The bubble-induced color Doppler feedback and the algorithm development to 
pinpoint the complete clot fractionation in real-time is critical to maximize the treatment efficacy 
for thrombolysis treatment and other histotripsy applications. 
1.6 Outline of This Dissertation 
 
This dissertation is organized into eight chapters, documenting the details of our work on 
the research, development and clinical translation of histotripsy thrombolysis. A brief summary 
of each chapter follows. 
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The present chapter gives an overall introduction of my dissertation. The focus of this 
dissertation work is first introduced. The necessary backgrounds of this work, including 
thrombosis diseases, histotripsy technology and previous histotripsy thrombolysis work, and 
relevant technical innovations, are then presented. 
Chapter 2 describes in detail the development of the integrated, portable histotripsy 
thrombolysis system.  The system consists of three subsystems: a histotripsy therapy system, an 
ultrasound imaging system and a motorized positioning system. It was developed with built-in 
capabilities for microtripsy and bubble-induced color Doppler. Therapy transducers, with an 
ultrasound imaging probe embedded inside, are developed specifically for thrombolysis 
application. Compact motorized positioner is designed and built onto a mechanical arm for 
flexible therapy transducer positioning. Integrated control software is also developed to 
implement complex treatment strategies. 
Chapter 3 demonstrates the feasibility of using microtripsy approach for thrombolysis in 
an in vitro flow model. Blood clots made from bovine blood are formed in a flow model and 
treated using microtripsy pulses by scanning the cavitation focus through target clots. Cavitation 
bubble clouds are consistently generated in the center of the vessel lumen without contacting the 
vessel wall. Flow channels are successfully generated through the clots with a diameter up to 
60% of the vessel diameter. The debris particles were small with over 99.9% < 10 µm and the 
largest at 153 um.  
Chapter 4 extends the feasibility study of microtripsy thrombolysis presented in Chapter 
3, investigating the effects of pulse repetition frequency (PRF) and dose (number of pulses) on 
thrombolysis treatments. Microtripsy treatments using different PRFs (5, 50, and 100 Hz) and 
doses (20, 50, and 100 pulses) were performed on blood clots in an in vitro flow model. The 
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results shows that a high PRF (50 or 100 Hz) may be a better clinical choice for microtripsy 
thrombolysis due to the larger resulting flow channel, shorter treatment time, and smaller debris 
particles. 
Chapter 5 further investigates the treatment efficacies of microtripsy thrombolysis on 
different clot types. Unretracted and retracted clots are prepared in vitro and treated using 
microtripsy pulses. Three treatment strategies are developed and applied during treatments in 
retracted clots. It is demonstrated that microtripsy can successfully generate a flow channel 
through retracted clots but with reduced treatment efficacy compared to unretracted clots. This 
work also shows that the treatment strategies incorporating the electronic focal steering can 
significantly increase the size of recanalized flow channels in retracted clots. 
Chapter 6 investigates the potential of bubble-induced color Doppler (BCD) to 
quantitatively monitor microtripsy thrombolysis in real-time. Bubble-induced motion after each 
ultrasound pulse is first cross-validated using BCD and optical particle image velocimetry (PIV). 
Then a strong correlation is demonstrated to exist between the degree of histotripsy clot 
fractionation and BCD feedback, regardless clot types. Finally, a real-time algorithm is 
developed and verified to reliably detect the completion of histotripsy fractionation using BCD 
feedback. This work provides a quantitative method to monitor histotripsy thrombolysis and 
other histotripsy-mediated treatments. 
Chapter 7 validates the efficacy and safety of microtripsy thrombolysis through a 
comprehensive pre-clinical study in a porcine DVT model. Microtripsy thrombolysis treatments 
are conducted in 14 pigs, of which acute clots are induced in femoral veins. Results show that 
blood flow is restored or significantly increased after treatment in 13 pigs and only minor 
hemolysis and microscopic hemorrhage outside vessel wall are observed. This work further 
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demonstrates the potential of microtripsy thrombolysis for fast, precise, and effective clot 
recanalization, minimizing risks of vessel damage and hemolysis. 
Chapter 8 summarizes the findings and contributions of this dissertation work, and 
discuss future work that will be necessary to push this noninvasive thrombolysis technology 
further towards clinical use.  
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Development of Histotripsy Thrombolysis System 
 
 
2.1 Introduction  
 
The development of an integrated, portable histotripsy thrombolysis system is described 
in detail in this chapter. This system is designed specifically for clinical use and incorporates all 
the necessary hardware components for microtripsy and BCD implementations. It serves as a 
platform where new functionalities, new treatment parameters and strategies can be implemented 
and tested, and also serves as an integrated therapy device for clinical validations. The system 
consists of three subsystems: a histotripsy therapy system, an ultrasound imaging system, and a 
motorized positioning system. The whole system is built based on a commercial ultrasound 
imaging system. A multi-degree-of-freedom mechanical arm is installed into the cart of the 
imaging system. A histotripsy transducer with an ultrasound imaging probe embedded inside is 
mounted onto a compact motorized 3-dimensional positioner which is installed at the top of the 
mechanical arm. Ultrasound images from the embedded imaging probe are displayed in real-time 
on a 15-inch screen. Treatment is controlled and managed through a control panel which 
includes a touch screen, a pair of joysticks and several physical buttons and knobs. Two versions 
of control software are developed: one for engineering tuning and testing, and one for clinical 
use. 
 




2.2.1 Initial Prototype 
 
Therapy transducers for thrombolysis application were designed following the four 
criteria. 1) The transducer focal zone needs to be sufficiently small to be entirely contained 
within the femoral vein. 2) The transducer focal distance will be longer than the maximum 
overlying tissue depth but sufficiently short to minimize the distance between the transducer 
surface and the skin. 3) The surface area of the transducer will be within the available acoustic 
window but sufficiently large to obtain high focal pressure required for microtripsy. 4) The 
center frequency will be determined by attenuation from the overlying tissue, the maximum 
surface pressure of the transducer, the desired focal size, and acoustic saturation.  
Based on these criteria and our initial DVT patient data, an initial prototype of histotripsy 
thrombolysis transducer was designed using the initial ultrasound imaging data collected from 
DVT patients and constructed using the SLA method developed in our lab [1]. This 1.25-MHz 
transducer has 18 square piezoelectric elements (1.5-cm x 1.5-cm), with an 8 cm (laterally) x 8.3 
cm (elevationally) aperture size and a 6-cm focal length (Figure 2.1). A 4.8-cm x 2.2-cm 
rectangular central hole allows the insertion of a linear ultrasound imaging probe to guide and 
monitor the treatment. This design provides a 4 cm working distance (from the front transducer 
edge to the focus) that can cover the full range of overlying tissue, while minimizing the standoff 
distance between the surface of the therapy and imaging transducers and the patient skin.  
The transducer was calibrated using a fiber-optic probe hydrophone (FOPH) adapted 
from a previously published design [2]. The −6 dB focal beam volume of the transducer was 
measured to be 6.5 mm (axially) x 2 mm (laterally) x 1.5 mm (elevationally) at a peak negative 
pressure of 15MPa, which is sufficiently small to limit the entire cavitation cloud within the 
femoral vein of both humans and pigs (5 ~ 21.7 mm) [3, 4]. The pressure profiles on the three 
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axes and the focal waveform are shown in Figure 2.2. By summating the pressure outputs of 3 
sub-groups of the elements, the maximal focal peak negative pressure was estimated to be 48 
MPa in free field and 36 MPa through 5 cm of soft tissue by taking acoustic attenuation into 
account. 
 
Figure 2.1: Initial prototyping of histotripsy thrombolysis transducer. (a) CAD design and (b) the final transducer 




Figure 2.2: Pressure profiles of the initial prototype along the three axes and the focal pressure waveform measured 





2.2.2 Final Design 
 
After verifying the prototyping transducer in in vitro experiments, a final version of the 
clinically designed histotripsy thrombolysis transducer was designed and contracted to an 
experienced transducer company (Imasonic, France). The transducer has an effective 9.8-cm 
(laterally) x 8-cm (elevationally) aperture size, a 7-cm focal length and 5-cm working distance 
(Figure 2.3). The rectangular central hole for ultrasound imaging probe is 6-cm (lateral) x 2.4-
cm (elevationally). It contains 18 strip elements along the elevational direction (Figure 2.3(c)), 
which allows electrical steering of the focus along the lateral direction.  
 
Figure 2.3: Final histotripsy thrombolysis transducer. (a) CAD design. (b) Transducer front surface. (c) Element 
design. (d) Focal length illustration. 
 
 
The −6 dB focal beam volume of the transducer was measured to be 6.5 mm (axially) x 2 
mm (laterally) x 1.5 mm (elevationally) at a peak negative pressure of 15MPa (Figure 2.4(a)-
(c)). The pressure profiles at multiple steered locations along the lateral direction and their 
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corresponding 2D pressure fields are shown in Figure 2.5. By summing the pressure outputs of 3 
sub-groups (6 contiguous elements in each group), the peak negative pressure at the geometry 
focus was estimated to be over 45 MPa  in free field and 34 MPa through 5 cm of soft tissue by 
taking acoustic attenuation into account. The pressure only drops around 10% at the steered 
location 2 mm away from the geometry focus, which means the cavitation region can be widened 
to 5mm along the lateral axis. 
 
Figure 2.4: Pressure calibration of the clinical histotripsy thrombolysis transducer. (a)–(c) Pressure profiles along 
the three axes. (d) Estimated focal pressure waveform by summing the three sub-group waveforms. 
 
 
Figure 2.5: (a) Pressure profiles along the lateral direction at multiple steered locations. (b) Overlapped 2D pressure 
fields on the lateral-elevational plane at multiple steered locations. 
18 
 
2.3 Ultrasound Imaging 
 
2.3.1 Ultrasound Imaging System 
 
A commercial ultrasound imaging system (SonixTouch; Analogic Ultrasound, 
Vancouver, Canada) is deployed as the base of the histotripsy thrombolysis system (Figure 2.6). 
It is a FDA-approved diagnostic ultrasound system packaged with an Ultrasound Research 
Interface (URI). The URI module has the ability to run special research tools for performing 
tasks such as transducer prototyping, low-level ultrasound beam sequencing control, and 
development of commercial ultrasound applications running on its platform. It has 256 transmit 
channels and 64 receive channels, with 80 MHz transmit delays calculation clock and 40 MHz 
receive sampling clock. This system accepts a wide range of ultrasound imaging probes: linear, 
phased, curve linear, 2D, high frequency (40 MHz) and so on. Full ranges of C++ software 
development kits (SDKs) are provided by the manufacturer from very low level of US 
transmit/receive control to the high level of remote control and custom application development. 
The cart of this imaging system is extended to hold our therapy transducer amplifier and motor 
drivers inside.  
 
Figure 2.6: Commercial SonixTouch® ultrasound imaging system. 
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2.3.2 Custom Ultrasound Imaging Probe 
 
The histotripsy thrombolysis treatment is guided by real-time ultrasound imaging 
feedback using a linear array imaging probe (7.5 MHz center frequency). It has 128 elements and 
compatible with the ultrasound imaging system. A rectangular customized housing is designed to 
minimize its volume and ease the insertion to the central hole of the therapy transducer (Figure 
2.7). The imaging probe and its housing were constructed by Vermon, Inc. (France). The 
imaging probe can be inserted through the center hole of the therapy transducer (Figure 2.3) and 
only has one degree of freedom to move along the axial axis of the therapy transducer. The 
imaging probe can be moved close to the patient’s skin to avoid degradation of imaging quality. 
A simple locking structure is designed on the back of the therapy transducer to allow holding and 
releasing the imaging probe. By locking the imaging probe position coaxially with the therapy 
transducer, the imaging plane will be always aligned with the therapy plane. It is connected to 
the ultrasound imaging system and real-time ultrasound images from this probe are displayed on 
the imaging system.  
 
 





2.4 Positioning System 
 
The positioning system includes two parts: a multi-degree-of-freedom mechanical arm 
and a compact motorized 3-dimensional positioner. The mechanical arm is purchased from DK 
Technologies (Barum, Germany). With a press/release lock, the arm can be moved and 
positioned anywhere within a range of 0.5 m (Figure 2.8). The compact motorized 3-
dimensional positioner is developed in house for finer position adjustment. It is assembled using 
three linear stages to form three perpendicular moving axes. A step motor is installed at the end 
of each linear stage. The three motors are driven by a programmable logic controller and the 
whole positioner can be controlled physically through the joy sticks installed on the cart and 
virtually through software (Figure 2.9). This positioner provides a step size of 20 µm, a moving 
range of 12, 5, and 4 cm in x, y, and z direction respectively. Using this positioning system, the 









Figure 2.9: The compact motorized positioner can be controlled by joy sticks and software commands through a 
programmable logic controller. 
 
 
2.5 System Integration 
 
The histotripsy thrombolysis system is integrated based on the ultrasound imaging 
machine (Figure 2.10). The positioning system is installed on the extended cart of the imaging 
system and the motors are connected to the programmable logic controller placed inside of the 
extended cart. The joy sticks and an emergency button are installed on the right of the original 
control panel of the imaging system and connected to the same programmable logic controller. 
The therapy transducer with the embedded imaging probe is mounted onto the compact 
motorized positioner and connected to its amplifier placed inside the cart. The imaging probe is 




Figure 2.10: Integrated histotripsy thrombolysis system. 
 
2.6 Software Development 
 
Integrated software with a clinician-friendly interface is developed to control the therapy, 
imaging, and positioning systems together, and to implement complex therapy and monitoring 
algorithms. Systemic integration is very important to connect the therapy and positioning control 
and imaging feedback. Control needs to be determined and adjusted by the feedback for desired 
effects to be achieved. Two versions of control software are developed using C++ and Qt 
framework:  one for engineering testing and tuning, and one for treatment use. The software 
applications are designed according to the practical experiences on in vivo animal thrombolysis 
treatments we conducted and the discussions with two clinicians.  
The two software versions share a similar structure as shown in Figure 2.11. Individual 
C++ classes to control ultrasound imaging, histotripsy therapy and positioning are developed and 
tested first and then integrated into one entity. Each C++ class is like a virtual machine including 
all the basic functions of the corresponding subsystem. For the therapy, it is able to set all the 
treatment parameters (PRF, charging time, steering focuses, dose, etc.), treating sequences and 
23 
 
operation management. For positioning, it can move the transducer simultaneously along all 
three axes and read current positions from their driver. For the imaging, it can synchronize the 
imaging with the therapy to avoid interference between imaging pulses and therapy pulses. All 
the imaging parameters can be set and all the imaging data can be accessed by the corresponding 
C++ class. A user interface class is developed to serve as a main class to hold and connect the 
three sub-system classes and also to be responsible to interact with the users, such as responses 
to user’s inputs and display information on the screen.  
 
Figure 2.11: Schematic structure of control software. 
 
The major differences between the two software versions are the user interface design 
and the imaging SDK used. As discussed in 2.3.1, the imaging system provides different SDKs 
to control the imaging functionalities. For the engineering version, a remote control SDK (called 
Ulterius) is used to send commands to the commercial built-in software and receive image data 
from it. It requires a separate computer to communicate with the imaging system. All the 
operations are conducted on the separate computer using a mouse. For the clinical version, a 
more basic SDK (called Porta) is used to directly develop our own imaging modality without 
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using the built-in software. The programming is more complicated but at the same time more 
flexible. The treatment software is run directly on the imaging system and no separate computer 
is needed. With this version, user interface are designed specifically for clinicians and only touch 
screen and physical buttons are used for user inputs.  
The engineering version of the control software is developed for engineering and research 
purposes. The parameters and settings can be easily changed and different algorithms can be 
easily tested. The user interface of the engineering version is displayed in Figure 2.12. On the 
left part of the UI, real-time ultrasound images and performance information are displayed. On 
the right side, pre-treatment planning and treatment configurations can be set with step by step 
guidance. For pre-treatment planning, the treatment focus need to be first marked on the real-
time images. The software will then allow the operating clinician to align the focus with the clot 
inside vessel and plan the scanning path along the length of the clot. To verify the targeting 
accuracy, a small number of pulses will be applied to produce a hyperechoic zone to ensure 
several positions on the scanning path will be on or in the clot within the vessel. After the path 
verification, preset treatment parameters will be confirmed or new treating strategy can be 
specified. After the pre-treatment plan is specified, B-mode image or the bubble-induced color 
Doppler feedback (Chapter 6) will be chosen to monitor the treatment. Before starting treatment, 
all the settings can be updated and reviewed by the operator to avoid mistakes. During treatment, 





Figure 2.12: The user interface of the engineering version of the control software. Real-time ultrasound images are 
shown on the left of the window. Two operation tabs are displayed on the right, including a pre-treatment planning 
tab (Top) and a treatment tab (Bottom). 
 
The treatment software version is developed to simplify the operations for clinicians, who 
will eventually conduct the treatments instead of engineers. Our plan is to use the engineering 
version to test, tune and optimize the treatment parameters and settings and then set the optimal 
values in the clinical version. In this clinical version, the operation flow remains the same as the 
engineering version but with different user interfaces. The 15-inch screen on the therapy system 
is used purely for display (Figure 2.13). Only the touch screen, the surrounding physical buttons 
and joysticks are used for user inputs (Figure 2.14). There are imaging setting tab, pre-treatment 








Figure 2.14: Control panel with a touch screen and physical buttons and knobs, with different touch screen 
interfaces shown. There are tabs: one for imaging setting, one for pre-treatment planning and one for treatment. 





The development of an integrated, portable thrombolysis system is discussed in this 
chapter. Major efforts have been put into the therapy transducer design and development and the 
software development. Using this system as a platform, the studies and experiments in the 
following chapters was able to be conducted to investigate new therapy and imaging methods 
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and further improve the efficacy and safety of microtripsy thrombolysis. Such a clinically 
designed integrated system is an important milestone to advance the clinical translation of this 
new exciting noninvasive thrombolysis technology. This integrated system is used for the studies 
performed in Chapters 3-7. A list of the system components is attached in Appendix below.  
2.8 Appendix 
 
(1) One Ultrasonix (SonixTouch) system with one mechanical arm and one compact motorized 
positioner. 
(2) One Imasonic 18-element ultrasound transducer with one 3-board amplifier and one FGPA 
chip. 
(3) One L11-5 Ultrasonix imaging probe (made by Vermon) with custom housing (black color). 
(4) Four regular Ultrasonix imaging probes: L40, PA7, C7, L14.  
(5) One HP® laptop. 
(6) Three cables: one cable for FPGA communication, one USB-Serial cable for positioner PLC 
communication and one Ethernet cable for Ultrasonix-laptop communication. 
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Noninvasive Thrombolysis using Histotripsy beyond the “Intrinsic” Threshold 
(Microtripsy) 
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3.1 Introduction  
 
Thrombosis is the formation of a blood clot inside an artery or vein. Arterial obstruction 
via thrombosis in the cerebral vasculature leads to stroke, which is the fifth leading cause of 
death in the United States [2]. Deep vein thrombosis, or DVT, affects 300,000 people a year in 
the United States. Occurring mostly in the legs, it is the most common form of venous 
thrombosis. The current gold standard of thrombolytic treatment involves the infusion of 
thrombolytic drugs such as tissue plasminogen activator (tPA) [3, 4]. However, administration of 
thrombolytic drugs systemically has limited effectiveness requiring long treatment time (several 
hours to days) and is associated with increased risks of major bleeding [5]. Other treatment 
options are catheter-based endovascular procedures that are site-specific but more invasive and 
associated with bleeding, vascular damage, and infections [6-9]. 
Ultrasound has been a promising technique for promoting clot breakdown for several 
decades. Significant efforts have focused on enhancing the efficacy of thrombolytic drugs with 
low intensity ultrasound [10-13]. Several clinical trials have been conducted and the results are 
promising [14-16]. Ultrasound combined with microbubbles has also been demonstrated to 
successfully break down clot in the presence or absence of thrombolytic drugs [17-19]. Another 
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approach using high-intensity focused ultrasound (HIFU) alone for thrombolysis has been 
investigated in vitro and in vivo [20-22].  
Histotripsy fractionates soft tissue by well-controlled acoustic cavitation using 
microsecond-long, high-intensity and focused ultrasound pulses [23-25]. The feasibility of using 
histotripsy as a noninvasive, drug-free, and image-guided thrombolysis technique has been 
demonstrated previously. In vitro studies show that histotripsy can completely break down large 
clots (140-300 mg) within 5 min with none detected larger than 100 µm [26] and in vivo studies 
in a porcine deep vein thrombosis model, showed histotripsy therapy can re-establish blood flow 
and decrease thrombus burden. However, vascular damage was still observed in some 
treatments, as cavitation is not entirely confined in the vessel lumen and sometimes occurs in 
contact with vessel wall [27]. 
In our previous histotripsy thrombolysis studies [26, 27], a shock scattering mechanism 
was used to generate the cavitation bubble cloud, which employs multi-cycle pulses, often with 
the peak negative pressure below 20 MPa and the peak positive pressure above 50 MPa [28]. 
Individual sparse microbubbles are first formed and expanded in the initial 1-2 cycles. The high 
amplitude positive shock is scattered from these individual bubbles, and the inverted shockwave 
interferes with negative cycles in the incident wave, resulting in very high negative pressures and 
producing a layer of dense bubbles. Using the shock-scattering mechanism for thrombolysis, the 
initial bubbles are preferentially generated on the vessel walls where the weak nuclei tend to 
reside, potentially subjecting the vessel wall to high stress. In our in vivo study [27], no vessel 
penetration was observed, however, denudation of endothelium was found in isolated locations 
of the vein wall. Endothelial injury occurs with all interventional devices and is generally 
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considered reversible, but damage to the vein valve may result in irreversible functional damage, 
leading to chronic venous insufficiency associated with severe morbidity [29]. 
To avoid cavitation damage to the vessel wall, we have recently discovered a new 
mechanism to initiate a cavitation cloud via a single pulse of <2 cycles with only one high 
negative pressure phase. When the peak negative pressure directly exceeds a distinctive 
“intrinsic threshold” for the medium (27 MPa for blood clots) [30, 31], a cavitation cloud is 
formed matching the volume exceeding the threshold. Using this intrinsic threshold mechanism 
and a very short acoustic pulse (< 2 cycles) to prevent shock-scattering, the volume of the 
histotripsy-induced cavitation cloud and lesion corresponded well to the volume of the focal 
regions above the intrinsic cavitation threshold. Because the supra-threshold portion of the 
negative half cycle can be precisely controlled, lesions considerably smaller than a wavelength 
are easily produced, hence the term Microtripsy [31]. 
We hypothesize that microtripsy can accurately generate and confine cavitation in the 
vessel lumen, without contacting the vessel wall, which results in accurate recanalization within 
the clot and potentially eliminating vessel damage. In this chapter, microtripsy thrombolysis 
experiments were conducted in an in vitro flow model of DVT. Microtripsy was used to generate 
the cavitation cloud within the clot formed inside a vessel-mimicking phantom. The cavitation 
cloud was scanned through the clot to create a flow channel to restore blood flow. Two different 
scan intervals (SI) and two different peak negative pressures (P-) of applied microtripsy pulses 
were used to create different flow channels. The goal of this study is to show the potential of 
using this new microtripsy thrombolysis method to avoid the contact of cavitation with the vessel 




3.2 Material and Methods 
 
3.2.1 Flow Model 
 
An in vitro flow model, similar to that described by Spengos et al. [32], was developed to 
mimic the condition of occlusive deep vein thrombosis where no flow is present but pressure is 
still applied on the clot. As shown in Figure 3.1, the flow model consisted of a reservoir, a 
pressure sensor, a vessel phantom, a filter set, and a fluid collector. All the components were 
connected with silicone tubing (Masterflex L/S 17; Cole-Parmer, Vernon Hills, IL, USA). The 
reservoir stored saline for perfusion and was placed above the vessel phantom to apply a constant 
pressure of 3.7 mm Hg, which was measured by the pressure sensor (MG-9V; SSI Technologies, 
Janesville, WI, USA). The 3.7 mm Hg was chosen according to reported femoral vein pressure 
[33, 34]. The vessel phantom was placed horizontally and its inlet and outlet are at the same 
height. The upstream pressure measured by the sensor at the inlet side equaled the pressure drop 
across the clot in this model. When a channel was created through the clot by the microtripsy 
treatment, the flow was restored through the clot inside the vessel phantom due to the pressure 
applied. The restored flow of saline and clot debris particles from the treatment was then passed 
through a filter set, and the filtered saline was collected for further particle analysis of the 
remaining debris particles. 
 
Figure 3.1: Schematic diagram of the flow model. 
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3.2.2 Vessel Phantom 
 
The vessel phantom was developed to mimic a femoral vein in the leg (Figure 3.2). It 
was made from urethane polymer (Urethane RTV Mold-Making System; Tap Plastics Inc., San 
Leandro, CA, USA), which has a similar acoustic property to human tissue [35]. Urethane 
(liquid) was first degased to get rid of bubbles and then poured carefully into a mold similar to 
that described by Park et al. [36]. After solidification of the urethane, it was removed from the 
mold. The final vessel phantom had a 6.5 mm inner diameter and an 8 mm outer diameter. The 
6.5 mm inner diameter was chosen according to the reported DVT vein diameters (5 ~ 21.7 mm) 
[37]. On one side of the vessel phantom, the inner lumen was narrowed to 4.2 mm (35% 
stenosis) so that clot can be formed and stabilized by the stenosis to avoid slipping under 
pressure. The vessel phantom was held by a plastic frame with tube fittings at the two ends to 
connect the vessel lumen in-line with the rest of the flow model [36]. 
 
Figure 3.2: The vessel phantom is held by a plastic frame and connected in line with the flow model using tubing 
fittings. A 35% stenosis is located at the outlet side of the vessel phantom to fix the clot formed aside so that it does 




3.2.3  Clot Formation 
 
Fresh bovine blood was collected from a local abattoir. Blood from 8 animals was used in 
this study. Before use, bovine blood was degassed to avoid formation of large stable gas bubble 
in the clot. A citrate-phosphate-dextrose (CPD) solution (#C7165; Sigma-Aldrich Co., St. Louis, 
MO, USA) was immediately mixed with bovine blood as an anti-coagulant at a ratio of 1 mL 
CPD per 9 mL blood. The blood sample was stored at 4°C and used within 72 hours. To 
stimulate the clotting cascade, calcium chloride (#21107; Sigma-Aldrich Co., St. Louis, MO, 
USA) was mixed with bovine blood to a final concentration of 20mM/L. To form clot inside the 
vessel phantom, the stimulated blood was poured into the vertically-placed vessel phantom with 
the stenosis sealed by a balloon catheter. After staying in 37 °C water bath for 2 hours, a clot 
with a length of 2 cm was matured and cross-linked with the vessel interior and stenosis. The 
balloon catheter was then removed and the vessel phantom was connected back into the flow 
model with the stenosis end of the clot distal to the pressure reservoir. 
3.2.4  Microtripsy Thrombolysis System 
 
Thrombolysis treatment was conducted by an integrated image-guided microtripsy 
thrombolysis system (Figure 3.3) developed in our laboratory. The system integrated three sub-
systems: therapy system, ultrasound imaging system and positioning system. A 1-MHz 18-
element microtripsy thrombolysis transducer was designed in our laboratory based on the 
anatomy of DVT patients and manufactured by Imasonic (S.A., Besancon, France) (Figure 3.4). 
The transducer has an effective 9.8 cm (lateral) x 8 cm (elevational) aperture and a 7 cm focal 
distance. The focal beam volume (−6 dB) of the transducer was measured to be 6.5 mm (axial) x 
1.3 mm (lateral) x 1.5 mm (elevational) at a peak negative pressure of 15 MPa using a fiber-optic 
probe hydrophone (FOPH) [38]. An ultrasound imaging probe with rectangular custom housing 
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(L7.5MHz; Vermon, France) was inserted into the rectangular central hole of the transducer to 
guide and monitor microtripsy thrombolysis therapy. Ultrasound imaging was provided by 
SonixTouch
®
 system (Analogic Ultrasound, Vancouver, Canada). The therapy transducer was 
mounted on a motorized 3-dimension micro-positioner, which had a range of 10 cm x 5 cm x 4 
cm. A manual arm to which the micro-positioner was attached gave a range radius of about 1 
meter for pre-treatment positioning. Control software was developed to manage and coordinate 
the therapy, imaging, and positioning systems. 
 
Figure 3.3: Integrated microtripsy thrombolysis system. It consists of an ultrasound imaging system, a microtripsy 





Figure 3.4: 1 MHz 18-element microtripsy transducer with an ultrasound imaging probe at the center. With the 
imaging probe fixed in both lateral and elevational directions, the imaging plane is automatically aligned with the 





Before treatment, the vessel phantom connected to the flow model was occluded by a clot 
formed inside. The vessel phantom with the clot was placed in a water tank filled with degassed 
water. The therapy transducer was placed above the vessel phantom facing down. The treatment 
focus was first calibrated by marking the hyperechoic cavitation region on the real-time 
ultrasound images. With the treatment focus aligned at the center of the vessel lumen, a 
treatment path from one end to the other end of the clot was determined by registering key 
position coordinates along the clot using the real-time ultrasound images and micro-positioner.   
During treatment, the microtripsy thrombolysis system applied a fixed number of pulses 
at each location along the treatment path with a pulse repetition frequency (PRF) of 50 Hz. An 
example of microtripsy waveform is shown in Figure 3.5. The therapy transducer was moved 
with a pre-set interval to scan the treatment focus to next location along the path (Figure 3.6). 
Four groups of treatments were conducted using two scan intervals and two peak negative 
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pressures (Table 3.1). Peak negative pressure larger than 20 MPa can’t be directly measured and 
therefore was estimated by linear summation (P(-)LS) of P- outputs from 6 separate groups of 
transducer elements (3 elements per group). According to the predication of treatment focal 
region using the area where the applied negative pressure exceeds the intrinsic threshold in the 
clot (27 MPa) [30, 31], peak negative pressures of 30 MPa and 36 MPa were chosen to give 
reasonable axial lengths of focal region to fit within the 6.5-mm vessel lumen. Scan intervals of 
0.7 mm and 0.3 mm were chosen as the half and quarter of the mean elevational width (-6dB) of 
the predicted focal regions, respectively. To ensure complete clot homogenization for sufficient 
treatment, 1000 histotripsy pulses were applied per scan location for the treatment groups with 
0.7 mm scan interval (SI0.7mm) and 300 pulses for the groups with 0.3 mm scan interval (SI0.3mm). 
Ultrasound video was taken throughout each treatment. The total treatment time to scan through 
a 2-cm clot was 10 min for SI of 0.7 mm and 7 min for SI of 0.3 mm. 
 
Figure 3.5: Pressure waveform of a microtripsy pulse. Since peak negative pressure larger than 20 MPa cannot be 
directly measured, this estimated waveform was linearly summed from the directly-measured waveforms of 6 







Figure 3.6: Schematic illustration of the treatment strategy. After a fixed number of microtripsy pulses are applied 
at one location along the treatment path, the therapy transducer is moved with a pre-set scan interval to the next 
location and repeats. 
 
 















Group A 0.7 mm 30 MPa 1000 pulses 6 / 6 
Group B 0.7 mm 36 MPa 1000 pulses 6 / 6 
Group C 0.3 mm 30 MPa 300 pulses 6 6 12 





Cavitation generated by microtripsy was monitored with B-mode ultrasound imaging 
during the treatment. Since cavitation bubble could appears as a dynamic hyperechoic region on 
the ultrasound images, the intensity variance between the ultrasound images within the vessel 
lumen was used to quantify the cavitation region. Cavitation cloud size was quantified using the 
ultrasound video taken during the treatments with 0.3 mm SI. For each treatment, 1000 pairs of 
ultrasound images were randomly extracted from the video and an average cavitation region was 
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generated. An ellipse was fitted into the cavitation region using a function provided by Matlab 
(MathWorks, Natick, MA, USA) to calculate its major and minor diameters. 
3.2.7 Flow Channel Quantification 
 
To quantitatively evaluate the flow channel generated through the clot by the microtripsy 
thrombolysis treatment, each treated clot was scanned using a 20MHz linear ultrasound image 
probe (Analogic Ultrasound, Vancouver, Canada). Mounted on the micro-positioner, the imaging 
probe was placed right above the vessel phantom and its imaging plane was aligned 
perpendicular to the central axis of the vessel phantom. High quality B-mode images of cross 
sections of each treated clot were captured every 0.3 mm along the vessel. Since the fractionated 
clot region was hypoechoic when the flow was restored, we applied a contrast threshold 
compared to surrounding intact clot to detect the cross section of the flow channel on ultrasound 
image. The cross area (Across) of the flow channel was calculated and an ellipse was fitted into 
the flow channel region using the same method as that for quantifying cavitation region to obtain 
its major and minor diameters (Dmajor and Dminor). The mean Across, Dmajor and Dminor over all valid 
scan images of each treated clot were used to characterize the generated channel. Diameter of 
circle (Dcircle) with equivalent area of Across and opening percentage (Popen = Dcircle/Dvessel) were 
also derived to assess potential clinical effectiveness.  
3.2.8 Restored Flow Measurement 
 
Restored flow rate is one critical index for clinical effectiveness of current thrombolysis 
treatments. In our in vitro treatments, restored flow rate was measured to evaluate microtripsy 
thrombolysis effectiveness. The flow channel creation was determined when fluid came out from 
the vessel phantom to the reservoir. After the first 150 mL of restored fluid was collected for 
debris analysis, the flow was turned off using a valve in line with the flow system. The system 
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pressure was adjusted back to 3.7 mm Hg and a measuring beaker was placed under the 
downstream outlet. The flow was turned on again, and the saline through the treated clot was 
collected by the beaker for a period of 30 seconds. The restored volume flow rate was then 
calculated as the volume of the saline collected divided by the time. Owing to the brevity of the 
time period and the small change in reservoir volume, pressure was assumed to be constant over 
this time period. A control measurement with no blockage in the circulation system was also 
conducted to compare with restored flow rate. 
3.2.9 Debris Particle Measurements 
 
There is a concern that clot debris particles generated by microtripsy thrombolysis may 
embolise and occlude downstream vessels. To address this issue, two different methods were 
utilized to measure and analyze the debris particles. First, a filter weight and Coulter Counter 
combination method was adopted in 24 clot treatments (six per treatment group for all 
parameters). The restored flow of saline with suspended debris particles was serially filtered 
through three filters with pore sizes of 1000, 500 and 100 µm. The dry weight of each filter was 
measured prior to each treatment. After treatment, the filters were dried in room temperature 
over 48 hours and reweighed. Because of potential weight increase introduced by sodium 
chloride crystals formation on the filters, a control group (N = 10) was measured in the same way 
with only saline filtered through. The filtered, collected fluid with debris particles smaller than 
100 µm were suspended in the fluid was analyzed using a Coulter Counter (Multisizer 3; 
Beckman Coulter, Brea, CA, USA). The measurable size range was 2-60 µm by using a 100-µm 
aperture tube [39]. Second, a microscopic inspection and Coulter Counter combination method 
was adopted in another 12 clot treatments (6 per treatment group with 0.3mm SI). Clot debris 
suspended in the restored flow was filtered by only one filter with a pore size of 300 µm. 
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Macroscopic inspection was conducted to check if there was any debris particle trapped on the 
300 µm filter. High-resolution optical images were taken of the filter paper before and after each 
treatment and the number of distinguishable particles was counted and recorded. The filtered, 
collected fluid debris particles through the 300 µm filter suspended in the fluid was analyzed 
using the Coulter Counter. The measurable size range was 2-300 µm by using two aperture tubes 
(100 µm and 560 µm). 
3.2.10 Statistics 
 
All statistical comparisons in this study were performed using a student’s t-test. P-values 
<0.01 were considered significant. Numerical data are expressed as mean ± standard deviation. 





For all experiments, cavitation was monitored by ultrasound imaging during the 
microtripsy thrombolysis treatment. The cavitation bubble cloud was clearly distinguished as a 
dynamic hyperechoic region on the B-mode images and presented an elliptical shape with its 
major axis along the ultrasound propagation direction. Using this 6.5-mm diameter vessel 
phantom, no cavitation was observed on either external or internal sides of the vessel walls 
during treatment. In the treatment groups with the low P(-)LS, the bubble cloud was well-
confined and consistently maintained in the center of the vessel lumen without contact with the 
internal vessel wall (Figure 3.7a). In the treatment groups with the high P(-)LS, the bubble cloud 
was still well-confined but enlarged due to the increased P- (Figure 3.7b). Among all the 
treatments with the 30 MPa P(-)LS and 0.3 mm SI, the major and minor diameters of the 
cavitation region were estimated as 3.41 ± 0.54 mm and 1.95 ± 0.37 mm, respectively. And with 
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the 36 MPa P(-)LS and 0.3 mm SI, the major and minor diameters of the cavitation region were 
estimated as 4.53 ± 0.65 mm and 2.12 ± 0.35 mm, respectively.  
 
Figure 3.7: Cavitation bubble clouds during treatments. (a) Using 30 MPa P(-)LS. (b) Using 36 MPa P(-)LS. 
Ultrasound was propagated from the top to the bottom of the images. 
 
 
3.3.2 Flow Channel 
 
A flow channel was successfully generated through the clot after all microtripsy 
thrombolysis treatments (Figure 3.8). The channels were measured using the ultrasound images. 
Within each treatment, the flow channel was well confined inside the clots without contact with 
internal vessel wall. The cross sections of the generated flow channel at different scan positions 
across the clot were consistent. The boundaries of the channel from surrounding intact clots were 
sharp and clear. Representative cross-sectional images of flow channels generated were shown in 
Figure 3.9. For the treatment groups with the scan interval of 0.7 mm (SI0.7mm), the cross-
sectional shape of the channels was closer to a circle, and there were small areas with reduced 
brightness (probably limited fractionation) on one side of the channel contour which 
corresponded to the tail of the bubble cloud. For the treatment groups with the scan interval of 
0.3 mm (SI0.3mm), the cross-sectional shape of the channels was generally larger and more like an 
ellipse with its major axis along the ultrasound propagation direction (i.e. the axial direction of 




Figure 3.8: Ultrasound images of a treated clot in the vessel phantom. (a) Before treatment. The vertical arrow 
locates the stenosis is. (b) Flow channel presence after treatment. (c) Color flow presence after treatment. Glass 
beads (Part# 10089; TSI, Shoreview, MN, USA) were mixed in the perfusion saline after the treatment to obtain this 
color Doppler image. Flow is from the right to the left of the images.  
 
 
Figure 3.9: Representative ultrasound images of flow channel generated from the 4 treatment groups. The generated 
flow channels show as the hypoechoic zones inside clots (block arrow). Reduced echogenicity is found at one side 
of the flow channels with 0.7 mm SI (line arrow), where the tail of the cavitation cloud was. Ultrasound was 
propagated from the top to the bottom of the images. 
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Quantitative results characterizing the channel size in each treatment group are shown in 
Table 3.2. For easier comparison, cartoon illustrating the cross section of the generated channel 
inside of the vessel lumen in proportion to the actual sizes from Table 3.2 is also shown in 
Figure 3.10. Using the same P(-)LS, the mean Across of the flow channel generated with SI0.3mm 
was over three times larger than that generated with SI0.7mm. One-sided t-tests were performed 
between Group A and C (30 MPa P(-)LS), and Group B and D (36 MPa P(-)LS). Both showed 
significant increases of Across by reducing SI from 0.7 mm to 0.3 mm (both P < 0.0001). The 
mean equivalent opening Popen in the SI0.3mm groups was above 48%, which was about twice of 
that in the SI0.7mm groups. The ratio of Dminor to Dmajor for the SI0.7mm groups was over 67% 
whereas that for the SI0.3mm groups was approximately 50%. Within the groups using the same 
scan interval, the mean Across of the flow channel generated with 36 MPa P(-)LS was larger than 
that generated with 30 MPa P-. By applying one-sided t-test on Group C and D (0.3 mm SI), it 
showed the increase of Across with increased P(-)LS was also statistically significant (P < 0.0001). 
The ratio of Dminor to Dmajor stayed almost the same between the low P(-)LS and high P(-)LS 
groups. The biggest Dmajor (5.52 mm) was found in the group with 0.3 mm scan interval and high 
P(-)LS, whereas the smallest Dmajor (1.22 mm) was seen in the group with 0.7mm scan interval 
and low P(-)LS. 
Table 3.2: Quantifications of the flow channels (Mean ± Standard Deviation)  
SI 0.7 mm 0.3 mm 
P(-)LS 30MPa 36MPa 30MPa 36MPa 
Across (mm
2
) 1.79 ± 0.60 2.46 ± 0.93 6.33 ± 1.65 11.15 ± 1.22 
Dmajor (mm) 1.85 ± 0.41 2.15 ± 0.51 4.04 ± 0.49 5.46 ± 0.36 
Dminor (mm) 1.25 ± 0.16 1.50 ± 0.24 2.03 ± 0.32 2.77 ± 0.18 
Dcircle (mm)* 1.51 ± 0.23 1.77 ± 0.30 2.84 ± 0.35 3.77 ± 0.20 
Popen ** 23 ± 3% 27 ± 4% 44 ± 5% 58% ± 3% 
* Dcircle is the diameter of circle has the same area as the cross-sectional area (Across) of flow channel. 




Figure 3.10: Illustrations of the cross sections of the flow channels for the 4 treatment groups. Fitted ellipse is 
determined by Dmajor and Dminor from Table 3.2. Equivalent circle is determined by Dcircle from Table 3.2. 
  
3.3.3 Restored Flow Rate 
 
No flow was observed on Color Doppler and no fluid was collected by the fluid collector 
prior to any treatment. Flow was successfully restored after each microtripsy thrombolysis 
treatment. Representative color Doppler flow images are shown in Figure 3.8c. As expected, the 
path and the volume of the flow matched well with the generated channel. Flow rate was 
measured after each treatment (Figure 3.11). With a constant pressure, larger channel would be 
expected to permit higher flow rate, which is confirmed by these flow rate results. One-sided t-
tests were performed to compare the restored flow rates between different treatment groups. For 
both P(-)LS used, significant flow rate increase (from about 50 mL/min to above 300 mL/min) 
was observed as the SI decreased (P < 0.0001). And with the SI of 0.3 mm, the flow increase 
from the low P(-)LS groups to the high P(-)LS groups was also statistically significant (P < 
0.0001). The lowest flow rate was 30 mL/min in one of the treatments with 0.7 mm scan interval 
and low P(-)LS. The highest flow rate was 520 mL/min in one of the treatments with 0.3 mm scan 
interval and high P(-)LS. Within the SI0.3mm treatment groups, the lowest flow rate was 
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240mL/min. The flow model with no blockage had a maximal flow rate of 640 mL/min under 
the pressure of 3.7 mm Hg. 
 
Figure 3.11: Restored flow rates of the 4 treatment groups. Treatments associated with creation of larger cross-
sectional area opening were associated with larger flow rates. The flow rates in the control group were measured 
under the same pressure as the treatment groups but without blockage in vessel phantom. For both P(-)LS used, 
statistical analysis (one-sided t-tests) showed significant flow rate increase as the SI decreased (P < 0.0001). And 
with the SI of 0.3 mm, the flow rate increase from the low P(-)LS groups to the high P(-)LS groups was also 
statistically significant (P < 0.0001). 
 
  
3.3.4 Debris Particle Measurements 
 
In the 24 treatments using the filter weight and Coulter Counter combination method, the 
mean weight change of each filter size in each treatment group was shown versus the control 
group in Figure 3.12. Over all the treatments and all the filter sizes, the filter’s dry weight 
increased by a mean of 1.4 mg with a standard deviation of 1.0 mg. For the control group, the 
filter’s dry weight changed by a mean of 1.1 mg with a standard deviation of 0.4 mg. T-test was 
performed between the control group and each treatment group for each filter size. No significant 
difference was found for any filter size between control and any of the treatment groups. Smaller 
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debris particles (2 to 60 µm) suspended in the filtered fluid were analyzed using a Coulter 
Counter. In all the treatments, over 99.9 % of the debris particles were smaller than 10 µm and 
centered around 4 µm. Normalized debris particle distribution ranging from 2 to 60 µm was 
plotted vs. debris particle size for each treatment group in Figure 3.13. The absolute number of 
debris particles increased over 2 times from the SI0.7mm group to SI0.3mm group but didn’t change 
much between the two P- groups. 
 
Figure 3.12: Filter weight increases after treatment. 
 
 
Figure 3.13: Debris particle distributions are normalized by the maximal value of the 4 treatment groups. 
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For the 12 treatments using the microscopic inspection and Coulter Counter combination 
method, no debris particle pieces ≥ 300 µm were observed by microscopic inspection on the 
filters of any treatment. Table 3.3 shows the number percentage of the debris particles ranging 
from 2 µm to 300 µm for each of the two treatment groups. Over 99.9 % of the debris particles 
were smaller than 10 µm, with the largest particle at 153 µm. The debris particles became orders 
of magnitude less as the size increased from 10 µm to 100 µm. The total number of debris 
particles ranging from 100 µm to 300 µm observed for each of the 12 treatments with the 
maximum debris size was listed in Table 3.4. 
 
Table 3.3: Number percentage of debris particles 
Debris Diameter(µm) 2-10 10-30 30-60 60-100 100-300 >300 
SI 0.3mm, P(-)LS 30MPa 99.89% 0.11% <0.001% <0.0001% <0.0001% None 
SI 0.3mm, P(-)LS 36MPa 99.96% 0.04% <0.001% <0.0001% <0.0001% None 
 
Table 3.4: Observed debris particles larger than 100 µm 
Group SI 0.3mm, P(-)LS 30MPa SI 0.3mm, P(-)LS 36MPa 
Clot No. 1 2 3 4 5 6 7 8 9 10 11 12 
No. of Particles 1 0 0 0 0 2 0 6 3 0 2 0 






As expected, the cavitation bubble cloud was completely confined inside the targeted clot 
within the vessel lumen. No cavitation bubble cloud was in contact with the vessel wall on 
ultrasound imaging. Ultrasound images of cavitation bubble clouds in the vessel phantom, 
generated by shock scattering and intrinsic threshold mechanism respectively, are compared in 
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Figure 3.14. By using microtripsy via a single-cycle length pulse, shocking scattering was 
limited to avoid bubble cloud elongation and unexpected cavitation on vessel wall surface. As 
cavitation by intrinsic threshold mechanism was less affected by surrounding interfaces, 
microtripsy may become a better option for thrombolysis application by avoiding any cavitation 
on surrounding vessel walls.  
 
Figure 3.14: Cross-sectional ultrasound images of cavitation bubble clouds in the vessel phantom. The vessel 
phantom was filled with saline. Vessel wall is indicated by line arrow and bubble could is indicated by block arrow. 
Left: Using shock scattering mechanism (5-cycle pulses). Right: Using intrinsic threshold mechanism (microtripsy, 
1-cycle pulse). The same peak negative pressure was applied in both cases. 
 
 
3.4.2 Elimination of Vessel Damage 
 
As shown previously [26], cavitation was strongly correlated with clot fractionation. So 
the well-confined cavitation within the vessel lumen resulted in accurate clot recanalization. On 
the high-resolution B-mode images, the generated channels were confined in the clots within the 
vessel lumen and showed clear boundaries from the surrounding intact clot. The intact clots 
attached to the vessel wall didn’t show any speckle reduction suggesting no clot fractionation, 
which confirmed that no cavitation occurred near vessel walls.  
3.4.3 Accuracy of Cavitation Cloud Size Estimation 
 
Caution must be paid before trusting the estimation of cavitation cloud size. First, the 
hyperechoic region visualized on the b-mode images may not be the original cavitation bubble 
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cloud itself but the bubble nuclei after cavitation bubble collapse. It took more than 2ms to 
collect acoustic signals to form a b-mode image, whereas cavitation bubble collapses within 
several hundred microseconds. Second, since the bubble nuclei after collapse are dynamic, the 
size and shape of this hyperechoic region may change with the time delay and imaging 
parameters we used to look at it after each pulse. Third, with lesion developing during treatment, 
the change in both location and size of the hyperechoic region may also cause error in this 
averaging-based estimation.  
3.4.4 Predictions of Flow Channel Sizes 
 
Table 3.5 below lists the diameters of the flow channel, -6dB focal zone of the therapy 
transducer, supra-threshold estimations of focal region, and cavitation cloud diameters. The 
supra-threshold method estimates the treatment region by the area where the applied negative 
pressure exceeds the intrinsic threshold in the clot (27MPa) [30, 31]. Two-sided t-tests were 
performed to compare the diameters of flow channel with the other three categories. First, the 
flow channels generated by microtripsy were significantly smaller in the axial direction 
compared to the -6dB focal zone of the therapy transducer. Second, the supra-threshold 
estimations were statistically significantly different from the flow channel sizes. Compared to a 
better match between this supra-threshold estimation and the lesion size showed by Lin et al. 
[31], the mismatch observed in this study was probably related to cavitation memory effect by 
using a much higher PRF (50 Hz) compared to 1 Hz used by Lin et al. As Wang et al. [40] 
demonstrated that at the 50 Hz PRF, residual bubbles from previous pulses persisted and moved 
between pulses functioning as cavitation nuclei for subsequent pulses, which may effectively 
change the cavitation zone. Third, there is no significant difference between the major and minor 
diameters of cavitation cloud and those of flow channel in the 30 MPa P(-)LS case, suggesting 
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that the cavitation zone visualized by B-mode ultrasound image could provide a good predication 
of the flow channel sizes. The B-mode visualization of the cavitation cloud in this study was not 
optimized. Further investigation will be conducted to optimize the imaging parameters and 
address the issues discussed in the last section so that this technique may be used to predict flow 
channel sizes accurately and reliably.  
 
Table 3.5: Comparisons among the diameters of the flow channel, -6dB focal zone of the 
therapy transducer, supra-threshold estimations of focal region, and cavitation cloud diameters. 
Two-sided t-tests were performed to compare the diameters of flow channel with the other three. 
Superscript mark “ * ” indicates that this group is statistically significant ly different from the 
flow channel diameter group. Superscript mark “ ° ” indicates there is no statistically significant 













30 MPa 4.04 ± 0.49 mm 6.5 mm* 3.70 mm* 3.41 ± 0.54 mm° 
36 MPa 5.46 ± 0.36 mm 6.5 mm* 5.30 mm* 4.53 ± 0.65 mm* 
Minor 
Diameter 
30 MPa 2.03 ± 0.32 mm 1.3 mm* 1.10 mm* 1.95 ± 0.37 mm° 
36 MPa 2.77 ± 0.18 mm 1.3 mm* 1.45 mm* 2.12 ± 0.35 mm* 
 
3.4.5 Channel Size Controls 
 
It is clinically desirable to generate a sufficiently large channel to maximize the restored 
flow while minimizing the vessel damage. The capability of microtripsy to finely control the 
cavitation size by adjusting P- will potentially allow the formation of flow channel with different 
sizes for individual patients with different vein diameters, but still confined with the vessel 
lumen without damaging the vessel wall. In clinical situations the exact P- delivered at the target 
inside body can’t be directly measured. As the cavitation cloud can be directly seen on the real-
time images using ultrasound imaging, the applied microtripsy P- can be adjusted to achieve a 
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desired size of the cavitation cloud based on the imaging feedback while ensuring that the 
cavitation is well confined within the vessel lumen without contacting the vessel wall. This 
approach is supported by the match between the flow channel sizes and the cavitation cloud sizes 
measured by B-mode ultrasound image. As such the control of flow channel size may be realized 
via microtripsy in clinical situations. 
Although increasing P- allows enlarging the diameters (Dmajor and Dminor) of channel, to 
avoid potential vessel damage the maximal Dmajor is limited by the inner diameter of vessel. As 
the single focal zone shape is elliptical with the short axis significantly smaller than diameter of 
the vessel lumen, the cross sectional area of the flow channel can also be increased by steering 
the focus along the short axis (laterally) to create multiple lesions within one cross sectional 
plane. Our transducer is capable of electrically steering the focus laterally within a few 
millimeters to further enlarge channel and improve effectiveness of recanalization. As 
microtripsy utilizes extremely short, single-cycle pulses with long waiting time, the focus can be 
electrically scanned to other locations between pulses, thus the lateral steering strategy to achieve 
a larger, more circular flow channel can be implemented without increasing treatment time.   
3.4.6 Restored Flow Rate 
 
With our current in vitro setting (6.5 mm diameter and 3.7 mm Hg pressure), the restored 
flow rate could reach up to 500 mL/min. Compared to the control flow rate (640 mL/min) where 
the same pressure was applied but no blockage presented in the flow system, our treatment 
restored up to 78 %. In clinical situations, the normal blood flow rate in femoral vein ranges 
from 268 mL/min to 721 mL/min [37, 41] assuming a mean velocity of 13.88 cm/s. Compared to 
these clinical data, our 500mL/min recanalization rate suggests the potential of microtripsy to 
significantly improve blood circulation after treatment of DVT.  
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3.4.7 Treatment Time Optimization 
 
In this study the 2cm-long clots could be recanalized within 7 minutes. The treatment 
efficiency can be further improved with optimization of acoustic parameters. Three acoustic 
parameters can be optimized to improve the treatment efficiency, including peak negative 
pressure, dose of histotripsy pulses per location, and pulse repetition frequency. This study 
shows that the flow channel size and flow rate restored by microtripsy are higher with higher P-. 
The dose of 300 pulses per location used in this study was chosen empirically to ensure complete 
clot fractionation and is probably overdosed. As the clot properties can vary across patients and 
even an individual clot can be heterogeneous, we are investigating a new feedback method that 
can indicate the complete clot fractionation in real-time, which will allow us to adaptively apply 
the optimal dose at each treatment location during treatment [42, 43]. The treatment time can be 
further reduced by increasing the PRF, however higher PRF may increase the risk of heating the 
overlying tissue and lower treatment efficiency by introducing cavitation memory effect [40]. 
Further parameter study is warranted to identify the microtripsy parameter set that can rapidly 
and accurately create a desired flow channel through the clot without damaging the vessel wall 
or overheating the overlying tissue. 
3.4.8 Comparison of Different Scan Intervals 
 
The flow channel size also depends on the scan interval. There was noticeable difference 
of channel sizes and shapes between the treatment groups with the 0.7 mm and 0.3 mm scan 
intervals. The lesion volume at an individual focus generated by microtripsy is a raindrop shape 
with a main circular lesion and a smaller tail. The channels generated from the SI0.3mm group 
were larger and had elliptical shapes, which matched the volume and shape of the individual 
focal volume, while the channel generated in the SI0.7mm group was more circular with a smaller 
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opening. This difference was because the 0.7 mm interval was larger than the size of the tail, 
resulting in incomplete fractionated clot at the tail-end between the lesions at adjacent locations 
and a smaller opening. When the scan interval was equal or smaller than the tail (i.e. the 0.3 mm 
interval), raindrop shaped channels with larger opening was generated. Although smaller scan 
interval will results in more treatment locations on the path, the dose per location can be 
accordingly reduced due to more overlapping volume. As shown in this study, the smaller scan 
interval (0.3 mm) with the reduced dose per location (300 pulses) produced a larger flow channel 
with a faster treatment time (7 min for SI0.3mm vs. 10 min for SI0.7mm). 
3.4.9 Debris 
 
Sonothrombolysis studies have not seen clot debris large enough to cause significant 
embolism. Although debris particles generated in previous histotripsy studies were no greater 
than 100 µm and also unlikely to cause hazardous emboli, we wanted to confirm the new 
microtripsy parameters would produce debris in line with that observed previously [26, 27]. We 
used two methods to measure the debris particle size distribution. Using the filter weight and 
Coulter Counter combination method, weight increases of the dried filters before and after 
recanalization treatments were observed, but no significant difference was found between these 
increases and those in the control group and no debris particles were directly visualized on any of 
the filters. The filter weight increase may be due to sodium chloride crystal dried from residual 
saline on the filter. Changes of environmental humidity and temperature may also play a role in 
increasing the filter weight. The macroscopic inspection and Coulter Counter method was also 
used to characterize debris particles, which was expected to be more sensitive and accurate than 
the filter weight method. Debris particles larger than 100 µm were uncommonly observed and 
the largest debris particle was only 153 µm. The results using this method are also supported by 
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microscopic images of debris fluid smear [44] (Figure 3.15). Most of the particles appear to be 
red blood cells (RBC) or RBC fragments and the larger particles were clusters of RBCs. Particles 
of this size range are unlikely to form hazardous emboli, as 100 µm mechanical filters have been 
successful at preventing embolization in catheter-based thrombolysis procedures [45]. 
 
 
Figure 3.15: Example microscopic images of debris fluid smear from one treatment. (a) 10 times magnification. 
White arrow points to a large debris particle (~40 µm). (b) 40 times magnification. Most of individual particles are 





 Histotripsy has been previously demonstrated to be a promising non-invasive and drug-
free thrombolysis strategy with the advantages of fast treatment and real-time image guidance. 
However, histotripsy using conventional shock-scattering approach may generate cavitation on 
the vessel wall, leading to potential vessel damage. In this chapter, a new histotripsy approach, 
Microtripsy, was shown to precisely and consistently confine the cavitation within the vessel 
lumen, avoiding any contact with the vessel wall to prevent vessel damage. Microtripsy 
accurately generated flow channels inside the vessel phantom with 6.5-mm inner diameter, 
which is at the lower end of the reported DVT vein diameter range [37]. The flow channel 
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created by microtripsy formed opening up to 60 % of the vessel lumen size and restored flow up 
to 500 mL/min. The 2cm-long clot was recanalized within 7 min and the generated channel could 
be enlarged by increasing the peak negative pressures of microtripsy pulses. The debris particles 
generated by microtripsy were measured with over 99.9% smaller than 10 µm and the largest 
particle at 153 µm, which are unlikely to form hazardous emboli. Future work will focus on 
optimizing acoustic parameters of microtripsy to further enhance treatment safety and efficiency. 
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Noninvasive Thrombolysis using Microtripsy: A Parameter Study 
 
This chapter has been published in IEEE Transactions on Ultrasonics, Ferroelectrics, and 
Frequency Control. 2015; 62(12):2092-2105. © IEEE. Reprinted, with permission, from [1]. 
 
 
4.1 Introduction  
 
Thrombosis is the formation of a blood clot inside an artery or vein, blocking blood flow 
in the circulatory system. Arterial obstruction via thrombosis in the cerebral vasculature leads to 
stroke, which is a leading cause of disability and death in the United States [2]. The most 
common form of venous thrombosis is deep vein thrombosis (DVT), which occurs usually in the 
legs and can lead to pulmonary embolism (PE). DVT/PE (also called venous thromboembolism) 
affects over 300,000 people each year in the United States and causes deaths of 60,000 to 
100,000 [3]. Severely symptomatic patients may require thrombolytic treatments instead of 
simply taking anticoagulant medicines. The current standard thrombolytic treatment involves the 
infusion of thrombolytic drugs such as tissue plasminogen activator (tPA) [4, 5]. Administration 
of thrombolytic drugs systemically has limited effectiveness with long treatment time (several 
hours to days) and is associated with a high risk of major bleeding [6]. Catheter-directed 
thrombolysis has the advantage over systematic thrombolysis by means of local application at 
the thrombosis site, but it is invasive and still carries the risks of bleeding, vascular damage, and 
infections [7, 8]. 
Ultrasound has been shown to enhance or induce thrombolysis for several decades [9]. 
Significant efforts have been focused on enhancing the efficacy of thrombolytic drugs with 
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ultrasound [10-15], with several clinical trials showing promising results [16-18]. In addition, 
ultrasound combined with microbubble contrast agents has been demonstrated to successfully 
augment clot dissolution in the presence or absence of thrombolytic drugs [19-21]. Ultrasound 
has also been investigated as an independent thrombolysis method under approaches utilizing 
acoustic cavitation [22-27]. 
Histotripsy is non-thermal ablation method that mechanically fractionates soft tissue 
through well-controlled acoustic cavitation generated by microsecond-long, high-pressure 
ultrasound pulses [28-30]. The feasibility of using histotripsy as a noninvasive, drug-free, and 
image-guided thrombolysis technique was first demonstrated in vitro and in vivo by Maxwell et 
al. [25, 26]. In those studies, multi-cycle (usually ≥5 cycle) ultrasound pulses were used to 
generate the cavitation bubble cloud via a shock scattering mechanism [31]. Using the shock 
scattering approach, the cavitation cloud is less-confined and tends to be generated in contact 
with vessel wall where the weak nuclei reside, resulting in potential vessel damage from 
histotripsy treatment. A new histotripsy approach, termed microtripsy, has been recently 
investigated for thrombolysis application to improve treatment precision and avoid potential 
vessel damage [27]. Microtripsy uses an intrinsic threshold mechanism where a cavitation cloud 
is initiated via a single ultrasound pulse with only one high negative pressure phase. When the 
peak negative pressure directly exceeds a distinctive “intrinsic threshold” for the medium (27 
MPa for blood clots), a cavitation cloud is formed within the focal region exceeding the 
threshold [32, 33]. The location and size of the cavitation cloud generated using the intrinsic 
threshold mechanism is more reproducible and predictable than the shock scattering mechanism. 
Our microtripsy thrombolysis study showed that, cavitation can be precisely generated and 
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confined in the vessel lumen without contacting vessel wall, allowing for a precise flow channel 
to be created within the clot while minimizing the risk of vessel damage [27].   
In our previous microtripsy thrombolysis study, the pulse repetition frequency (PRF) of 
applied ultrasound pulses was fixed to 50 Hz and the treatment dose (i.e. the number of 
ultrasound pulses applied at each treatment location) was chosen to be more than sufficient for 
complete clot fractionation. A higher PRF is expected to result in a shorter treatment time. 
However, a previous study suggested that higher PRF (>10 Hz) introduced cavitation memory 
effects where residual bubble nuclei from collapse of transient cavities from the previous pulse 
might become cavitation sites for subsequent cavitation events. As a result, the cavitation might 
reoccur at the same locations from pulse to pulse and the per-pulse fractionation efficiency could 
be lowered [34]. In the case for thrombolysis, the cavitation memory effects may result in an 
incomplete flow channel and different distributions of clot debris particles. Also, there was a 
concern that using 1-2 cycles pulses with a high PRF (>10Hz) may still result in pre-focal 
cavitation on the vessel wall. The pre-focal cavitation on the vessel wall can potentially damage 
the vessel and weaken the focal cavitation within vessel lumen by shielding the ultrasound 
energy propagation to the treatment focus. Finally, when high PRF are utilized, residual bubble 
nuclei from cavitation memory effects may shift the location of cavitation towards the ultrasound 
transducer [35]. In such a situation, to avoid damage to the interior vessel wall, the treatment 
focus within vessel lumen would need to be relocated prior to treatment to compensate for the 
potential shift. 
This chapter explores the influence of treatment PRFs on microtripsy thrombolysis and to 
address the above concerns with high treatment PRFs. Microtripsy thrombolysis treatments using 
different PRFs were performed on blood clots in an in vitro flow model. As the number of pulses 
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necessary to completely fractionate the clot may vary with different PRF, we also tested different 
treatment doses (i.e., number of pulses) for each PRF. During each treatment, cavitation was 
monitored in real-time to detect any pre-focal cavitation incident. After treatments, the flow 
channels generated were characterized by 3D-scans using a high-frequency ultrasound imaging 
probe. Pre-focal cavitation, the size and shape of generated flow channel, and the relative 
location of flow channel with respected to the treatment focus were quantified. The size 
distribution of generated clot debris particles was also measured. By comparing these results 
between different treatment PRFs as a function of dose, an optimized treatment PRF was 
selected for future microtripsy thrombolysis studies. 
4.2 Methods and Materials 
 
4.2.1 Flow Model 
 
An in vitro flow model, similar to that described by Spengos et al. [36], was designed to 
mimic occlusive deep vein thrombosis where no blood flow is present but pressure is still applied 
on the clot. As shown in Figure 4.1, the flow model consisted of a reservoir, a pressure sensor, a 
vessel phantom, a filter, and a fluid collector. All the components were connected with silicone 
tubing (Masterflex L/S 17; Cole-Parmer, Vernon Hills, IL, USA). The reservoir was placed 
above the vessel phantom and filled with saline to perfuse the system using gravity-driven 
pressure. The vessel phantom was mounted horizontally inside a tank filled with degased water. 
The height difference between the saline level in the reservoir and the vessel phantom was 
adjusted to apply a constant pressure of 3.7 mm Hg, which was measured by the pressure sensor 
(MG-9V; SSI Technologies, Janesville, WI, USA). The 3.7 mm Hg was chosen according to 
reported femoral vein pressure [37, 38]. The valves remained open all the time during each 
treatment. Flow was restored when a channel was created through the clot by microtripsy 
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treatment. The restored flow, together with clot debris particles generated from the treatment, 
was passed through the filter and the filtered fluid was collected for further small particle 
analysis.  
 
Figure 4.1: Schematic diagram of the flow model. 
 
4.2.2 Vessel Phantom 
 
The vessel phantom was developed to mimic a human femoral vein (Figure 4.2). The 
phantom was made from urethane polymer (Urethane RTV Mold-Making System; Tap Plastics 
Inc., San Leandro, CA, USA), which has similar acoustic properties to human tissue [39]. Two 
parts of urethane (liquid) were first mixed at a 1:1 ratio and degased in a vacuum chamber to 
remove bubbles. The mixture was then poured carefully into a 3D-printed mold. The mold 
includes two components: a hollow tube with an 8 mm inner diameter and a rod in the center of 
the hollow tube. To make a stenosis in the vessel phantom, the rod was made with a 6.5 mm 
diameter on one side and a 4.2 mm diameter on the other side.  After solidification of the 
urethane (~ 24 hours), the vessel phantom was removed from the mold. The vessel phantom had 
an 8 mm outer diameter, a 6.5 mm inner diameter on one side, a 35% stenosis and a 4.2 mm 
inner diameter on the other side. The 6.5 mm inner diameter was chosen according to reported 
DVT vein diameters (5 to 21.7 mm) [40]. The stenosis in this in vitro setup provided additional 
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stabilization of the formed clot by preventing slipping under pressure. The vessel phantom was 
held by a 3D-printed frame with tube fittings at the two ends to connect the vessel in-line with 
the rest of the flow model [41]. 
 
Figure 4.2: The vessel phantom is held by a 3D-printed frame and can be connected in line with the flow model 
using tubing fittings. A 35% stenosis is located in the vessel phantom to fix the clot formed to one side so that it 
does not slip under pressure. The inner diameter is 4.2 mm on the left of the stenosis and 6.5 mm on the right. A clot 
is formed on the right side of the stenosis as shown in the figure. 
 
 
4.2.3  Clot Formation 
 
Fresh bovine blood was collected from a local abattoir. A citrate-phosphate-dextrose 
(CPD) solution (#C7165; Sigma-Aldrich Co., St. Louis, MO, USA) was immediately mixed with 
fresh bovine blood as an anti-coagulant at a ratio of 1 mL CPD per 9 mL blood. The blood 
sample was stored at 4°C and used within 72 hours. Before use, bovine blood was warmed up to 
the normal cow body temperature (38.6 °C). To stimulate the clotting cascade, calcium chloride 
(#21107; Sigma-Aldrich Co., St. Louis, MO, USA) was injected into bovine blood to a final 
concentration of 20 mM/L. To form clot inside the vessel phantom, the stimulated blood was 
poured into the vertically-placed vessel phantom with the stenosis sealed by a balloon catheter. 
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Any visible bubble was removed. After 2 hours in a water bath at 38.6 °C, the clot was matured 
and cross-linked with the vessel interior and stenosis. The balloon catheter was then removed 
and the vessel phantom was connected back into the flow model with the stenosis end of the clot 
distal to the pressure reservoir. The connecting tubes were carefully refilled with saline. All the 
clots in this study were made with a length of 2 cm. 
4.2.4  Microtripsy Thrombolysis System 
 
An integrated pre-clinical system for image-guided microtripsy thrombolysis was 
developed in our laboratory and used for all the treatments in this study (Figure 4.3). It includes 
three subsystems: microtripsy therapy, ultrasound imaging and positioning system. The therapy 
subsystem used a 1 MHz 18-element microtripsy transducer that was designed based on the 
anatomy of DVT patients and manufactured by Imasonic (S.A., Besancon, France) (Figure 4.3). 
The transducer had an effective 9.8 cm (lateral) x 8 cm (elevational) aperture and a 7 cm focal 
length. It was driven by a pulse amplifier developed in our lab to generate very short (< 2 
cycles), high intense ultrasound pulses. The focal beam volume (−6 dB) of the transducer was 
measured to be 6.5 mm (axial) x 1.3 mm (lateral) x 1.5 mm (elevational) at a peak negative 
pressure of 15 MPa using a fiber-optic probe hydrophone (FOPH) [42]. The imaging subsystem 
was developed based on a SonixTouch® imaging machine (Analogic Ultrasound, Vancouver, 
Canada).  An ultrasound probe with custom rectangular housing (L7.5MHz; Vermon, France) 
was inserted into the rectangular central hole of the therapy transducer to guide and monitor 
microtripsy thrombolysis treatment. Software development kits were provided by the 
SonixTouch
®
 manufacturer to allow custom application developments. The positioning 
subsystem included a multi-positioning arm and a compact motorized positioner on the arm. The 
therapy transducer was mounted on the compact positioner. With 6 degrees of freedom and a 
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range around 1 meter, the multi-positioning arm can be manually moved and hold using a 
press/release lock for coarse target localization. With 3 degrees of freedom and a range of 10 cm 
x 5 cm x 4 cm, the motorized positioner was controlled by both software and joy sticks for finer 
localization. Control software was developed to manage and coordinate the therapy, imaging, 
and positioning systems. 
 
 
Figure 4.3: Integrated microtripsy thrombolysis system. It consists of an ultrasound imaging system, a microtripsy 
therapy system, and a motorized positioning system. The insert shows the therapy transducer with a linear imaging 





The vessel phantom with an occlusive clot inside was connected to the flow model and 
placed in a tank filled with degassed water. Using the multi-positioning arm, the therapy 
transducer was manually placed above the vessel phantom and its lateral axis was oriented 
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perpendicular to the vessel phantom so that the cross section of vessel was imaged during 
treatment. Pre-treatment planning was performed to determine the treatment path prior to each 
microtripsy clot treatment following three steps. First, cavitation was generated in empty water 
field and the center of the hyperechoic cavitation region was marked as the treatment focus on 
the ultrasound imaging window. Second, guided by the real-time ultrasound images, the 
transducer was moved using the motorized positioner to align the treatment focus at the center of 
vessel lumen. The transducer was then adjusted to move the treatment focus from one end of the 
clot to the other end. Several locations (spaced around 3 mm) from one end of the clot (close to 
the pressure reservoir) to the other end were recorded by the control software. Third, after these 
locations were registered, the control software linearly interpolated these key locations into a 
scan path of denser treatment locations with an interval of 0.3 mm.  
For one treatment, the microtripsy thrombolysis system applied a fixed number of 
microtripsy pulses (dose) at each location with a fixed pulse repetition frequency (PRF) and then 
moved automatically to next location on the treatment path. A peak negative pressure of 30 MPa 
was used for microtripsy pulses throughout this study, as this pressure level was right above the 
intrinsic threshold and was shown to create precise flow channels in our previous microtripsy 
thrombolysis study. An example of microtripsy waveform is shown in Figure 4.4. Peak negative 
pressure larger than 20 MPa can’t be directly measured and therefore was estimated by linear 
summation (P(-)LS) of direct P- outputs from 3 separate groups of transducer elements (6 
elements per group). In this parameter study, three different PRFs (5, 50, and 100 Hz) combined 
with three treatment doses (20, 50, and 100 pulses) were examined. A maximal dose of 100 
pulses was chosen to ensure the generated flow channel was confined within the clot. Six clots 
were treated with each of the parameter combinations. Real-time ultrasound images for treatment 
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monitoring were recorded as a video throughout each treatment. Imaging with a central 
frequency of 7.5 MHz was synchronized with the microtripsy pulses. The depth of the image was 
6 cm and the cavitation focus was located in the center at a depth of 5 cm. There were 128 scan 
lines for each image. When a microtripsy pulse was fired, it scanned from left to right line by 
line (100 µs per line). There was a delay of ~6.4 ms to image the cavitation after a pulse fire. 
 
Figure 4.4: Pressure waveform of a microtripsy pulse. Because peak negative pressure larger than 20 MPa cannot 
be directly measured, this estimated waveform was linearly summed from the directly measured waveforms of 6 
separate element groups (3 adjacent elements per group). 
 
 
4.2.6 Cavitation Monitor 
 
Ultrasound image video taken during each treatment provided qualitative visualization of 
cavitation. Adopted from the previous studies [31, 43, 44], an acoustic cavitation detection 
method was also used to monitor cavitation in this study. One element in the therapy transducer 
was employed for both transmitting microtripsy pulse and receiving the backscattered signals of 
the microtripsy pulse from cavitation bubbles as well as emissions from bubble collapse. The 
element was connected to an oscilloscope (Lecroy372c, Teledyne LeCroy Inc., Chestnut Ridge, 
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New York, USA) through a high-voltage probe (PPE2kV, Teledyne LeCroy Inc., Chestnut 
Ridge, New York, USA). The oscilloscope was set in a sequential mode and synchronized with 
microtripsy pulses to digitize the received cavitation signals. Starting at 87 us after a microtripsy 
pulse was generated by the transducer, a 20 us long waveform of the backscatter signals of the 
therapy pulse from the cavitation bubble cloud was acquired with a sampling rate of 250 MHz. 
The 87 us delay time was chosen based on the round-trip travel time of ultrasound propagation to 
and from the cavitation focus. The 20 us time window was selected to cover the whole vessel 
region on the ultrasound propagation path. Before each treatment, a control waveform containing 
acoustic reflections only from vessel walls was acquired using a microtripsy pulse with a P- of 
20 MPa (below the intrinsic threshold for cavitation). During each treatment, 300 treatment 
waveforms containing both vessel reflections and backscatter signals from cavitation were 
collected.  
The primary purpose of monitoring cavitation in this study was to detect whether there 
was pre-focal cavitation on vessel walls when using different treatment PRFs. The control 
waveform was scaled by the ratio of the P- of the therapy pulses over 20MPa (control) to better 
estimate the reflected acoustic signal from vessel walls during treatment. Using the control 
waveform, the time windows corresponding to front vessel wall region (proximal to therapy 
transducer) and vessel lumen region were determined in each treatment waveform (Figure 4.5). 
When cavitation occurred, the signal amplitude at the corresponding temporal location on the 
treatment waveform was greatly increased as the incident therapy pulse was backscattered from 
cavitation bubbles. Cavitation was detected when the peak amplitude of the backscatter signal 
exceeds a threshold for each region, which was set as twice  the peak amplitude of the scaled 
control waveform in that region. The percentages of pre-focal cavitation occurrence on front 
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vessel wall and focal cavitation occurrence in vessel lumen were calculated for each treatment 
(the number of pulses when cavitation was detected/total number of measured pulses). 
 
Figure 4.5: Control waveform of cavitation monitor. The two bursts in the figure are the reflected signals from the 
front vessel wall (left) and rear vessel wall (right), respectively. The corresponding temporal zones of the Front 
Vessel Region (FVR) and Vessel Lumen Region (VLR) can be determined by these two reflections.  
 
4.2.7 Flow Channel Quantification 
 
To quantitatively evaluate flow channels generated by microtripsy with different PRFs 
and doses, each treated clot was scanned using a 20 MHz high-resolution ultrasound probe. The 
probe was separately mounted onto the motorized positioner after each treatment. With the 
imaging plane perpendicular to the vessel central axis, the probe was moved by the positioner 
from one end to the other end of the clot taking one cross-sectional image every 0.3 mm along 
the vessel. 67 scan images were collected from each treated clot. Since the fractionated clot 
region appeared hypoechoic (very low brightness on image) when flow was restored, whereas 
intact clot region was hyperechoic (high brightness on image), we applied a brightness threshold 
to detect the cross section of flow channel on each scan image. Inside the vessel lumen on each 
scan image, the area with pixel intensity less than 20 (0-255 overall range) was thresholded out 
as the cross section of the flow channel. The value of 20 was selected according to the intensity 
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histogram of the scan images. To quantify the size and shape of the flow channel, the cross area 
(Across) of the flow channel region was calculated and an ellipse was fitted into the flow channel 
region to estimate its major and minor diameters (Dmajor and Dminor) using a function provided by 
Matlab (MathWorks, Natick, MA, USA). To evaluate the influence of different PRFs and doses 
on flow channel location inside of clot, the axial location of flow channel (Laxial) was calculated 
as the distance from the center of the flow channel (actual treatment location) to the center of 
vessel lumen (intended target) along the axial direction (i.e. ultrasound propagation direction). 
The sharpness of channel boundary transitioning from unfractionated area to fractionated area 
was also quantified by measuring the width of boundary transition zone (Wbound), which was 
detected as the area with the pixel intensity higher than 20 but less than 30 outside the 
completely fractionated lesion. The mean Across, Dmajor, Dminor, Laxial and Wbound over all valid 
scan images of treated clots using the same PRF and dose were used to characterize the flow 
channel under this parameter combination.   
4.2.8 Restored Flow Measurements 
 
Restored flow rate was measured to evaluate microtripsy thrombolysis effectiveness 
under this in vitro environment. After the flow channel was created, the volume of downstream 
saline in the fluid collector within 30 seconds was measured. The restored volume flow rate was 
then calculated as the volume of the saline collected divided by the time. Owing to the brevity of 
the time period and the small change in reservoir volume, pressure was assumed to be constant 
over this time period. A control measurement with no blockage in the flow system was also 
conducted to compare with restored flow rate. 




There is a concern that clot debris particles generated by microtripsy thrombolysis may 
embolise to occlude downstream vessels or seed clotting elsewhere to create a new thrombus. To 
address this issue, a method combining macroscopic inspection and Coulter Counter analysis 
were utilized to measure clot debris particles generated during microtripsy treatment. When flow 
was restored in each treatment, clot debris was flushed by the restored flow and filtered by a 
filter sheet with a pore size of 300 µm. Macroscopic inspection was conducted to check if there 
was any debris particle trapped on the 300 µm filter. High-resolution optical images were taken 
of the filter sheet before and after each treatment and the number of distinguishable particles 
larger than 300 µm was counted and the size of individual large debris particles were measured. 
The filtered fluid with suspended debris particles smaller than 300 µm was analyzed using a 
Coulter Counter (Multisizer 3; Beckman Coulter, Brea, CA, USA). With this Coulter Counter, 
the measurable range of particles was from 2 to 60 µm using a 100-µm aperture tube and from 
60 to 300 µm using a 560-µm aperture tube [45]. The measurements using these two aperture 
tubes were combined to generate a distribution of particles from 2 to 300 µm. 
4.2.10 Statistics Analysis 
 
All statistical comparisons in this study were performed using Student’s t-test. P-values < 
0.05 were considered significant. Numerical data are expressed as mean ± standard deviation. 





Cavitation bubble clouds appeared as a dynamic hyperechoic region on real-time 
ultrasound images providing both location information and approximate size of cavitation 
bubble. According to the ultrasound videos taken during the treatments, no pre-focal cavitation 
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on front vessel wall was observed when using either 5 Hz or 50 Hz treatment PRF. Although pre-
focal cavitation was observed with higher treatment PRF (100 Hz), it happened infrequently and 
appeared small, weak, and sparse (Figure 4.6). Focal cavitation was still present even when the 
pre-focal cavitation occurred (Figure 4.6). In all the treatments, focal cavitation was well 
confined in the vessel lumen with no contact to the interior vessel wall (Figure 4.6).  
 
Figure 4.6: Ultrasound images of vessel lumen during treatment. Left: Focal cavitation at the center of the vessel 
lumen only (block arrow). Right: Focal cavitation (block arrow) with weak pre-focal cavitation (line arrow).  
 
 
Quantitative results were obtained using the acoustic cavitation detection method. The 
percentages of detected pre-focal and focal cavitation incidents during the treatments are shown 
in Table 4.1. Representative waveforms captured during treatment are also plotted in Figure 4.7. 
No pre-focal cavitation was detected when using 5 Hz treatment PRF. Pre-focal cavitation was 
rarely detected when using 50 Hz PRF (1.20%) and occasionally detected when using 100 Hz 
PRF (5.43%). Focal cavitation occurred persistently regardless of treatment PRF and whether 
pre-focal cavitation happened or not. These results matched well with our qualitative 
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Table 4.1: The percentages of detected pre-focal and focal cavitation. 





5 Hz 0.00 ± 0.00% 100% 
50 Hz 1.20 ± 0.51% 100% 
100 Hz 5.43 ± 1.82% 100% 
 
 
Figure 4.7: The waveforms of cavitation monitor during treatment. Left: Focal cavitation only. Right: Pre-focal 
cavitation and focal cavitation together. The vertical dashed lines divide the Front Vessel Region (FVR) and the 
Vessel Lumen Region (VLR).  
 
 
4.3.2 Flow Channel 
 
Flow channels generated using different treatment PRFs and doses were thoroughly 
scanned using the high-resolution ultrasound imaging probe. Representative cross-sectional 
images of the flow channels after the microtripsy treatments are shown in Figure 4.8. The 
differences of the flow channels generated using different treatment PRFs were analyzed from 




Figure 4.8: Representative high-resolution ultrasound images of flow channel generated from each treatment 
parameter combination. The generated flow channels show as the hypoechoic zones inside clots. Ultrasound 




Figure 4.9: The cross-sectional area (Across) of generated flow channel using each treatment PRF was shown as a 





The flow channel size was quantified as the cross area (Across) of the flow channels on 
ultrasound scan images. The mean Across and its standard deviation using each treatment PRF was 
shown as a function of dose in Figure 4.9. With a final dose of 100 pulses, the mean Across of 
flow channel generated using 5, 50 and 100 Hz PRF were 3.60, 3.96 and 4.65 mm
2 
respectively. 
One-sided t-tests showed that the final flow channel generated using 100 Hz PRF was 
significantly larger than those using 50 Hz (P<0.001) and 5Hz (P<0.001). Flow channel 
developments as a function of dose showed different trends when using different PRFs. The rate 
of increase in Figure 4.9 illustrated the per-pulse efficiency of clot fractionation. The highest 
rate of increase at the beginning of treatment was observed for 5 Hz PRF, which indicated better 
per-pulse fractionation efficiency than those using 50 and 100 Hz PRF. After 20 pulses, the rate 
of increase almost plateaued. For 50 Hz PRF, a slower rate of increase was observed compared 
to 5 Hz PRF but faster than 100 Hz before 20 pulses. As more pulses were applied, the rate of 
increase gradually decreased but it did not reach complete saturation within 100 pulses. The 
lowest rate of increase at the start of the treatment was observed for 100 Hz PRF. However, as 
the treatment continued, the rate of increase remained almost linear all the way up to 100 pulses. 
By fitting 5-degree polynomials into the developing curves of flow channel in Figure 4.9, it was 
estimated to take 28, 73 and 89 pulses to reach 90% of flow channel size generated by 100 pulses 
for 5, 50 and 100 Hz PRF respectively. These trends suggested that higher treatment PRF had 
lower per-pulse fractionation efficiency (rate of increase) but longer growth “period” before 
saturation. 100 Hz PRF were 20 times faster than 5Hz PRF to reach the same dose, which 





- Location  
 
Figure 4.10: The axial location (Laxial) of generated flow channel using each treatment PRF was shown as a function 
of dose. (N = 6 × 67). 
 
 
The relative location of the flow channels generated by different PRFs were evaluated 
using channel axial location (Laxial), which was defined as the axial distance from the cross-
sectional center of flow channel (actual treatment location) to the cross-sectional center of the 
vessel lumen (intended target). For all the treatments, the center of the treatment focus was 
rigidly placed at the center of the vessel lumen. The mean Laxial of flow channel generated by 
each treatment PRF is shown in Figure 4.10 as a function of treatment dose. For 5 Hz PRF, the 
center of the generated flow channel remained around 0.35 mm above the vessel center. For 50 
and 100 Hz PRF, the flow channels were first generated approximately 0.9 mm above the vessel 
center (closer to the therapy transducer). As more pulses were applied, the centers of flow 
channels were shifted back towards the vessel center and finally stayed at around 0.6 mm above 
the vessel center. As shown in Figure 4.8, the flow channels generated by 5 Hz PRF were 
enlarged symmetrically with increasing the number of pulses while retaining the center location, 
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whereas the flow channels generated by 50 and 100 Hz PRF showed an asymmetric growth and 
their center locations shifted along the direction of ultrasound propagation.  
- Shape 
 
Figure 4.11: The ratio (RD) of the major diameter over the minor diameter of generated flow channel using each 
treatment PRF was shown as a function of dose. (N = 6 × 67). 
 
 
The shape of flow channels created using different treatment PRFs were quantified as the 
ratio (RD) of major diameter (Dmajor) over minor diameter (Dminor) of the cross sections of flow 
channels. The mean RD of each treatment PRF is shown in Figure 4.11 as a function of treatment 
dose. A RD value of 1 indicates a circular shape and higher RD indicates a narrower cross section 
of flow channel. Overall, higher treatment PRF created narrower flow channels (higher RD). At 
the beginning of treatment, 50 Hz and 100 Hz PRF had a RD of 3.33 and 2.99, respectively, 
whereas 5 Hz PRF had a RD smaller than 2.5. RD at 50 and 100 Hz PRF decreased by 5.7% and 
7.2 % respectively as the dose increased from 20 to 50 pulses and remained almost the same 
afterwards. However RD at 5 Hz PRF increased by 3.6% from 20 to 50 pulses and continued 
increasing by 7.0% from 50 to 100 pulses. After 100 pulses, RD was 2.66, 2.77, and 3.13 for PRF 
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of 5, 50, and 100 Hz, respectively, which indicated a more elongated elliptical flow channel at a 
higher PRF. 
 
- Boundary Sharpness 
 
Figure 4.12: The width of boundary transition zone (Wbound) of generated flow channel using each treatment PRF 
was shown as a function of dose. (N = 6 × 67). 
 
 
The boundary sharpness of flow channels generated using different treatment PRFs were 
quantified as the width of boundary transition zone containing partially fractionated region 
outside the completely fractionated flow channel (Wbound). The mean Wbound of each treatment 
PRF is shown in Figure 4.12 as a function of treatment dose. As shown, when using 5 Hz PRF, 
Wbound remained at approximately 0.11 mm as more pulses applied. In the cases of 50 and 100 
Hz PRF with small dose (20 pulses), Wbound was larger (0.135 ± 0.020 mm for 50 Hz PRF and 
0.154 ± 0.025 mm for 100 Hz PRF). As the dose increased all the way to 100 pulses, Wbound 
using 50 and 100 Hz PRF was decreased to a level close to that at 5 Hz PRF. 





Figure 4.13: Restored flow rates of each treatment parameter combination. Treatments associated with creation of 
larger cross-sectional area opening were associated with larger flow rates. (N = 6). 
 
 
Prior to any treatment, no flow was observed on color Doppler imaging. After each 
microtripsy thrombolysis treatment, flow was successfully restored even with the minimal dose 
(20 pulses). The restored flow rate was measured after each treatment. With the constant pressure 
(3.7 mm Hg) applied, larger channel would be expected to permit higher flow rate, which is 
confirmed by the flow rate results shown in Figure 4.13. With 20 pulses, 5 Hz PRF had the 
highest flow rate (185mL/min) whereas for 100 Hz PRF it was only 60 mL/min. However, with a 
final dose of 100 pulses, both 50 and 100 Hz PRF achieved a mean flow rate over 300 mL/min, 
higher than that of 5 Hz PRF (276 mL/min). As a reference, the flow model with no blockage 
had a flow rate of 640 mL/min under the same pressure. 
4.3.4 Debris Size Distribution 
 
According to the Coulter Counter measurements, all the treatments shared a very similar 
debris particle distribution from 2 to 300 µm, regardless of the treatment PRF and dose used. A 
representative distribution of debris particles is shown in Figure 4.14. It was normally 
distributed with an expectation of 4.2 µm and over 99.9 % of the debris particles were smaller 
than 10 µm. The debris particles became orders of magnitude less as their size increased from 10 
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µm to 100 µm. Detailed results of debris particles larger than 100 µm are presented as follows. 
The average number of debris particles from 100 to 300 µm from treatments using different 
PRFs and doses were shown in Table 4.2. Very few particles larger than 100 µm were observed 
after each treatment and there was no significant difference between different treatment PRFs 
and doses. The largest sizes of debris particles smaller than 300 µm from different treatments 
were shown in Table 4.3. The largest particle to pass through the 300 µm filter was 236 µm, 
which was generated from a treatment with 100 Hz PRF and 50 pulses dose. The total number of 
debris particles trapped on the 300 µm filter sheets, together with their sizes, is shown in Table 
4.4. No particle > 300 µm was trapped in 20 out of the 28 clot treatments. In 7 out of the 28 
treatments, there was only one particle > 300 µm trapped per treatment. And in only one 
treatment, there were two particles trapped together. The large particles (400, 570 and 630 µm) 
all appeared in treatments using 5 Hz PRF. 
 






Table 4.2: Average number of particles >100 µm over 6 treatments for each parameter set. 
 
20 Pulses 50 Pulses 100 Pulses 
PRF 5 Hz 0 ± 0 7.0 ± 4.2 2.3 ± 2.6 
PRF 50 Hz 7.0 ± 3.3 3.3 ± 2.9 3.3 ± 3.9 
PRF 100 Hz 5.3 ± 4.3 14.0 ± 5.8 4.7 ± 4.4 
 
Table 4.3: Largest particle size <300 µm. 
 20 Pulses 50 Pulses 100 Pulses 
PRF 5 Hz 93 µm 128 µm 110 µm 
PRF 50 Hz 148 µm 102 µm 104 µm 
PRF 100 Hz 126 µm 236 µm 114 µm 
 
Table 4.4: Particles larger than 300 µm. The underline indicates they are from the same 
treatment. 
 
20 Pulses 50 Pulses 100 Pulses 
PRF 5 Hz 1 (307 µm) 1 (630 µm) 2 (570, 400 µm) 
PRF 50 Hz 0 0 1 (300 µm) 






For all PRFs, focal cavitation was generated within the vessel lumen without contacting 
the vessel wall. No pre-focal cavitation was observed at 5 Hz PRF. As treatment PRF was 
increased to 50 and 100 Hz, instances of pre-focal cavitation were observed to occur on the front 
vessel wall during the treatments. However, because of the low frequency of occurrence (< 6%) 
and sparse bubble appearance, the pre-focal cavitation is expected to have limited impact on 
treatment efficacy and is unlikely to cause clinically relevant damage to exterior vessel wall, 
which has previously been showed to be resistant to cavitation damage [46]. However, further in 
vivo evaluation is necessary to validate this hypothesis. The cause of the pre-focal cavitation with 
higher PRF is potentially associated with both the water-vessel interface and cavitation memory. 
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In our experimental setup, the water-vessel interface was about 4 mm from the treatment focus in 
the vessel lumen closer to the ultrasound transducer. Bubble nuclei tend to reside on this 
interface and a previous study suggested the cavitation threshold was lowered at the tissue-fluid 
interface [47]. With higher PRF, residual bubble nuclei from cavitation persisted on the interface 
between microtripsy pulses due to cavitation memory and made the cavitation generation on the 
interface easier by acting as seeds for subsequent pulses. So with the enhancement by cavitation 
memory effects using higher PRF [48-50], pre-focal cavitation was manifested at the vessel 
interface.  
In this chapter, we used the acoustic signals received from one transmit element to detect 
cavitation incidents. This method served well to detect whether a cavitation incident occur on the 
front vessel wall and/or in the vessel lumen, but the location of cavitation could not be accurately 
extracted. Potentially the accuracy and sensitivity of cavitation detection can be further improved 
by using one or more separate ultrasound transducers with higher frequency.   
4.4.2 Flow Channels 
 
With different treatment PRFs, the location, size, and shape of created flow channels 
varied, and the progression of the flow channel generation also changed. At 5 Hz PRF, the flow 
channel was generated consistently at the target focal location in the vessel lumen. Using high 
PRFs (50 and 100 Hz), the lesion was first generated at the front of the focal region in the vessel 
(close to the front vessel wall and the transducer) and then developed back towards the vessel 
center away from the transducer where the treatment focus was originally placed. The reason 
why at higher PRF the lesion started closer to the transducer and grew asymmetrically away 
from the transducer is potentially related to the cavitation memory effects.  At the beginning of 
treatment, residual bubble nuclei were formed from the first few pulses and trapped all over the 
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focal region in the clot. With a high PRF, a subsequent ultrasound pulse arrived before the 
complete dissolution of residual bubble nuclei produced from the previous pulse. The nuclei 
proximal to the transducer acted as seeds to cause onsite cavitation, which absorbed and shielded 
the incident acoustic energy from propagating further towards the treatment focus, resulting in a 
cavitation cloud at the front of the treatment focal region. As more pulses were applied, the clot 
at the front of the focal region was fractionated, creating a small liquefied clot zone and a fluid-
tissue interface. Then the clot was gradually eroded from the liquefied region and grew away 
from the transducer towards the vessel center. Using low PRF (5 Hz), the lesion was first 
generated at the vessel center and then enlarged radially. In this case, residual bubble nuclei were 
probably dissolved before the subsequent ultrasound pulse, minimizing the cavitation memory 
effects.  
Per-pulse fractionation efficiencies were also different between these treatment PRFs, 
which can be potentially explained by the same rationale above based on the cavitation memory 
effects. At the beginning of fractionation, 5 Hz PRF showed better per-pulse fractionation 
efficiency probably because the cavitation was intrinsically generated covering the entire focal 
region in the vessel center without memory effects. As clot in the focal region was quickly 
fractionated using 5 Hz PRF, the per-pulse fractionation efficiency decreased significantly after 
20 pulses because less and less clot volume could be broken down in the focal region. But for 50 
and 100 Hz PRF, since a small lesion was generated on the proximal side and the clot was then 
gradually eroded from the lesion and expanded away from the transducer, the lesion size still 





Only a few (less than 20 average) debris particles > 100 µm were observed per treatment 
in this study. Only a total of nine debris particles > 300 µm were observed in 8 out of the 28 
treatments. From Table 4.4, we can see the largest particles (570 µm, 630 µm) were observed 
when using 5 Hz PRF. This may be associated with the low temporal fractionation rate of 5 Hz 
PRF.  At the end of recanalization, when fractionating the last clot segment, flow started to 
restore. Due to the slow fractionation of 5 Hz PRF, large clot pieces might be swept away before 
fractionated into smaller pieces. In contrast, since high treatment PRF has a much higher 
temporal fractionation rate, large clot pieces at the end of treatment might be fractionated down 
quickly before major flow was restored.  
Our previous study using a PRF of 50 Hz and an increased dose of 300 pulses showed no 
debris particles > 300 µm and less 100-µm-level particles, which indicates increasing treatment 
dose can probably eliminate large debris particles [27]. The debris observed in this study can be 
considered as the worst possible case. Even with this worst case, the generated debris shouldn’t 
cause any severe embolism in lung in the DVT application. First, the largest particle observed 
overall was only 630 µm. According to the morphometry of pulmonary arterial system reported 
by Singhal et al. [51], 500-µm-level particles may only obstruct one arteriole of order 9 which 
supplies only 0.016% of total capillary beds. Second, the number of debris particles larger than 
100 µm from one treatment was very small (less than 20), which wouldn’t be expected to cause 
massive pulmonary embolism. Third, mechanical thrombectomy treatments generate clot 
particles up to 1000 µm with no severe embolism reported from human patient treatments [52-
54].  




Even though 5 Hz PRF avoids the pre-focal cavitation formation, it generates cavitation 
consistently at the geometric focal region, and has better per-pulse fractionation efficiency at the 
treatment beginning, overall, 50 or 100 Hz PRF may be a better choice for microtripsy 
thrombolysis to use clinically due to the larger flow channels, smaller debris particles, and much 
higher temporal fractionation rate. Compared to 5Hz PRF, the higher PRFs in this study created 
larger flow channels after 100 pulse dose, and the maximal size of debris particles was smaller. 
The higher PRFs have a higher temporal fractionation rate and can shorten treatment time 
significantly. Assuming a dose of 300 pulses is used in clinical situation to minimize the debris 
particle size, it takes only about 15 minutes for microtripsy to recanalize a 10-cm long clot using 
100 Hz PRF compared to hours for 5Hz PRF. Reduced treatment time can be a very competitive 
advantage over the current thrombolysis treatments. We also see less large debris particles >300 
µm generated using higher PRF. With this observed trend, it is reasonable to consider even 
higher PRF which may achieve the same or better results with shorter treatment time. The reason 
why we didn’t get a chance to try PRF ! 100 Hz was the limitation of the therapy transducer. 
Since it was outputting a very high acoustic pressure, we were worried about damaging the 
transducer’s piezoelectric elements by heating with higher PRF.  
Despite these favorable results of using 50 and 100 Hz PRF, further investigation is still 
needed to evaluate the risk of potential vessel damages. It should be noted that sparse and 
infrequent pre-focal cavitation was observed on the vessel wall using 50 or 100Hz PRF. We were 
not able to evaluate this risk using this vessel phantom but future in vivo experiments may 
provide us a more detailed answer regarding this concern. In addition, using a higher PRF, the 
cavitation started closer to the transducer and grew away from the transducer, and the lesion 
center did not align exactly with the center of the geometric focal zone. Though with imaging 
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feedback we can take that into account in the pre-treatment planning to ensure the focal 
cavitation zone is completely confined within the vessel lumen, further in vivo evaluation of this 
offset is needed.  
4.4.5 Future Work 
 
Freshly formed clots were used in this study to mimic acute thrombosis. Literature shows 
that chronic retracted clots are more resistant to sonothrombolysis treatments [55, 56]. We plan 
to evaluate the efficacy and safety of the microtripsy thrombolysis on retracted clots. In addition, 
we are currently investigating a new real-time imaging feedback (Bubble-induced Color Doppler 
[57, 58]) for histotripsy thrombolysis treatment, and we plan to incorporate this feedback with 
microtripsy thrombolysis to adaptively deliver the optimal dose at each treatment location during 
treatment. Finally, in vivo studies will be conducted to validate the feasibility, safety and efficacy 
of microtripsy thrombolysis in a porcine deep vein thrombosis model [26, 59]. Since there may 
be a difference in cavitation behavior between in vitro and in vivo settings, we want to confirm 
what we observed in this in vitro study still applies in vivo.   
4.5 Conclusion 
 
 This chapter investigated the effects of PRF (5, 50, and 100 Hz) on microtripsy 
thrombolysis. The results demonstrated that focal cavitation was always well-confined in the 
vessel lumen without contacting the vessel wall regardless of the PRF used. Pre-focal cavitation 
on the vessel wall was occasionally observed when using 50 and 100 Hz PRF, but it appeared 
weak and infrequently. The 5 Hz PRF showed the best per-pulse fractionation efficiency at the 
beginning of treatment, but the 50 and 100 Hz PRFs generated larger flow channels with much 
shorter treatment times over the course of the treatment. In addition, results showed fewer large 
debris particles were observed with higher PRFs. Overall, the results of this study suggest that 50 
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or 100 Hz PRF may be a better choice for microtripsy thrombolysis to use clinically due to the 
larger resulting flow channel, shorter treatment time, and smaller debris particles. Further in vivo 
evaluation of potential vessel damage and treatment efficacy using high PRF for microtripsy 
thrombolysis is necessary and underway. 
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5.1 Introduction  
 
Thrombosis is the formation of a blood clot in the cardiovascular system that prevents 
blood from circulating. Arterial thrombosis in the cerebral vasculature leads to ischemic stroke, 
which is a leading cause of disability and death in the United States [2]. The most common form 
of venous thrombosis is deep vein thrombosis (DVT), which occurs predominantly in the legs 
and can sometimes lead to lethal pulmonary embolism (PE). DVT/PE (also called venous 
thromboembolism) affects over 300,000 people and causes deaths of 60,000 to 100,000 each 
year in the United States [3]. Patients with more extensive thrombosis sometimes require 
thrombolytic treatments. The current gold standard of thrombolytic treatment involves the 
infusion of thrombolytic drugs such as tissue plasminogen activator (tPA) [4, 5]. Systemic 
administration of thrombolytic drugs has limited effectiveness with long treatment time (several 
hours to days) and is associated with a high risk of major bleeding [6]. Catheter-directed 
thrombolysis has the advantage over systemic thrombolysis through local application at the 
thrombosis site, but it is invasive and carries the risks of bleeding, vascular damage, and 
infections [7, 8]. 
Ultrasound has been investigated as a tool to enhance or induce thrombolysis for several 
decades [9]. Significant efforts have been focused on enhancing the efficacy of thrombolytic 
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drugs using ultrasound [10-15], with several clinical trials showing promising results [16-18]. In 
addition, ultrasound combined with microbubbles has been demonstrated to successfully 
augment clot dissolution in the presence or absence of thrombolytic drugs [19-23]. Ultrasound 
has also been studied as a stand-alone thrombolysis method under approaches utilizing acoustic 
cavitation [24-30]. 
Histotripsy is a non-thermal tissue ablation method that mechanically fractionates soft 
tissue via well-controlled acoustic cavitation generated by microsecond-long, high-pressure 
ultrasound pulses [31-33]. The potential of using histotripsy as a non-invasive, drug-free, and 
image-guided thrombolysis method was demonstrated both in vitro and in vivo by Maxwell et al. 
[27, 28]. Multi-cycle (usually ≥ 5 cycles) ultrasound pulses were used in those studies to 
generate cavitation bubble clouds via a shock scattering mechanism [34]. A new histotripsy 
approach, termed microtripsy, has been recently investigated for thrombolysis application to 
improve treatment precision and avoid potential vessel damage [29, 30, 35]. In microtripsy, a 
cavitation cloud is initiated via a single-cycle ultrasound pulse with only one high, negative 
pressure phase exceeding a very distinct negative pressure intrinsic threshold of the medium [36, 
37]. The location and size of the cavitation cloud generated using microtripsy through the 
intrinsic threshold mechanism is more reproducible and predictable than the shock scattering 
mechanism [36, 37]. In those microtripsy thrombolysis studies,  cavitation was precisely 
generated and confined in the vessel lumen without contacting the vessel wall, allowing for a 
precise flow channel to be created within the clot while minimizing the risk of vessel damage 
[29].   
Previous studies showed that drug-mediated thrombolysis, including ultrasound-enhanced 
thrombolysis, was difficult to achieve with retracted clots [38-40]. As a clot is formed, clot 
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retraction initiated by platelets occurs and changes the structure and composition of the clot 
remarkably as it ages over time [41, 42]. In the clot retraction process, the fibrin network shrinks 
and effectively increases fibrin density per unit of clot volume and/or decreasing plasminogen 
concentration, and results in lower porosity and reduced permeability [43-45]. The high 
resistance of retracted clots to drug-mediated thrombolysis is believed to be due to the reduced 
permeability of the retracted clot to the thrombolytic agents. 
Unlike drug-mediated thrombolysis that depends on the permeation of thrombolytic 
agents into the clot, microtripsy fractionates clots by controlled cavitation. In the previous 
microtripsy thrombolysis study, a fast lysis rate was achieved with unretracted clots. Retracted 
clots are stiffer than unretracted clots and are expected to be more resistant to histotripsy-induced 
cavitation and fractionation [46, 47]. We hypothesize that microtripsy is effective to treat 
retracted clots, but with reduced treatment efficacy compared to unretracted clots. We further 
hypothesize that the treatment efficacy for retracted clots can be enhanced using treatment 
strategies incorporating electronic focal steering. By using a phased-array transducer with 
electronic focal steering capability, the treatment focus can be steered to enlarge the flow 
channel through the retracted clot without additional mechanical movements of the therapy 
transducer. These hypotheses are tested in this chapter by investigating the treatment efficacy of 
microtripsy thrombolysis on retracted clots and exploring efficacies of different microtripsy 
thrombolysis strategies incorporating electrical focal steering. Retracted clots were prepared in 
vitro following a protocol described by Sutton et al. [40], and their elasticity was characterized 
quantitatively. The retracted clots were treated in an in vitro flow model using three different 
strategies: single-focus strategy, electronically-steered multi-focus strategy and a dual-pass 
multi-focus strategy. After treatments, the generated flow channels were 3D-scanned using a 20 
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MHz ultrasound imaging probe, and the sizes of the flow channels were quantified. The restored 
flow and the distribution of generated clot debris particles were also measured. The treatment 
results of retracted clots were compared with those of the unretracted clots from a previous 
study. The treatment efficacies using three different microtripsy thrombolysis strategies were 
also compared side by side. 
5.2 Materials and Methods 
 
5.2.1 Flow Model 
 
An in vitro flow model, which has been described previously [29, 30], was deployed in 
this study. The flow model was designed to mimic the condition of occlusive venous thrombosis, 
where blood flow is completely blocked by the thrombus but blood pressure still applies. A 
saline reservoir, a pressure sensor, a vessel phantom, a filter, and a fluid collector were 
connected in sequence with silicone tubing (Masterflex L/S 17; Cole-Parmer, Vernon Hills, IL, 
USA) (Figure 5.1). The saline reservoir was placed higher than the rest of the system for 
perfusion under gravity-driven pressure. With an occlusive thrombus fixed inside, the vessel 
phantom was mounted horizontally in a tank filled with degassed water. The height difference 
between the saline level in the reservoir and the vessel phantom was set to apply a constant 
pressure of 3.7 mm Hg, which was measured by the pressure sensor (MG-9V; SSI Technologies, 
Janesville, WI, USA). A pressure of 3.7 mm Hg was chosen according to reported femoral vein 
pressure [48, 49]. The femoral vein in the upper leg is where DVT often occurs. The therapy 
transducer was positioned inside the tank facing the vessel phantom to conduct the microtripsy 
recanalization treatment. When a channel was generated through the clot, the restored flow, 
together with clot debris particles generated from the treatment, was passed through the filter, 




Figure 5.1: Schematic diagram of the in vitro flow model. 
 
 
The vessel phantom was developed in-house to mimic a human femoral vein (Figure 
5.2). It was made from urethane polymer (Urethane RTV Mold-Making System; Tap Plastics 
Inc., San Leandro, CA, USA), which has acoustic properties similar to human tissue [50]. The 
vessel phantom had an 8 mm outer diameter, a 6.5 mm inner diameter on one side, and a 4.2 mm 
inner diameter (35% stenosis) on the other side. The method of making the vessel phantom has 
been described previously in detail [29]. The 6.5 mm inner diameter was chosen according to 
reported DVT vein diameters (5 to 21.7 mm) [51]. The stenosis in this in vitro setup stabilized 
the clot and prevented it from flowing away during the treatment under pressure. The vessel 
phantom was held by a 3D-printed frame with tube fittings at the two ends to connect the vessel 




Figure 5.2: The vessel phantom was held by a 3D-printed frame and could be easily connected in line with the flow 
model using tubing fittings. A 35% stenosis in the vessel phantom was used to stabilize the clot so that it did not slip 
under pressure. The inner diameter was 4.2 mm on the downstream side of the stenosis and 6.5 mm on the upstream 
side. A clot was inserted to the upstream side of the stenosis as shown in the figure. 
 
 
5.2.2 Retracted Clot Formation 
 
Retracted clots were formed following a protocol similar to that described by Sutton et al. 
[40]. Fresh bovine blood was collected from a local abattoir. A citrate-phosphate-dextrose (CPD) 
solution (#C7165; Sigma-Aldrich Co., St. Louis, MO, USA) was immediately mixed with fresh 
bovine blood as an anti-coagulant at a ratio of 1 mL CPD per 9 mL blood. All the blood samples 
were used within the same day as they were collected. The bovine blood was first warmed up to 
the normal cow body temperature (38.6 °C). To stimulate the clotting cascade, calcium chloride 
(#21107; Sigma-Aldrich Co., St. Louis, MO, USA) was injected into the blood to a final 
concentration of 20 mM/L. To form a retracted clot, the stimulated blood (6.5 mL) was carefully 
poured into a hydrophilic glass tube (Borosilicate Glass Tubing, GSC International Inc., Nixa, 
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MO, USA) with an inner diameter of 8.5 mm. After 3 hours in a water bath at 38.6 °C, the tube 
with newly formed clot inside was moved into refrigeration and stored at 4°C for 7 days to allow 
for retraction.  
 
Figure 5.3: A clot was retracted in a hydrophilic glass tube after 7 days in 4°C incubation. The serum extruded from 
the clot can be clearly distinguished. 
 
After the 7-day incubation, the clot shrank and translucent serum was separated from the 
clot (Figure 5.3). The degree of clot retraction was quantified by measuring the serum volume 
left after taking out the retracted clot [53]. To ensure a reasonable consistency in degree of 
retraction, a retracted clot was selected to use only if its serum volume was within a range from 3 
to 3.2 mL. The qualified clot usually had a diameter around 6.5 mm and a length around 10 cm. 
The 10-cm long clot was cut into 2-cm length clots for individual experiments. Prior to each 
experiment, three steps were followed to place and fix the clot inside the vessel phantom. First, 
the clot was warmed up to 38.6 °C in fresh bovine blood. Second, the bovine blood with the clot 
inside was stimulated by calcium chloride with a final concentration of 20 mM/L. Third, the clot 
with the stimulated blood coating was inserted into the vessel phantom from the 6.5 mm inner-
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diameter side all the way to the stenosis side. The vessel phantom was then placed in a water 
bath at 38.6 °C, and after 2 hours the blood coating clotted and cross-linked the retracted clot to 
the interior of the vessel phantom like glue. The vessel phantom with the clot fixed inside was 
then connected in-line with the rest of the flow model and the connecting tubes were refilled with 
saline. 
5.2.3  Therapy System 
 
An integrated, portable, ultrasound image-guided microtripsy thrombolysis system was 
developed in our laboratory (Figure 5.4). It includes three subsystems: a microtripsy therapy 
system, an ultrasound imaging system, and a positioning system. The microtripsy therapy 
subsystem used a 1-MHz 18-element therapy transducer manufactured by Imasonic S.A. 
(Besancon, France) (Figure 5.4). The transducer had an effective 9.8 cm (lateral) x 8 cm 
(elevational) aperture and a 7 cm focal length. It was driven by a pulse amplifier developed in-
house to generate very short (< 2 cycles), high-pressure ultrasound pulses. The focal beam 
volume (−6 dB) of the transducer was measured to be 6.5 mm (axial) x 1.3 mm (lateral) x 1.5 
mm (elevational) at a peak negative pressure of 15 MPa using a fiber-optic probe hydrophone 
(FOPH) [54]. Peak negative pressures larger than 20 MPa cannot be directly measured and 
therefore was estimated by linear summation (P(-)LS) of the peak negative pressure outputs from 
3 separate groups of the transducer elements (6 elements per group). The imaging subsystem was 
developed based on an Ultrasonix imaging machine (SonixTouch; Analogic Ultrasound, 
Vancouver, Canada). A custom ultrasound imaging probe with compact rectangular housing 
(L7.5MHz; Vermon, France) was embedded into the central hole of the therapy transducer to 
guide and monitor microtripsy thrombolysis treatment. The positioning subsystem included a 
multi-positioning arm and a compact motorized positioner at the end of the arm. The therapy 
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transducer was mounted on the compact positioner. With 6 degrees of freedom and a range 
around 1 meter, the multi-positioning arm can be manually moved and held using a press/release 
lock for coarse target localization. With 3 degrees of freedom and a range of 10 cm x 5 cm x 4 
cm, the motorized positioner was controlled by both software and joy sticks for much finer 
localization with a resolution of 0.1 mm. Control software was developed to manage and 
coordinate the therapy, imaging, and positioning subsystems.  
 
Figure 5.4: The integrated microtripsy thrombolysis system is shown in the left picture. It consists of an ultrasound 
imaging system, a microtripsy therapy system, and a motorized positioning system. The ultrasound therapy 
transducer is shown in the middle. A linear imaging probe was embedded at the center of the therapy transducer. 
The arrangement of the 18 elements in the therapy transducer is illustrated in the right picture. (A = Axial, L = 
Lateral and E = Elevational) 
 
 
5.2.4  Pre-treatment Planning 
 
Pre-treatment planning was performed prior to each treatment. First, using the multi-
positioning arm, the therapy transducer was manually placed above the vessel phantom. The 
lateral axis of the transducer was oriented perpendicular to the vessel phantom so that the cross 
section of vessel and clot were imaged during treatment. Second, cavitation was generated in 
water, and the center of the hyperechoic cavitation region on the ultrasound imaging window 
was marked as the geometric focus of the transducer. Third, guided by ultrasound imaging, the 
therapy transducer was moved using the motorized positioner to align the geometric focus at the 
center of vessel lumen. The transducer was then moved to scan the focus from one end of the 
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clot (close to the pressure reservoir) to the other end (close to the stenosis side). Several locations 
(spaced around 3 mm) along the scan path were recorded. Fourth, after these locations registered, 
the control software linearly interpolated these key locations into a scan path of denser treatment 
locations with a fixed scan interval (SI). 
5.2.5 Treatment Strategies 
 
For each treatment, the treatment zone was scanned following the preset treatment path. 
The therapy system applied a fixed number of microtripsy pulses (doses) at each scan location 
before moving automatically to the next location. A 1.5-cycle pulse with only one high negative 
pressure phase and an estimated peak negative pressure (P(-)LS) of 30 MPa was used in this 
study, as this pressure level was shown to create precise flow channels in our previous 
microtripsy thrombolysis study [29]. An example waveform of microtripsy pulse is shown in 
Figure 5.5. Real-time B-mode ultrasound imaging was used to monitor microtripsy. The 
cavitation bubble cloud could be clearly distinguished as a bright dynamic region with 
ultrasound imaging. The ultrasound therapy transducer was moved by step motors to scan the 
cavitation bubble cloud along the preset treatment path.  If the cavitation cloud was slightly off 
the center of the vessel lumen during the treatment scan according to the real-time ultrasound B-
mode image, the location of cavitation bubble cloud was finely adjusted using joysticks to move 
it back to the center of the vessel lumen. Three treatment strategies were used: single-focus 
strategy, electronically-steered multi-focus strategy and dual-pass multi-focus strategy. In the 
following text, they are termed “single-focus”, “multi-focus” and “dual-pass” for short. A pulse 
repetition frequency (PRF) of 100 Hz was used in all the three strategies, and therefore the 




Figure 5.5: Pressure waveform of a microtripsy pulse. Because peak negative pressure larger than 20 MPa cannot 
be directly measured, this waveform was estimated by linearly summing the directly-measured waveforms from 6 
separate element groups (3 adjacent elements per group) and the peak negative pressure was 36 MPa. 
 
 
The single-focus strategy has been used in all the previous microtripsy thrombolysis 
studies [29, 30]. At each scan location, the treatment zone was only covered by the geometric 
focus of the therapy transducer (Figure 5.6). Five groups were treated using the single-focus 
strategy: four of them used different doses (100, 200, 600, and 1000 pulses) per scan location 
with a scan interval of 0.3 mm; the other group used a dose of 500 pulses with a scan interval of 
0.15 mm. Four clots were treated in each group. The treatment time of each group can be 
calculated based on the PRF, dose, and scan interval used. The treatment group with the smaller 
SI (0.15 mm) and the 500-pulse dose was included in this study to see if a finer scan interval can 
improve the treatment efficacy compared to the groups with the same treatment time. Table 5.1 
summarizes the parameters used for all treatment groups. 
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Using the multi-focus strategy, the treatment zone at each scan location was covered with 
multiple foci by electronically steering the focus of the therapy transducer in the lateral direction 
(Figure 5.6). This multiple foci strategy was expected to widen the generated flow channel. The 
steering of the focus alternatively at different treatment foci was also designed to reduce 
cavitation memory effects at each treatment focus to increase the clot fractionation rate per pulse. 
The previous study shows that residual nuclei from the previous pulse at the same or nearby 
location can last for a few hundred milliseconds (cavitation memory effects) and may negatively 
impact the treatment efficacy when the subsequent pulse arrived before the residual nuclei 
dissolve [55]. Two groups were treated using this strategy: one with 3 treatment foci at each scan 
location and one with 5 treatment foci. A dose of 200 pulses, a scan interval of 0.3 mm and a 
separation of 0.5 mm between foci were used for both groups. The dose was defined as the 
number of microtripsy pulses applied at each treatment focus. The treatment times of the 3 foci 
and 5 foci multi-focus treatments were the same as those of the single-focus 600-pulse (3.3 
min/cm) and 1000-pulse (5.5 min/cm) treatments, respectively. Four clots were treated in each 
group.  
The dual-pass strategy essentially divided the multi-focus treatment into two treatment 
passes. The dual-pass strategy was developed to further address the concern of the cavitation 
memory effects. In the first pass, the treatment zone was scanned through the clot and covered by 
one focus or two foci at each scan location. In the second pass, the treatment zone was scanned 
through the clot again and covered by two or three additional foci, resulting in effective three or 
five foci treated at each scan location, respectively (termed “1+2” or “2+3” patterns) (Figure 
5.6). The foci treated at each scan location within one pass were separated by 1 mm in the lateral 
direction without any overlapping of the cavitation zones between foci. The same treatment path 
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was used for both passes but in the second pass the scan locations were shifted 0.15 mm along 
the length of the clot. A dose of 200 pulses, a scan interval of 0.3 mm, and a separation of 0.5 
mm between the closest foci were used for both 1+2 foci and 2+3 foci dual-pass treatments. 
Because the motorized movement of the therapy transducer from one end of the clot to the other 
was very fast, the treatment times of the 1+2 foci and 2+3 foci dual-pass treatments were almost 
the same as the 3 foci (3.3 min/cm) and 5 foci (5.5 min/cm) multi-focus treatments. Four clots 
were treated in each group.  
 
 






















1 100 100 0.3 / 0.55 
2 1 100 200 0.3 / 1.1 
3 1 100 600 0.3 / 3.3 
4 1 100 1000 0.3 / 5.5 
5 1 100 500 0.15 / 5.5 
6 Multi-
focus 
3 100* 200** 0.3 0.5 3.3 
7 5 100* 200** 0.3 0.5 5.5 
8 Dual-
pass 
1+2 100* 200** 0.3 0.5 3.3 
9 2+3 100* 200** 0.3 0.5 5.5 
* Frequency from pulse to pulse. 




Figure 5.6: Schematic diagrams of the three treatment strategies in the vessel phantom, with the solid lines outlined 
the inner vessel lumen. The ellipses in the vessel lumen represent the treatment foci. A illustrates the single-focus 
strategy. B and C illustrate the 3 foci and 5 foci multi-focus strategies, respectively. D and E illustrate the 1+2 foci 
and 2+3 foci dual-pass strategies, respectively. In D and E, the gray foci were treated in the first treatment pass and 





5.2.6 Elasticity and Porosity Measurements 
 
The elasticity of the retracted clots was characterized to estimate its equivalent age in 
vivo and to compare with that of unretracted clots. A direct mechanical measurement method, 
previously described in detail by Xie [56], was adopted in this study to measure the Young’s 
modulus of retracted and unretracted clots. The measurements were conducted using a desktop 
device named MicroElastometer (Artann Laboratories, Lamberville, NJ, USA), which measures 
the displacement vs. force while a test sample is subject to compression, and the Young’s 
modulus of the sample is estimated based on the strain-stress relationship. The device consists of 
a step motor, a compression stamp, a sample plate, and a strain gauge. The step motor controls 
the compression stamp moving in the direction normal to the sample plate, and the compression 
force is measured by the strain gauge under the sample plate. The minimum travel distance of the 
stamp is 3 µm and the measurable force range is up to 2 N with a precision of 0.1 mN. Before 
measurement, the retracted clot was warmed up to room temperature (25 °C) after it was stored 
in 4 °C for 7 days and cut into 2 cm cylindrical samples (~ 6.5 mm diameter) for the elastic 
measurements. The axis of the cylindrical sample was positioned perpendicularly to the long side 
of the stamp. During measurement, the position of the stamp and the force reading was recorded 
in real-time by its software, and the Young’s modulus was estimated right after the measurement. 
The detailed algorithm and calculation can be found in the paper by Xie [56]. The unretracted 
clots were prepared following the method described previously [29], and their elasticity were 
measured using the same protocol as the retracted clots. Ten samples were measured for each 
clot type. Qualitative and quantitative histological evaluations on porosity (4 samples for each 
clot type) were conducted following the protocol described by Sutton et al. [40]. 




To quantitatively evaluate the flow channels generated using the different microtripsy 
strategies, each treated clot was scanned using a 20 MHz high-resolution ultrasound probe. The 
probe was separately mounted onto the motorized positioner before scanning. With the imaging 
plane perpendicular to the vessel axis, the probe was moved by the positioner from one end to 
the other end of the clot with a step size of 0.1 mm. One cross-sectional image of the clot was 
taken after waiting for 2 seconds at each location to allow for image stabilization. 200 scan 
images were collected in total from each treated clot. Because the fractionated clot region was 
hypoechoic (low brightness on image) when the flow was restored, in comparison to the 
hyperechoic (high brightness on image) intact clot region, we applied an intensity threshold to 
detect the cross section of flow channel on each scan image. Inside the vessel lumen on each 
scan image, the area with pixel intensity less than 20 (0-255 overall range) was thresholded out 
as the cross section of the flow channel. The value of 20 was selected according to the intensity 
histogram of the scan images. To quantify the size of flow channel, the cross-sectional area 
(Across) of the flow channel region was calculated.   
5.2.8 Restored Flow Measurement 
 
Restored flow rate was measured to evaluate the recanalization effectiveness using the 
different treatment strategies. After the flow channel was created, the volume of downstream 
saline in the fluid collector within 1 minute was measured. When the flow was very slow, the 
restored saline was collected for 5 minutes. The restored volume flow rate was then calculated as 
the volume of the saline collected divided by the time. Due to the brevity of the time period and 
the small change in reservoir volume, the pressure was assumed to be constant over this time 
period. A control measurement with no blockage in the flow system was also conducted to 
compare with the restored flow rate. 
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5.2.9 Debris Measurement 
 
A method combining macroscopic inspection and Coulter counter analysis was utilized to 
measure clot debris particle size distribution generated during the treatments. When flow was 
restored, clot debris was flushed by the restored flow and filtered by a filter sheet with a pore 
size of 300 µm. Macroscopic inspection was conducted to check for debris particles that may 
have been trapped on the 300 µm filter. Optical images with a resolution of 20 µm were taken of 
the filter sheet. The number of distinguishable particles larger than 300 µm was counted and the 
sizes of individual large debris particles were measured. The filtered fluid with suspended debris 
particles smaller than 300 µm was then analyzed using a Coulter counter (Multisizer 3; Beckman 
Coulter, Brea, CA, USA). The measurable range of particles was from 3 to 60 µm using a 100-
µm aperture tube and from 60 to 300 µm using a 560-µm aperture tube [57]. The measurements 
using these two aperture tubes were combined to generate a distribution of debris particles from 
3 to 300 µm. 
5.3 Results 
 
5.3.1 Elasticity and Porosity of Retracted and Unretracted Clot 
 
One representative retracted clot after the 7-day incubation is shown in Figure 5.7. The 
unretracted clots and the retracted clots were measured to have Young’s moduli of 2.31 ± 2.05 
kPa (N = 10) and 11.12 ± 1.41 kPa (N = 10), respectively. The retracted clots had a much higher 
stiffness than the unretracted ones. The Young’s moduli of clots at different ages in a rat model 
were measured ex vivo using the same mechanical method by Xie [56]. According to their 
results, the Young’s modulus of the retracted clots measured in this study fell between those of 
the 3-day-old in vivo clots (9.46 ± 0.87 kPa) and the 6-day-old in vivo clots (17.40 ± 5.77 kPa) in 
the rats, which is when it was expected for the clots to transition from acute phase to chronic 
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phase. This is similar to human clots of 2 weeks of age [56]. Histology sections showed 
consistent difference in porosity between the two clot types, similar to those reported by Sutton 
(Figure 5.8). Intracellular spacing in retracted clots and unretracted clots were measured to be 
0.23 ± 0.20 % and 3.31 ± 1.06 %, respectively. Significant difference was shown by one-sided t-
test (P<0.01). The porosity of the retracted clots in this study was lower than what was reported 
by Sutton et al., indicating that these clots were even more retracted. 
 
Figure 5.7: One long retracted clot separated from the serum before being cut into 2-cm segments. 
 
 
Figure 5.8: Representative histology sections of retracted (left) and unretracted (right) clots showing a cross section 






5.3.2 Comparison with Unretracted Clot 
 
Microtripsy was effective in treating retracted clots, but the flow channel generated using 
a single-focus method was significantly smaller than the flow channel formed through 
unretracted clots. A flow channel was generated through the retracted clot using the single-focus 
strategy even with a 100-pulse dose. Figure 5.9 shows the representative cross-sectional 
ultrasound images of a treated, retracted clot in this study on the left and a treated, unretracted 
clot from a previous study on the right [30]. The unretracted clots were treated using exactly the 
same treatment parameters as the 100-pulse single-focus treatment used on the retracted clots. 
The channels generated in the retracted clots were very small and hard to see from the high-
resolution ultrasound scan images, whereas the channels in unretracted clots were large and 
clear. The mean Across of the channels generated in the retracted clots was 0.0232 ± 0.0506 mm
2 
(N = 4 × 200), which was about 200 times smaller than that in the unretracted clots (4.6532 ± 
0.7761 mm
2
, N = 6 × 67).   
 
Figure 5.9: Representative ultrasound images of the cross sections of the flow channels generated using the single-
focus strategy in one unretracted clot (left) and one retracted clot (right). The exact same treatment parameters (30 
MPa P(-)LS , 0.3 mm Scan Interval and 100 pulses per treatment location) were used in both cases. The generated 
flow channels show as the hypoechoic zones inside clots (indicated by the block arrow in the left image). 
Therapeutic ultrasound propagated from the top to the bottom of the images.  
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5.3.3 Single-focus Treatments 
 
Using the single-focus strategy, a flow channel was successfully generated through 
retracted clots with all the microtripsy parameters tested. The size of the flow channel increased 
with increasing dose. The representative scan images of the channels generated by the five 
treatment groups using the single-focus strategy are shown in Figure 5.10. As the dose increased 
from 100 to 1000 pulses, the channels generated using the same 0.3-mm SI became larger (first 
four images), and the mean Across of the channels increased from 0.02 to 1.11 mm
2
 (Figure 5.11). 
The shape and boundary of the channels became clearer and sharper with the higher doses. The 
last image of Figure 5.10 shows a representative channel generated using the smaller 0.15-mm 
SI and the 500-pulse dose. The channels generated using the 1000-pulse dose and 0.3-mm SI 
were the largest among the single-focus treatments but the size was still small (1.1099 ± 0.2721 
mm
2
) compared to the 6.5-mm inner-diameter vessel lumen. The Across of channels using the 
0.15-mm SI and the 500-pulse dose (0.5269 ± 0.2391 mm
2
) were only half of those using the 
0.3-mm SI and the 1000-pulse dose. This indicates that reducing SI does not improve the 
treatment efficacy under the same treatment time.   
 
Figure 5.10: Representative ultrasound images of the cross sections of the flow channels generated using the single-
focus strategy with different doses. The last image shows the flow channel generated with a reduced scan interval 
(0.15 mm). The generated flow channels show as the hypoechoic zones inside clots (block arrows). Therapeutic 




Figure 5.11: The mean cross-sectional area (Across) of the flow channels generated using the single-focus strategy 
with different doses. The last bar shows the flow channel generated with a reduced scan interval (SI = 0.15 mm). (N 
= 4 × 200). 
  
5.3.4 Comparison of Three Strategies 
 
A flow channel was generated through retracted clots using all three strategies tested 
(Figure 5.12). Under the same treatment time, microtripsy thrombolysis generated the largest 
flow channels using the dual-pass strategy and the smallest channels using the single-focus 
strategy. When comparing the single-focus strategy to the multi-focus strategy, the channel size 
was increased by 30% under the same 3.3 min/cm treatment time from 0.63 ± 0.21 mm
2
 to 0.82 
± 0.41 mm
2
, and the increase was 44% under the same 5.5 min/cm treatment time from 1.11 ± 
0.27 mm
2
 to 1.60 ± 0.75 mm
2 
(Figure 5.13). When comparing the multi-focus strategy to the 
dual-pass strategy, the channel size was increased by 90% under the same 3.3 min/cm treatment 
time from 0.82 ± 0.41 mm
2
 to 1.55 ± 0.50 mm
2
, and under the same 5.5 min/cm treatment time 
the channel size increased by 160% from 1.60 ± 0.75 mm
2





analyses (one-sided Student’s t-test) also supported these significant increases of channel size 
generated using the multi-focus vs. single-focus (P < 0.01) and dual-pass vs. multi-focus strategy 
(P < 0.001).  
The shapes of the generated flow channels using the three strategies varied. Elliptical-
shaped channels were generated using the single-focus strategy. The channels generated using 
the multi-focus strategy appeared to have two separate lesions with a horizontal orientation, as 
shown in Figure 5.12. When using the dual-pass treatment strategy, the channels had a more 
circular shape than those generated using the other two treatment strategies. With the 1+2 foci 
dual-pass treatment, one small tail appeared at one side of the circular channel. With the 2+3 foci 
dual-pass treatment, two tails appeared.  
 
Figure 5.12: Representative ultrasound images of the cross sections of the flow channels generated using the single-
focus strategy (left column), the multi-focus strategy (middle column) and the dual-pass strategy (right column). The 
treatment times were 3.3 min/cm in the upper row and 5.5 min/cm in the lower row. The generated flow channels 





Figure 5.13: The mean cross-sectional area (Across) of the flow channels generated using the three strategies under 
the two treatment times (3.3 min/cm and 5.5 min/cm). (N = 4 × 200). 
 
5.3.5 Restored Flow 
 
Prior to any treatment, no flow was observed. After each treatment, flow was successfully 
restored even with the smallest channel created. Figure 5.14 shows the mean flow rate restored 
for the treatment groups presented in Figure 5.12. With constant pressure (3.7 mm Hg) applied, 
a larger channel would be expected to permit higher flow rate, which is confirmed by the 
restored channel cross-sectional area and flow rate results shown in Figures 5.13 and 5.14. The 
restored flow rate was highest when using the dual-pass strategy, while the lowest restored flow 
rate was generated using the single-focus strategy. The mean flow rate generated by the 2+3 foci 
treatments was 193.2 ± 47.5 mL/min (maximum at 324 mL/min), which was much higher than 
the other treatment groups. As a reference, the flow model with no blockage had a flow rate of 





Figure 5.14: Restored flow rates of the three strategies under the two treatment times (3.3 min/cm and 5.5 min/cm). 




The clot debris distribution was measured in the 600-pulse treatments, the 1000-pulse 
single-focus treatments, and the 1+2 foci and 2+3 foci dual-pass treatments. The debris size 
measurement was performed for four selected treatment groups instead of all groups due to the 
time-consuming nature of the measurement. The dual-pass treatment groups were selected 
because this strategy achieved the largest flow channel under the same treatment time (i.e., the 
highest treatment efficacy) among the three strategies. As a comparison and reference, the debris 
from the single-focus treatments under the same treatment time was measured. Theoretically, the 
debris generated from the single-focus treatments should be smaller than those using the other 
two strategies because the single-focus strategy used a three- or five-times higher dose at each 
treatment focus than the other two strategies, which was expected to break up the clot into 
smaller particles. For all measured treatments, over 99.9% of the debris particles were less than 
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10 µm, and the number of debris particles became orders of magnitude less as the size increased 
from 10 μm to 100 μm. Figure 5.15 shows the normalized mean distributions of clot debris from 
the four treatment groups. They all had a similar distributions centered at 4.2 μm, and the only 
difference was the number of debris particles. The debris particles larger than 100 μm generated 
using the two different treatment strategies were calculated and summarized in Table 5.2. In 
more than half of the treatments, no debris particles greater than 100 μm were observed. Only 
one debris particle (453 μm) was trapped on the 300-μm filter sheet in the total 24 measured 
treatments, and it was generated using the dual-pass strategy. In the treatments when particles 
between 100 and 300 μm were observed, only one or two such particles were observed for each 
treatment. Other than the single 453 μm particle mentioned above, the largest particle observed 
was 222.85 μm when using the single-focus strategy and 189.75 μm when using the dual-pass 
strategy. 
 
Figure 5.15: The mean distributions of debris particles (3 to 10 µm) generated using the single-focus and dual-pass 
strategies (N = 4 × 9). The volumes of the fluids collected from the restored flows were recorded in all the 
treatments. And the volumes used for Coulter Counter measurements were recorded as well. With this information, 
the number of the debris particles was first converted to unit volume (mL) for each treatment. Then the mean 





Table 5.2: Summary of the generated debris larger than 100 µm using the single-focus and dual-
pass strategies 
 
Single-focus Treatments Dual-pass Treatments 
Treatments with 
particles >100 µm 
3 out of 8 4 out of 8 
Average No. of particles 
>100 µm 
1.67 1.1 
Average Size of 
particles between 100 
and 300 µm 
117.57 µm 125.72 µm 
Maximal Particle Size 
<300 µm 
222.85 µm 189.75 µm 




Drug-based thrombolysis methods, including ultrasound-enhanced thrombolysis, have 
low efficacy for retracted clots or aged clots with low permeability [38-40, 43-45]. The 7-day 
retracted clots used in this study have Young’s moduli similar to the in vivo 3-6 day old rat clots, 
which were believed to turn from acute phase to chronic phase, similar to human clots of 2 
weeks of age [56]. The results from this chapter support our hypothesis that microtripsy 
thrombolysis remains effective for retracted clots, although the treatment efficacy is reduced. 
Flow channels were generated through all retracted clots when treated using microtripsy and 
restored flows were consistently observed. The reduced treatment efficacy of microtripsy 
thrombolysis matched the observations of a previous study by Vlaisavljevich et al., which 
showed decreased or no histotripsy fractionation for tissues of increased mechanical strength 
[46]. Vlaisavljevich’s study also showed that increasing tissue stiffness results in a significant 
decrease in cavitation bubble expansion, leading to reduced strain to tissue and increased 
resistance to histotripsy-induced tissue damage [47]. Our elasticity measurement indicates a 5-
times higher Young’s modulus for retracted clots compared to unretracted clots. In addition, the 
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retracted clots have a denser fibrin structure and less water, which increases the time needed for 
microtripsy to completely fractionate the increased number of fibrin fibers per unit volume.    
The results from the multi-focus and dual-pass treatments support the hypothesis that the 
microtripsy thrombolysis treatment efficacy for retracted clot can be enhanced by electronic 
focal steering. The multi-focus treatments showed a statistically significant improvement in 
channel size from the single-focus treatments. With the electronic focal steering, the treatment 
zone was covered by multiple cavitation foci. A wider flow channel and less required dose per 
focus were achieved by using the multi-foci strategy.  From Table 5.3, we can see that the actual 
widths of channels generated by the multi-focus treatments matched closely with what we 
expected for both 3 foci and 5 foci cases. For example, with 5 foci side-by-side separated by 0.5 
mm and each focus treated with 200 pulses, the flow channel generated by the multi-focus 
strategy was expected to be 2.45 mm in width (channel width of the 200-pulse single-focus 
strategy plus 4 times 0.5 mm separation, see Reference in Table 5.3). The actual width of the 
flow channels generated by the 5 foci multi-focus treatments was 2.41 mm, similar to the 
expected channel width. In comparison, the flow channel generated by the 1000-pulse single-
focus strategy was only 1.11 mm wide.  The height of the channel generated by multi-focus 
strategy was 2.00 mm, compared to 1.83 mm channel height generated by the 1000-pulse single-
focus strategy. However in some treatments, two separate lesions were generated by the multi-
focus strategy. The efficacy of the multi-focus strategy was lowered by this two-lesion pattern. 
Cavitation memory effects may be associated with the two-lesion pattern. As microtripsy pulses 
were applied with a 100 Hz PRF, a subsequent pulse arrived before the complete dissolution of 
the residual bubble nuclei from the previous cavitation. The cavitation bubble cloud generated at 
the proximal side of the focal region might prevent the incident acoustic energy from delivering 
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to the zone right below the proximal cavitation site, forming two discontinuous cavitation clouds 
separated by a “dead” zone resulting in two separate lesions.   
Table 5.3: Flow channel width and height 
 
3 Foci 5 Foci 
Expected* Multi-focus Dual-pass Expected ** Multi-focus Dual-pass 
Channel 
Width 
1.45 ± 0.21 1.39 ± 0.30 1.59 ± 0.32 2.45 ± 0.21 2.41 ± 0.39 2.78 ± 0.32 
Channel 
Height 
1.36 ± 0.24 1.66 ± 0. 37 2.68 ± 0.36 1.83 ± 0.23 2.00 ± 0.40 2.63 ± 0.34 
* For 3 foci, expected channel width = channel width by 200-pulse single-focus treatments (0.45 mm) + 2 × foci 
separation (0.5 mm); and expected channel height = channel width by 600-pulse single-focus treatments (1.36 mm). 
** For 5 foci, expected channel height = channel height by 200-pulse single-focus treatments (0.45 mm) + 4 × foci 
separation (0.5 mm); and expected channel height = channel height by 1000-pulse single-focus treatments (1.83 
mm). 
 
To further reduce the cavitation memory effects and eliminate the two-lesion pattern 
encountered in the multi-focus strategy, a dual-pass multi-focus strategy was investigated. With a 
larger effective separation (1 mm vs. 0.5 mm in the multi-focus strategy) between the steered 
foci within one treatment pass, the influence of the residual nuclei from the previous focus on the 
subsequent steered focus was reduced, which, in turn, helps fractionate the dead zone between 
the two lesions observed in the multi-focus treatments. In addition to reducing the cavitation 
memory effects, we hypothesize that the key to the dual-pass strategy is that the first treatment 
pass created “pilot” holes for the second pass. The pilot holes provided empty space and tissue-
fluid interfaces for the cavitation in the second pass, and, therefore, resulted in more active 
cavitation bubble expansions, complete fractionation of the dead zone, and higher fractionation 
efficacy. The results show that the dual-pass treatments achieved the best thrombolysis outcomes 
among the three strategies under the same treatment time. The actual widths of channels 
generated by the dual-pass treatments were even larger than the expected channel width based on 
the focal separation and size of the lesion generated by the single-focus strategy and those 
generated by the multi-focus treatments. The mean Across of flow channel generated by the 2+3 
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foci dual-pass strategy was over two times larger than that by the 5 foci multi-focus strategy, and 
over three times larger than that by the 1000-pulse single-focus strategy.  
The results in this chapter suggest that the dual-pass microtripsy thrombolysis could be 
an effective treatment option for in vivo chronic, retracted clots and possibly for other dense 
tissues, as the retracted clot is a good model for the chronic clot. Using this advanced treatment 
strategy, the in vitro retracted clots were recanalized successfully with a larger opening. 
Compared with the other two treatment strategies, the dual-pass treatments achieved much larger 
openings with the same treatment time. The treatment speed of our noninvasive microtripsy 
approach is faster compared to current thrombolysis approaches. The current clinical 
thrombolysis approaches include systemic thrombolytic drug infusion, catheter-directed 
thrombolysis (CDT), and percutaneous mechanical thrombectomy (PMT). The thrombolytic 
drug infusion and CDT treatments take from 24 to 56 hours [58, 59] and some PMT treatments 
can be done within 1 to 3 hours [60]. For our approach, a retracted clot (chronic >14 days) with a 
length of 10 cm [61] can be treated within 55 min. The treatment can be faster for unretracted 
clots (acute < 14days) [29] and with parameter optimization for retracted clots.  
The debris particles generated from the dual-pass treatments were within the safe range 
and showed no significant difference from those of the single-focus treatments. The largest 
particle observed overall was 453 µm. In mechanical thrombectomy procedures, clot particles up 
to 1000 µm are generated and no severe embolism has been reported from human studies [62-
64]. In addition, according to the morphometry of the pulmonary arterial system reported by 
Singhal et al. [65], 500-µm-level particles may only obstruct one arteriole of order 9 which 
supplies only 0.016% of total capillary beds. The total number of debris particles larger than 100 
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µm from one dual-pass treatment was less than 20, which would not be expected to cause 
massive pulmonary embolism.  
This chapter shows that microtripsy is effective for retracted clots and that electrical 
steering can enhance the treatment efficacy. Exploration of the effects of changing acoustic 
parameters, particularly PRF and pressure, is needed to further improve microtripsy 
thrombolysis. These parameters were not tested in this paper because our current setup limits the 
range of PRF and pressure for testing.  Future work will be conducted in this direction to further 
improve the treatment efficacy. For example, increasing the treatment PRF has the potential to 
further shorten the treatment time under the same treatment dose if the cavitation memory effects 
can be reduced. Cavitation residual nuclei can be consolidated to reduce cavitation memory 
effects by interweaving low pressure ultrasound pulses with histotripsy pulses [66]. Another 
possible investigation to further reduce cavitation memory effects would be to divide the 
treatment into more than two treatment passes. Increasing the peak negative pressure can enlarge 
the lesion size [29, 36, 47] and will be investigated with microtripsy.  
5.5 Conclusion 
 
 After each treatment, regardless of the treatment strategy, a flow channel was 
successfully generated through the retracted clot and flow was restored. Although the treatment 
efficacy of the single-focus treatment on retracted clot was reduced, both the multi-focus and the 
dual-pass treatments incorporating the electronic focal steering showed significant improvements 
in recanalized channel size when compared to the single-focus treatments. Under the 5.5 min/cm 
treatment time, the channels generated by the single-focus, multi-focus, and dual-pass treatment 
had cross-sectional areas of 1.11 ± 0.27 mm
2




and 4.13 ± 1.09 mm
2
, 
respectively. The restored flow rate for the dual-pass treatment was 193.25 ± 47.51 mL/min 
124 
 
(max 324 mL/min). The debris generated during the dual-pass treatments remained within a safe 
range. The results in this chapter show the potential of microtripsy thrombolysis for retracted clot 
recanalization with the enhancement of electronic focal steering and dual-pass strategy. Due to 
the much larger flow channels generated with no extra treatment time, the dual-pass treatments 
were shown to be the most clinically practical and effective among the three strategies. 
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6.1 Introduction  
 
Pathological thrombosis is implicated in many cardiovascular diseases. Venous thrombi 
such as deep vein thrombosis (DVT) can lead to pulmonary embolism (PE) and arterial thrombi 
can manifest as myocardial infarction (MI) or ischemic stroke. Current clinical thrombolytic 
methods include the use of thrombolytic drugs [2-4], catheter-based endovascular procedures [5, 
6], or a combination of the two [7, 8]. Administering thrombolytic drugs systemically requires 
long treatment times and has a high risk of major bleeding. Catheter-based methods are site-
specific but invasive and associated with frequent complications, such as bleeding, vessel 
damage, and infection.  
Low intensity ultrasound has been shown to enhance the efficacy of thrombolytic agents 
in vitro [9-11], in vivo [12], and in clinical trials [13-15]. There are also a number of studies that 
have successfully demonstrated the use of ultrasound and microbubbles to degrade clot in the 
presence or absence of thrombolytic agents [16-18]. Studies using microbubbles have suggested 
that cavitation is correlated with significant enhancement of thrombolysis [19]. High-Intensity 
Focused Ultrasound (HIFU) has been investigated as a stand-alone thrombolytic approach [20, 
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21], but the safety and efficiency of this technology still needs further investigation before 
clinical translation.  
Histotripsy fractionates soft tissue by well-controlled acoustic cavitation using 
microsecond-long, high-intensity and focused ultrasound pulses [22-26]. The feasibility of using 
histotripsy as a noninvasive, drug-free, and image-guided thrombolysis technique has been 
demonstrated previously.  In vitro studies show that histotripsy can completely break down large 
clots (140-300 mg) within 5 min into particles no larger than 100 µm [27] and in vivo studies in a 
porcine deep vein thrombosis model, showed histotripsy therapy can re-establish blood flow and 
decrease thrombus burden [28].  
Real-time quantitative feedback to monitor the progress of histotripsy clot fractionation 
would improve treatment efficacy and potentially minimize therapy dose, thereby improving 
safety.  Specifically, as cavitation is known to cause hemolysis and platelet aggregation [29-32], 
minimizing the therapy dose can mitigate these potential complications of histotripsy 
thrombolysis treatment. While a number of methods have been investigated to evaluate tissue 
damage by ultrasound thermal therapies using magnetic resonance imaging (MRI) [33-36] or 
ultrasound-based measurement of changes in tissue elasticity, sound speed or acoustic 
attenuation [37-42], none have been incorporated for real-time monitoring of ultrasound 
thrombolytic therapy. 
Cavitation detection has been used to correlate stable and inertial cavitation with the 
effect of thrombolysis in ultrasound-enhanced thrombolysis [19]. B-mode ultrasound imaging 
during histotripsy therapy can easily visualize cavitation due to the hyperechogenicity of the 
bubble cloud and provide precise targeting guidance, but its ability to serve as a quantitative 
therapy feedback is limited. Thus, we are investigating a modified color Doppler imaging 
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method to monitor motion induced by histotripsy pulses as a real-time quantitative feedback for 
histotripsy thrombolysis. This motion is only detectable when a cavitation bubble cloud is 
formed, and therefore this monitoring method was termed bubble-induced color Doppler (BCD) 
feedback. The motion itself likely results from a net force exerted by rapid bubble expansion or 
collapse in the focal region and can last over 10 ms after each pulse. This force generates a 
variable motion response depending on mechanical properties of the tissue in the focal region. 
We hypothesize that as the clot is increasingly fractionated and becomes softer and eventually 
liquefied the change in the bubble-induced motion can be monitored and quantified using BCD 
feedback as a real-time measure of the degree of clot fractionation.  
This chapter evaluates the potential of BCD feedback for histotripsy thrombolysis 
monitoring in four incremental steps. First, the bubble-induced motion is characterized in 
transparent fibrin clots using particle image velocimetry (PIV) that serves as the gold standard to 
compare with BCD. Second, using fibrin clots with a thin layer of embedded red blood cells, the 
visualized progress of histotripsy thrombolysis is quantitatively compared with its corresponding 
BCD feedback. Third, the correlation of BCD feedback with clot fractionation is validated in in 
vitro clots by comparing the BCD signal to the change of fractionated debris volume as a 
function of therapy dose. Finally, a real-time BCD feedback algorithm to predict complete clot 
fractionation during histotripsy thrombolysis is developed and tested. 
6.2 Materials and Methods 
 
6.2.1 Investigation of Bubble-induced Motion 
 
A transparent fibrin clot was developed to study the bubble-induced motion inside the 
clot (Figure 6.1). Reconstituted plasma was used to form the transparent fibrin clot, following 
the procedure as previously described [43]. Fresh bovine blood was collected from a local 
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abattoir. A citrate-phosphate-dextrose (CPD) solution (C7165; Sigma-Aldrich Co., St. Louis, 
MO, USA) was immediately added and gently mixed in the bovine blood as an anti-coagulant at 
a ratio of 1 mL CPD per 9 mL blood. The resulting blood sample was stored at 4°C and used 
within 72 hours. The blood sample was first centrifuged at a relative centrifugal force (RCF) of 
1400g for 30 minutes. Then the plasma supernatant was separated from the buffy coat and red 
blood cell (RBC) pack, and incubated in 55°C water bath for 5 minutes to precipitate the native 
fibrinogen [44]. The plasma solution was further centrifuged at a RCF of 1400g for 3 minutes to 
completely separate the precipitated fibrinogen. Bovine fibrinogen (F8630; Sigma-Aldrich Co., 
St. Louis, MO, USA) was then added to the processed plasma with a concentration of 400 
mg/dL. To stimulate the clotting cascade, bovine thrombin (T4648; Sigma-Aldrich Co., St. 
Louis, MO, USA) and calcium chloride (21107; Sigma-Aldrich Co., St. Louis, MO, USA) were 
mixed with the reconstituted plasma to a final concentration of 1 IU/mL and 20mM/L 
respectively [45, 46]. The mixture was then poured into a rectangular mold and incubated in 
37°C water bath for 2 hours. The mature clot became a rectangular plate of approximately 30 
mm (width) x 50 mm (length) x 5 mm (thickness) and embedded in transparent agarose 
hydrogel, which helped maintain the shape and position of the clot in water. The transparent 
fibrin clot allows for direct visualization of the cavitation microbubbles and bubble-induced 
motion inside the clot. 
 
Figure 6.1: Transparent fibrin clot embedded in agarose hydrogel. The clot was molded to be rectangular in shape. 




Figure 6.2: A schematic illustration of the experimental setup. A 6-element 1.5-MHz histotripsy transducer was 
placed facing down in a water tank filled with degassed water. The transducer was driven by a high-voltage 
amplifier that was connected to a field-programmable gated-array (FPGA) development board specifically 
programmed for controlling the firing of the transducer. A 5-MHz ultrasound imaging probe was inserted in the 
central hole of the histotripsy transducer and connected to Verasonics® ultrasound imaging system to image at the 
transducer focus. A high-speed camera and a continuous-wave light source were placed on the two sides outside the 
water tank. The FPGA controller sent triggers to the Verasonics® system and the high-speed camera to synchronize 
them with therapy pulses. The therapy focus was positioned within the transparent fibrin clot phantom. The central 
plane of the clot plate, the ultrasound imaging plane and the focal plane of the camera were aligned to overlap with 
each other. 
 
In order to capture the bubble-induced motion following each histotripsy pulse inside the 
fibrin clot, optical imaging for particle image velocimetry (PIV) and ultrasound imaging for 
bubble-induced color Doppler (BCD) were applied simultaneously during histotripsy treatment.  
The experimental setup is illustrated in Figure 6.2. The optically and acoustically transparent 
clot was treated by a 1.5-MHz focused ultrasound transducer with an aperture size of 7.1 cm 
(lateral) x 8 cm (elevational) and a focal length of 5.5 cm. In the center of the transducer housing 
is a 6 cm x 2.4 cm rectangular hole for the insertion of imaging probes. The transducer was 
calibrated using a fiber-optic probe hydrophone (FOPH) adapted from a previously published 
design [47]. The focal beam volume (-6 dB) of the transducer was measured to be 4.2 mm (axial) 
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x 1.5 mm (lateral) x 1.9 mm (elevational) at a peak negative pressure of 15 MPa. The histotripsy 
treatment consisted of 1.5-cycle ultrasound pulses with a pulse repetition frequency (PRF) of 30 
Hz, at an estimated peak negative pressure of 36 MPa and a peak positive pressure of 58 MPa at 
the focus. The focal pressure waveform was measured directly with FOPH up to the peak 
negative pressure of 25 MPa (Figure 6.3). At the peak negative pressure beyond 25 MPa, the 
pressure cannot be directly measured due to instantaneous cavitation and is estimated by 
summing the measurable pressure outputs from two sub-groups of the elements. The total 
exposure at each sample spot was 1000 pulses. 
 
Figure 6.3: A representative pressure waveform of the 6-element 1.5-MHz histotripsy transducer taken at the 
highest pressure (peak negative) level that could be directly measured by the fiber optical hydrophone. 
 
For PIV analysis, optical images of the treatment focal zone were captured by a high-
speed camera (Phantom V210; Vision Research, Wayne, NJ) using a 135 mm macro lens. The 
transparent clot phantom was illuminated by a continuous wave (CW) light source from the 
opposite side of the phantom from the camera. Each image (800 × 256 pixels) covered an 
approximately 7.3 mm × 2.3 mm field of view, allowing the observation of the full treatment 
zone (4.2 mm × 1.5 mm). The high-speed camera was synchronized to capture images at a frame 
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rate (FR) of 10 kHz immediately after the delivery of a histotripsy pulse. Limited by the memory 
size of the high-speed camera, 100 optical images were captured after every 4th histotripsy pulse, 
covering the first 10 ms after the pulse. A period of 10 ms was sufficiently long to capture the 
most significant motion.   
For BCD imaging, a 5-MHz ultrasound imaging probe (ATL L7-4, Philips, Andover, 
MA) was placed in the central hole of the therapy transducer and aligned with the transducer 
focus. The color Doppler acquisitions were realized using a Verasonics
®
 imaging system (V-1 
Data Acquisition System, Verasonics, Kirkland, WA). The color Doppler field of view was 
chosen to cover the whole treatment zone. Immediately after the delivery of a histotripsy pulse, 
the Verasonics
®
 system started to transmit color Doppler pulses and acquire echo signals at a 
PRF of 10 kHz. A total of 100 Doppler acquisitions were collected per histotripsy pulse, 
covering the first 10 ms.   
To estimate the bubble-induced motion in the treatment zone, the captured optical images 
were analyzed using PIV via a Matlab-based analysis tool (PIVlab, Version 1.32). Dark 
fragments of broken fibrin fibers resulting from histotripsy fractionation provided contrast to 
track the motion. Each velocity map at a certain delay after a histotripsy pulse was estimated 
using the image captured at that delay time and the subsequent image. The image pair was 
compared using a three-pass Fast Fourier Transformation (FFT) window deformation algorithm 
to estimate the motions. The interrogation window sizes were chosen to be 64, 32 and 16 pixels 
respectively, all with 50% interrogation overlap. Since there were 100 images captured after each 
histotripsy pulse, 99 velocity maps were generated showing velocity information at delay times 
ranging from 0 to 9.9 ms after the pulse. 
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The bubble-induced motions were also estimated using color Doppler data. The acquired 
color Doppler data sets were processed offline using the functions provided by Verasonics 
software. Each velocity map at a certain delay after a histotripsy pulse was estimated using the 
color Doppler data acquired at that delay time and 9 subsequent acquisitions. The ensemble 
length of 10 was chosen as a compromise between the accuracy and the capability of depicting 
fast change. By processing every set of 10 consecutive acquisitions in a rolling fashion along 100 
acquisitions after each histotripsy pulse, 91 velocity maps were generated showing velocity 
information at different delay times ranging from 0 to 9.1 ms following the pulse.  
The mean axial velocity, which was defined as velocity components on the direction of 
ultrasound propagation, was calculated over the region of interest on each PIV and BCD velocity 
map. The averaging was applied only over non-zero values within the region of interest. For each 
histotripsy pulse, a curve of mean axial velocity as a function of time elapsed after the pulse was 
formed to characterize net axial motion. A full profile of mean axial velocity throughout each 
treatment was generated by PIV and BCD respectively, with each vertical line representing a 
mean velocity curve after each pulse. An averaging effect originally existed during color Doppler 
processing to generate each BCD velocity map because it was estimated using 10 acquisitions 
collected over a period of 0.9 ms. In order to fairly compare BCD with PIV, 9-point rolling 
averaging was applied on the mean velocity curves of PIV to simulate the averaging effect on 
BCD. 
6.2.2 Correlation of BCD Feedback and Histotripsy Thrombolysis 
 
The correlation between the degree of histotripsy thrombolysis and the BCD feedback 
was investigated using a three-layer fibrin clot, which allowed the direct visualization and 
quantification of histotripsy fractionation progression. The three-layer fibrin clot constituted of a 
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thin (~500 um) layer of RBC fibrin clot in the center and two thick (~3 mm) layers of transparent 
fibrin clot on the two sides. As the middle layer embedded with RBC is fractionated, it 
transitions from opaque to transparent. The degree of fractionation can be quantified as the area 
of the transparent region within the opaque RBC layer, which is calculated based on the light 
intensity change in the captured optical images. To evaluate the correlation, the progression of 
the degree of clot fractionation (lesion progression) in the three-layer clot was compared with 
two metrics extracted from the corresponding BCD feedback: time of peak rebound velocity 
(tPRV) and mean velocity of focal zone at a fixed delay (Vf,delay) after each pulse. 
The three-layer fibrin clot (Figure 6.4) was developed to directly visualize the 
progression of histotripsy thrombolysis. To form a bottom layer (~3 mm thick) of transparent 
fibrin clot, the reconstituted plasma described above was poured into a rectangular mold right 
after stimulation and then coagulated at room temperature for 30 minutes. The solution for RBC 
fibrin clot was made by combining the previously separated RBC pack and the reconstituted 
plasma to a hematocrit of 30%. The solution was then stimulated and applied on the surface of 
the bottom layer using blood smearing technique [48] to make an approximate 500 µm thick 
RBC fibrin clot layer. At last, a top layer (3mm thick) of transparent fibrin clot was made on the 
coagulated RBC fibrin clot layer. The three-layer clot was then incubated in 37°C water bath for 
2 hours. The mature clot was a rectangular plate of approximately 30 mm (wide) x 50 mm (long) 
x 6.5 mm (thick) and embedded in transparent agarose hydrogel. For all the stimulations, the 
same concentrations of thrombin (1 IU/mL) and calcium chloride (20 mM/L) were used.  Three 
soft three-layer clot phantoms with a fibrinogen concentration of 400 mg/dL and two hard clot 
phantoms with doubled fibrinogen concentration were made. All clots were treated within one 




Figure 6.4: Three-layer fibrin clot embedded in agarose hydrogel. (a) A picture of a three-layer fibrin clot phantom 
from top view. (b) A schematic of the phantom from side view. 
 
The same setup as in the previous section was used for this experiment. The plane of the 
thin RBC clot layer was positioned perpendicular to the optical axis of the high-speed camera 
and aligned to the camera’s focal plane by visually adjusting the sharpness of the thin RBC layer 
on the optical images. Since the camera’s focal plane was already aligned rigidly with the 
histotripsy focus and the ultrasound imaging plane, this procedure aligned the thin RBC clot 
layer onto the therapy focus. The histotripsy treatment was performed by the same transducer 
and using the same treating parameters (1.5-cycle, 30 Hz PRF and 36 MPa peak negative 
pressure). When treating a spot, the high-speed camera captured one image of the treatment zone 
before each histotripsy pulse arrived to record the lesion as a function of the number of applied 
therapy pulses. The same color Doppler data were acquired and processed using the same 
settings as that in the previous section. A total of 30 spots were treated in the soft clots (10 in 
each of the three soft clot phantoms) and 20 spots were treated in the hard clots (10 in each of the 
two hard clot phantoms) by histotripsy thrombolysis.  
The size of the produced lesions was quantified using the acquired optical images. As the 
targeted volume was increasingly fractionated by the increasing number of applied histotripsy 
pulses, the treated region within the RBC layer changed gradually from opaque to translucent on 
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the optical images. Since the clot phantom was back lit with CW light, the captured optical 
images would appear as shadow graphs in which the untreated region appeared dark and the 
fractionated region appeared bright (Figure 6.5). These optical images were analyzed by Matlab 
(R2012b, The MathWorks Inc., Natick, MA) using a method similar to those described in 
previous papers [49-51]. The lesion on each image was detected using a threshold approach. For 
each spot, a pixel brightness threshold was first chosen and set at 10% above the average pixel 
brightness of the first image where no damage was done. The grayscale images were converted 
into binary images using this threshold. The regions with brightness that was higher than the 
threshold would become 1 (white) in the binary image and be considered fractionated. In 
contrast, the regions with brightness less than the threshold would become 0 (black) and be 
considered intact. The lesion area was then plotted as a function of the number of applied therapy 
pulses to form the lesion progression.  
 
Figure 6.5: Representative lesion formation of a treated spot in a soft three-layer fibrin clot. The lesions at different 
stages (pulse 0, 50, 100, 200, 300 and 1000) are shown here. These images were taken in the axial-lateral plane of 
the transducer, and the histotripsy pulses propagated from the top to the bottom of the field. 
 
To find the saturation of lesion progression, i.e. the treatment completion, the change rate 
of the lesion area during each treatment was analyzed by a slope detection algorithm. The slope 
detection algorithm used a segment-wise approach similar to what was described in a previous 
study by Turner et al. [52]. The mean change rate (slope) of lesion area over a certain time 
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window (segment) was estimated by fitting a least-square linear model into all lesion area data 
within this window. The change rate as a function of applied histotripsy pulses during the whole 
treatment was generated by rolling the time window through the entire treatment period. The 
algorithm is illustrated in Figure 6.6. The saturation dose was determined when the change rate 
was, for the first time, smaller than 10% of the maximal change rate detected at this treating 
location. To investigate whether the saturation doses of the metrics extracted from BCD 
feedback indicate the saturation dose of its corresponding lesion progression, the same algorithm 
was also applied to analyze the progressions of the BCD metrics using the same parameters. 
 
Figure 6.6: The illustration of the slope detection algorithm. The lesion progression data shown here is from one 
treated sample. The slopes over three representative time windows are indicated. The highest change rate appears at 
the beginning of the treatment around the first time window (slope 1) and the saturation starts to occur around the 
second time window (slope 2). 
 
 
6.2.3  Validation of BCD Feedback in In Vitro Clots 
 
The BCD feedback was validated through histotripsy treatment of in vitro clots. The 
treatment focus was scanned through the length of the clot to create a channel. The volume of 
clot debris particles generated from histotripsy with different treatment doses was measured to 
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evaluate the degree of clot fractionation. This metric on degree of clot fractionation was then 
compared with the BCD feedback.  
To make in vitro clots (Figure 6.7), the separated RBC pack and the reconstituted plasma 
(fibrinogen concentration: 400 mg/dL) described previously were recombined to a hematocrit of 
30% [43]. After stimulating with thrombin (1 IU/mL) and calcium chloride (20 mM/L), the 
mixture was poured into a tube and incubated in 37ºC water bath for 2 hours. Each mature clot 
had a cylinder shape with a diameter of 6.5 mm and a length of 11 mm.  
 
Figure 6.7: RBC fibrin clot. The separation between the two adjacent tick marks on the scale ruler is 1 mm. 
 
 
The experimental setup is illustrated in Figure 6.8. The histotripsy recanalization was 
performed using an 18-element 1.25-MHz focused transducer with an aperture size of 8 cm 
(lateral) x 8.3 cm (elevational) aperture size and a focal length of 6 cm. This 1.25-MHz 
transducer was used instead of the 1.5-MHz transducer because its longer working distance 
makes it easier to operate with this experimental setup and its larger focal volume fits better with 
the actual vessel. The same calibration method was used here as for the 1.5-MHz transducer in 
the previous sections. The focal volume (–6 dB beamwidth) was measured as 6.5 mm (axial) x 2 
mm (lateral) x 1.5 mm (elevational) at a peak negative pressure of 15 MPa. The histotripsy 
treatment consists of 1.5-cycle ultrasound pulses with the same PRF (30Hz) and peak negative 
pressure (36MPa) as using the 1.5MHz transducer. A pressure waveform directly measured by 
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the fiber optical hydrophone is shown in Figure 6.9. The same L7-4 ultrasound imaging probe as 
in the previous sections was placed opposite to the histotripsy transducer and aligned rigidly with 
the treatment focus. A vessel phantom (6.5 mm inner diameter and 0.5 mm wall thickness) was 
made of urethane polymer (TAP Urethane RTV, Tap Plastics Inc., San Leandro, CA) to mimic in 
vivo vessel [53] and placed between the transducer and imaging probe, with the treatment focus 
targeting at the center of the vessel lumen and the ultrasound imaging plane perpendicular to the 
longitudinal direction of the vessel.  
 
Figure 6.8: (a) A schematic illustration of the in vitro experiment setup. An 18-element 1.25-MHz histotripsy 
transducer was placed facing up in a tank filled with the degassed water. The transducer was driven by a high-
voltage amplifier which was connected by an FPGA controller. A 5-MHz ultrasound imaging probe was positioned 
opposite to the transducer, aligned rigidly to the treatment focus and connected to the Verasonics® ultrasound 
imaging system. The FPGA controller sent triggers to the Verasonics® system to synchronize them with therapy 
pulses. Vessel phantom was placed between the transducer and the ultrasound imaging probe. (b) A picture of the 
vessel phantom. (c) Strategy of recanalization treatment. Each ellipse represents a treatment focal spot and after the 





Figure 6.9: A representative pressure waveform of the 1.25-MHz histotripsy transducer taken at the highest pressure 
(peak negative) level which can be directly measured by the fiber optical hydrophone. 
 
 
RBC fibrin clot (6.5 mm in diameter and 11 mm in length) was carefully inserted into the 
vessel phantom. After being filled with 0.9% saline, the vessel phantom was sealed by rubber 
plugs. To generate a channel within the clot, the treatment focus was aligned to one end of the 
clot, and a certain dose of histotripsy pulses were applied at the location. The treatment focus 
was then moved to the adjacent location with a 0.7 mm separation along the clot length, and the 
same dose of treatment was conducted. This procedure continued until the focus reached the 
other end of the clot. Six different histotripsy doses (0, 250, 500, 1000, 1500 and 3000 pulses) 
were used to canalize in vitro clots. Nine clots were treated for each of these histotripsy doses. 
During the treatment, BCD feedback data were also acquired. An ensemble of 10 color Doppler 
acquisitions was collected with a PRF of 10 kHz at 0.5 ms delay after each pulse. A delay of 0.5 
ms was chosen to capture the first major rebound period of the bubble-induced motion. The 
mean velocity of focal zone (Vf,0.5ms) was then estimated as a function of the number of applied 
histotripsy at each treatment location. 
After a clot was treated, the fractionated clot debris was measured accordingly. The 
saline in the vessel phantom together with the treated clot were carefully moved to a medicine 
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cup. The treated clot was then cut into 4 cylinder segments and the cup was gently shaken so that 
clot debris pieces resulting from the histotripsy fractionation could be released to the saline 
solution. After the large intact clot segments were carefully removed, the solution was diluted 
with 0.9% saline up to 20 mL. The debris size and volume of a 0.5 mL sample was then 
measured using a Coulter Counter (Multisizer 3, Beckman Coulter, CA, USA). For the Coulter 
Counter measurement, a 30-µm aperture tube was used, which allowed measurement of debris 
sizes between 0.6-18 µm in diameter. Any debris particles larger than 30 µm will block the tube 
and would be noted and recorded. For each treatment, three measurements were conducted. 
6.2.4  Real-time Monitoring of Histotripsy Thrombolysis using BCD Feedback 
 
The feasibility of using the BCD feedback for real-time monitoring and detection of 
treatment completion of histotripsy thrombolysis was investigated. The same setup as for the 
three-layer fibrin clots was used. A three-layer fibrin clot was made with a fibrinogen 
concentration of 400 mg/dL. The fibrin clot was treated by the same 1.5-MHz transducer using 
the same parameters (1.5-cycle, 30 Hz PRF and 36 MPa estimated peak negative pressure). The 
mean velocity of bubble-induced motion within the focal zone at 2 ms delay (Vf,2ms) was 
collected in real time, and the slope saturation of the mean velocity was detected using the real-
time version of the slope detection algorithm. A delay of 2 ms was chosen to capture the first 
major rebound period of the bubble-induced motion. The Verasonics
®
 imaging system was 
synchronized with histotripsy pulses. Starting at 2 ms after each histotripsy pulse, an ensemble of 
10 color Doppler acquisitions was captured with a PRF of 10 kHz. Vf, 2ms was estimated from the 
ensemble real-time and stored as a data point. Every time a new data point was collected, the 
latest 100 data points were fed into the slope detection function to estimate the current change 
rate (slope) of Vf,2ms. The saturation was detected when the current change rate was smaller than 
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10% of the maximal change rate that appeared previously in this spot. The system would process 
and determine the saturation dose in real-time but the treatment will continue until 1000 pulses in 
total were applied. To verify that the saturation of Vf,2ms from BCD feedback indicates treatment 
completion, high-speed images of the middle RBC clot layer were captured during the treatment, 
and the lesion progression was quantified using the method described in the previous section. 
The treatment completion was defined by the detected saturation of the lesion progression (in 
optical images) and compared with the saturation dose detected in real-time by BCD feedback. 
Ten locations were treated in total with the real-time BCD monitoring. The difference between 
real-time detected saturation dose by BCD and the treatment completion dose was calculated. 
6.3 Results 
 
6.3.1 Investigation of Bubble-induced Motion 
 
The PIV velocity estimations based on the optical images provided detailed information 
of bubble-induced motion within the histotripsy focal zone in the transparent fibrin clot. The 
behaviors of bubble-induced motions observed in all three treated locations were consistent and 
shared the same trend. Right after the histotripsy pulse, a bubble cloud was created, generating a 
short period of chaotic motion up to 300 µs. Two streams of coherent motions were formed 
following the chaos. In three-fourths of the focal zone proximal to the histotripsy transducer, the 
coherent motion was first pushing away from the therapy transducer and then rebounding back. 
In the rest one-fourth of the focal area distal to the therapy transducer, the coherent motion was 
observed to be the opposite, first moving toward the transducer and then rebounding away. The 
rebound oscillations continued in both the proximal and distal areas with decreasing velocity 
until energy was completely absorbed. The chaotic motion was very short and irregular 
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compared to the major coherent motion. A representative series of PIV estimations on the 
corresponding optical images are shown in Figure 6.10.  
 
Figure 6.10: Representative PIV estimations overlaid with the corresponding optical images taken after the 100th 
histotripsy pulse. These images were taken in the axial-lateral plane of the transducer, and the histotripsy pulses 
propagated from the top to the bottom of the field. At 0.2 ms after the pulse, the cavitation bubbles show and no 
coherent motion is detected. At 0.5 ms, coherent motion is forming and pushing away from the transducer in the 
majority of the focal area proximal to the transducer and another stream of coherent motion at the distal side is 
moving towards the transducer. At 1.5 ms, the coherent motion at the proximal side is rebounding back and the 
coherent motion at the distal side is rebounding away. The motions repeat at 5 ms and 7.5 ms as in 0.5 and 1.5 ms. 
 
The behavior of the bubble-induced motion estimated by BCD matched that of the 
proximal-side motion (in the proximal 3/4 of the focal zone) estimated by PIV in all the three 
treated samples. After the chaotic motion, the motion detected by BCD was coherently pushing 
away from the therapy transducer and then rebounding back. The same push/rebound cycle was 
also apparent. As the ultrasound imaging probe was positioned coaxially with the therapy 
transducer, ultrasound imaging of BCD and therapy beams propagate in the same direction. BCD 
only detected the motions at the proximal-side of the focal zone, probably because the distal-end 
of the focal zone was shielded by the bubbles generated in the proximal-side. When placing the 




The full profiles of PIV and BCD mean velocity estimations over a representative 1000-
pulse treatment are shown in Figure 6.11. For both PIV and BCD, the mean axial velocities were 
calculated over only the proximal three-fourths of the focal zone. For both estimations, the 
temporal profile of the bubble-induced motion expanded with the increasing number of 
histotripsy pulses as the clot was increasingly fractionated and saturated around 300 histotripsy 
pulses when the clot was likely liquefied. The raw data from the three treated samples were 
analyzed to assess the statistical significance of the posited increasing trend. To account for the 
correlated nature of the data within each of the experiments, we performed linear regression fit 
using generalized estimating equations, a well-established approach for repeated measures 
analysis [54]. We modelled the correlation between measurements within each experiment using 
an auto-regressive structure, which models higher correlation between points that are temporally 
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0.0028. Consistently, the PIV data was best fit by a quadratic polynomial of time 
(PIV=11.3329+0.275*Time-0.004*Time
2
). The linear and quadratic terms were statistically 
significant with respective p-values of 0.011 and 0.006. These analysis results (positive linear 
coefficients and p-values < 0.05) provide strong support that the increasing trend is statically 
significant. Although the velocity amplitudes estimated from PIV and BCD did not match 
exactly, the trend of the overall motion had a good agreement. The time period to reach the first 
peak rebound velocity after each histotripsy pulse increased until it plateaued at ~1.5 ms after 
approximately 300 pulses. The time period to the peak second rebound velocity also had the 
same trend. In Figure 6.12, the times of the peak rebound velocity (tPRV) and peak second 
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rebound velocity (tPRV2) were extracted from the same treatment and compared between PIV and 
BCD estimations, the similarity of which was quantified using the Pearson linear correlation 
coefficient. The mean correlation coefficient was 92% over all the three treated locations.  
 
Figure 6.11: Representative full profiles of mean axial velocity at the focal zone. (a) PIV estimation (only the 
proximal side). (b) BCD estimation. Positive values indicate motion towards the therapy transducer and negative 
values indicate motion away from the transducer. The horizontal axis shows the number of applied pulses and the 





Figure 6.12: The times of peak rebound velocity (tPRV) and peak second rebound velocity (tPRV2) estimated by PIV 
and BCD as a function of the number of the applied histotripsy pulses from one of the treated locations. The lower 




6.3.2 Correlation of BCD Feedback and Histotripsy Thrombolysis 
 
The BCD feedback was correlated with the lesion progression measured by the optical 
images in the three-layer fibrin clots. For each treated spot, a progression curve of lesion area as 
a function of the number of the applied histotripsy pulses was generated to indicate the degree of 
thrombolysis and compared with the progression curves (20 points running-averaging) of the two 
metrics extracted from BCD feedback. For each spot treated in the soft clots, the lesion area 
increased almost linearly at the beginning and plateaued at around 300 pulses. The progression 
of the corresponding two BCD feedback metrics (tPRV and Vf,delay) followed a similar trend. They 
increased rapidly at the beginning and saturated around the same dose. After the saturation, the 
two BCD metrics fluctuated around the saturation level. A comparison of the lesion progression 
and the progressions of two BCD metrics from a soft clot spot was illustrated in Figure 6.13. For 
the hard clots, the lesion progression had the same increase-and-saturate pattern as those in the 
soft clots but saturated later around 600 pulses (Figure 6.14). The progressions of the two BCD 





Figure 6.13: Comparison between BCD feedback and histotripsy thrombolysis from a representative treated spot in 
a soft fibrin clot. (a) The progression curve of lesion area is compared with the time of peak rebound velocity (tPRV) 
from its BCD feedback. (b) The progression curve of lesion area is compared with the mean velocity of the focal 
zone at 2ms delay (Vf,2ms) from its BCD feedback. (c) The Pearson linear correlation between the progressions of 
lesion area and tPRV. (d) The Pearson linear correlation between the progressions of lesion area and Vf,2ms. The 
detected saturation doses were also illustrated. 
 
 
Figure 6.14: Comparison between BCD feedback and histotripsy thrombolysis from a representative treated spot in 
a hard fibrin clot. (a) The progression curve of lesion area is compared with the time of peak rebound time (tPRV) 
from its BCD feedback. (b) The progression curve of lesion area is compared with the mean velocity of the focal 
zone at 1ms delay (Vf,1ms) from its BCD feedback. (c) The Pearson linear correlation between the progressions of 
lesion area and tPRV. (d) The Pearson linear correlation between the progressions of lesion area and Vf,1ms. The 





To quantitatively verify the correlation between the lesion progression and the BCD 
feedback for every treatment spot, their saturation doses were determined using the same slope 
detection algorithm described in Methods (Figure 6.15, Table 6.1). The differences of the 
saturation dose between the lesion progression and each of the two BCD metrics from each 
treatment were calculated and listed in Table 6.2. Using the tPRV and Vf,delay metrics, the 
saturation doses detected closely followed the complete clot fractionation analyzed from the 
lesion optical images, both in soft and hard clots. The tPRV metrics presented a slightly better 
accuracy than the Vf,delay. For example, in the soft clots, the mean difference between the 
saturation doses of tPRV and clot fractionation was 21 pulses and that of Vf,delay was 25 pulses, 
while it took 319 pulses (mean) to completely fractionate the clot. In the hard clots, the mean 
saturation difference between tPRV and clot fractionation was 38 pulses and that of Vf,delay was 71 
pulses, while it took 618 pulses (mean) to completely fractionate the clot.  In 17 of 50 treatments, 
the saturations of the BCD feedback were detected earlier (less than 40 pulses) than that of clot 
fractionation. The Pearson correlation coefficients among the three progression curves were also 
calculated. For the Pearson correlation coefficient calculation, the segments covering data points 
up to 100 data points after the saturation of the clot fractionation curve were first selected from 
the BCD tPRV and Vf,delay. These data were then compared with the clot fractionation data. The 
mean Pearson correlation coefficient over all the treatments (N = 50) is 93.2% for tPRV and 92.6% 




Figure 6.15: The saturation doses of lesion progression, and its corresponding tPRV and Vf,delay. 50 spots were 
collected in total, 30 of which were in soft fibrin clots and 20 were in hard fibrin clots. The 20 spots from the hard 
fibrin clots are all on the top of the ones from soft fibrin clots. 
 
 
Table 6.1: The saturation doses (Mean ± SD) 
Progressions Soft Clots (pulses, N=30) Hard Clots (pulses, N=20) 
Lesion 319  ±  35 617  ±  72 
tPRV 341  ±  59 656  ±  80 
Vf,delay 344  ±  52 688  ±  62 
 
 
Table 6.2: The differences between the BCD detected saturation doses and the corresponding 







(pulses, N = 50) 
tPRV 
Mean ±  SD 21 ±  55 38 ± 43 28 ± 51 
Median (25%, 75%) 21 (-31, 66) 32 (19, 56) 31 (-13, 65) 
Vf,delay 
Mean ±  SD 25 ±  53 71 ±  77 43.7 ±  67 





Table 6.3: The Pearson correlation coefficients (Mean ± SD) between the BCD progression 
curves and their corresponding lesion progression curves 
BCD Progressions Soft Clots (N= 30) Hard Clots (N= 30) Total (N= 50) 
tPRV 93.7 ±  3.2% 92.4 ±  3.8% 93.2 ±  3.5% 
Vf,delay 91.7 ±  7.9% 94.0 ±  3.3% 92.6 ±  6.5% 
 
6.3.3 Validation of BCD Feedback in In Vitro Clots 
 
 
Figure 6.16: Comparison between the change of the fractionated debris volume and Vf,0.5ms from the BCD feedback. 
 
The BCD feedback was validated in in vitro clots by comparing the progressions of 
Vf,delay with the change of clot debris volume generated by histotripsy treatment. The increasing 
and saturation trend of the average BCD feedback over all the 3000-pulse treatments matched 
well with that of the debris volumes measured at different therapy doses. The mean velocity of 
focal zone at 0.5ms delay (Vf,0.5ms) from the BCD feedback was used and the total debris volume 
was used to characterize the debris distribution. In Figure 6.16, the mean of total debris volume 
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over all samples of each dose was plotted versus its corresponding histotripsy pulses used. The 
mean of total debris volume kept increasing for the first 1000 pulses and remains around the 
same level afterwards. The mean progression of Vf,0.5ms over all the treated spots in the 3000-
pulse treatments was also plotted versus the number of applied pulses in the same figure. The 
Vf,0.5ms saturated at 1183 pulses (calculated by the slope detection algorithm) after rapidly 
increasing, which matched well with the clot debris volume measurement. 
The size of the debris pieces generated by the histotripsy thrombolysis treatment was no 
greater than 30 µm, as no blockage was observed during all the Coulter Counter measurements. 
The mean debris distribution over all the measurements of each dose is shown in Figure 6.17. 
The debris mainly ranged from 2µm to 6µm and 95% of them were smaller than 10µm. 
 
 
Figure 6.17: The debris distributions after histotripsy treatments with different doses. The 1000-pulse, 1500-pulse 
and 3000-pulse lines almost overlap with each other. The debris volume of the 500-pulse one (dashed line) is a little 








The ability of real-time BCD monitoring was validated in this set of experiment. The 
saturation dose using BCD feedback Vf,delay was detected in real time and compared with the 
saturation dose of its corresponding lesion progression quantified using optical imaging in the 
three-layer clot. The mean saturation dose detected by the BCD Vf,2ms was only 39 pulses (N = 
10) more than the saturation dose detected by the lesion progression in the clot phantom, with a 
standard deviation of 55 pulses. On average it took 326 pulses to completely fractionate the clot. 
The saturations detected by BCD were later than the saturations of the lesion progressions in 6 
out of 10 treatments. In the worst case, the difference between the two saturation doses was 61 
pulses. The real-time Vf,2ms and its real-time change rate (slope) data from a spot are shown in 
Figure 6.18.  
 
Figure 6.18: (a) Real-time Vf,2ms of BCD feedback from one treated spot. (b) The real-time calculated change rate of 
Vf,2ms. (c) The corresponding progression of the lesion area. The vertical dashed line indicates the saturation dose 
real-time detected by the BCD feedback and the vertical solid line indicates the true saturation dose of the lesion 






By the results of PIV and BCD estimations, the bubble-induced motions followed the 
same pattern after each histotripsy pulse: push away, rebound and then repeat, no matter how 
many pulses have been applied. High-speed images show that this motion is only observable 
when a bubble cloud is generated, hence called bubble-induced motion. The amplitude mismatch 
between PIV and BCD estimations may be caused by their resolution difference. PIV using 
optical images had better resolution and sensitivity which can detect smaller velocity than BCD. 
Since averaging only applied over non-zero values in the region of interest, PIV with more non-
zero but small values led to a smaller mean velocity than BCD. 
It is most likely the echoes for BCD primarily originated from the residual bubbles left 
from cavitation, as bubbles are much stronger reflectors compared to RBC and fibrin fragments. 
In all of our experiments, a 5MHz linear ultrasound probe was used for BCD. With this imaging 
frequency, whole blood (bovine, swine and canine) and fibrin clot (w/o RBCs) showed very 
weak speckles on B-mode images. But when monitoring histotripsy treatment on B-mode using 
the same probe, a region much brighter than blood and clot was observed even long after the 
arrival of the therapy pulse, which we used for BCD analysis. This hyperechoic region is thought 
to be dominated by residual cavitation nuclei.  
The exact mechanism behind the bubble-induced motion is still under investigation. It 
could be caused by asymmetric bubble expansion during the formation of the bubble cloud, 
violent collapse of the bubble cloud and/or acoustic radiation force. The observed motion may be 
the result of these factors working on the targeted medium (i.e. tissue and blood clot). And as 
histotripsy pulses change the mechanical property of the medium, the motion behavior (velocity 
amplitude, push/rebound timing and duration) is changed accordingly. An important property of 
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the bubble-induced motion captured by both PIV and BCD is the two-stages of behavior of the 
coherent motions during each treatment. The first stage is characterized by a rapid changing of 
the motion behavior and the second stage is characterized by saturated, stable motion behavior. 
The BCD feedback tracks this change of the motion behavior, which is correlated to the tissue 
fractionation.  
This two-stage phenomenon during histotripsy fractionation occurs for the motions both 
at the proximal side and the distal side of the focal zone. Although the motion behaviors at the 
two sides are different, they share the same changing trend and turn from the rapid changing 
stage into the stable stage at the same time (Figure 6.19). The results from the validation of BCD 
feedback in in vitro clots show that the distal-side motions can be also used to monitor the 
thrombolysis treatment. The distal-side motion is different from the proximal-side probably due 
to a counterforce formed by untreated tissue outside the distal end of the focal zone. If a larger 
volume (multiple treatment zones) of tissue is being fractionated simultaneously and BCD is 
collected only from the center of the focal zone in the absence of surrounding intact tissue, the 
motions at the proximal and distal sides of the focal zone will be similar in form [55]. 
 
Figure 6.19: Representative full profiles of mean axial velocity of PIV estimation. (a) Proximal side (three fourths 
of the whole focal zone). (b) Distal side. Although the motions at the two sides are different, the changing trends 
appear the same. To the left of the dashed line (around 300 pulses) is the rapid changing stage and to the right of the 





Histotripsy thrombolysis treatment can be monitored by BCD feedback via increase and 
saturation of the tPRV or Vf,delay. The treatment completion is indicated by the saturation rather 
than a specific threshold value of a parameter. Validated using in vitro clots, the saturation of 
Vf,delay was detected in real-time to indicate treatment completion, and the saturation detection 
was within 50 pulses of complete clot fractionation. Regardless of different clot stiffnesses, the 
saturation doses of two BCD metrics are both highly consistent with the completion of clot 
fractionation. This capability of the BCD feedback to adaptively detect the treatment completion 
accurately even in clots with different properties is important in clinical situations when clots 
with different ages exhibit large, varied stiffness and a clot can itself be heterogeneous. The high 
Pearson correlation coefficient between the clot fractionation progression curve and the 
corresponding two BCD curves up to the saturation point also supports the feasibility of BCD 
feedback as a monitor for histotripsy thrombolysis.  
The potential explanation for the increased temporal profile and saturation trend of BCD 
metrics as the clot is increasingly fractionated and eventually liquefied is that the change of 
bubble-induced motion depends on the change of mechanical properties of the targeted tissue. As 
the tissue is fractionated by histotripsy, the tissue elasticity is reduced until the tissue is 
completely liquefied [27, 56, 57]. As a result of the reduced tissue elasticity, the motion induced 
in the tissue by a given force is expected to exhibit a lower frequency oscillation (i.e. longer 
tPRV), as shown in a simulation study using finite element method (FEM) [58]. When the clot is 
completely fractionated, the bubble-induced motion reaches the maximum temporal expansion. 
Based on this principal, the BCD feedback captures the temporal characteristics of the bubble-
induced motions in the two metrics (tPRV and Vf,delay) to quantitatively characterize the degree of 
histotripsy thrombolysis.  
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It shows that BCD feedback (Vf,delay) was achieved real-time using a frame rate of 30 Hz, 
which is sufficient for real-time monitoring of histotripsy thrombolysis. To monitor Vf,delay, 
standard ultrasound color Doppler imaging is sufficient. The color Doppler pulses need to be 
synchronized with the histotripsy pulses, along with the appropriate pre-set Doppler parameters. 
No additional hardware is needed and the computation is simple and straightforward. To have 
the best signal-to-noise ratio and the closest trend representing the expanding temporal profile of 
the bubble-induced motion, the delay of Vf,delay with respect to each histotripsy pulse need to be 
carefully chosen so that the acquisition period can cover the major rebound period of the bubble-
induced motion. A delay of 0.5 ms was chosen to capture the major rebound when the imaging 
probe was placed opposite to the therapy transducer detecting the distal-side motion, whereas a 
delay of 2 ms was chosen when the imaging probe was detecting the proximal-side motion. In 
reality, the main rebound period is unknown before treatment and it is a challenge to choose the 
right delay in the clinical application. Two potential solutions can be used to solve this issue. 
One is to enlarge the ensemble length of the acquisition from 10 to 20 or 30 frames so that the 
acquisition period will be wide enough to cover the main rebound period and the rebounding 
motion features can be reflected through an averaging effect. The other solution is to treat a 
testing spot in the clot before a full treatment and get the full velocity profile to decide the main 
rebound period and the appropriate delay. Real-time tracking of tPRV is also possible and has the 
advantages of lower noise level and better match with the overall trend of the motions compared 
to Vf,delay. In the future, with a programmable ultrasound imaging system, real-time tracking of 






 The results of this chapter show that the potential of using BCD feedback to 
quantitatively monitor clot fractionation during histotripsy thrombolysis and accurately predict 
the completion of clot fractionation in real-time. The metrics of BCD, tPRV and Vf,delay, are both 
strongly correlated with the degree of clot fractionation. Particularly, the saturation of the 
increase in tPRV and Vf,delay coincide with the completion of clot fractionation in both soft and 
hard clots. This correlation will enable real-time monitoring of histotripsy thrombolysis and 
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Noninvasive Thrombolysis using Microtripsy in a Porcine Deep Vein 
Thrombosis Model 
 
A majority component of this chapter has been submitted to Journal of Vascular and 
Interventional Radiology. 
7.1 Introduction  
 
Deep vein thrombosis (DVT) is the most common form of venous thrombosis and can 
lead to pulmonary embolism (PE). DVT/PE affects over 300,000 people and results in the deaths 
of 60,000 to 100,000 people each year in the United States [1]. In addition to anticoagulation, 
some DVT patients, especially those with severe symptoms, may require thrombolytic 
treatments, including systemic administration of thrombolytic drugs [2, 3], catheter-directed 
infusion of thrombolytic drugs, or mechanical thrombectomy. Systemic administration of 
thrombolytic drugs has limited effectiveness and requires prolonged time for affect (several 
hours to days) [4]. Catheter-directed thrombolysis can deliver drugs locally at the thrombosis 
site, but it is invasive and carries risks of bleeding, vascular damage, clot detachment, and 
infection [5]. In more severe cases, such as phlegmasia cerulea dolens, surgical or percutaneous 
mechanical thrombectomy may be performed [6]. 
Histotripsy is a noninvasive tissue ablation method that mechanically fractionates soft 
tissue using ultrasound [7-9]. High-intensity, microsecond-long ultrasound pulses are focused to 
generate well-controlled acoustic cavitation to fractionate target tissue without thermal necrosis. 
The feasibility of using histotripsy as a noninvasive and image-guided thrombolysis method was 
first shown by Maxwell et al. [10, 11]. Histotripsy was used to fractionate blood clots into 
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acellular debris using ultrasound alone both in vitro and in an in vivo porcine DVT model. The 
safety concerns (primarily hemolysis) of histotripsy in circulating blood were also addressed by 
Devanagondi et al. [12]. In the previous studies, multi-cycle (usually ≥ 5 cycle) ultrasound 
pulses were used to generate acoustic cavitation via a shock scattering mechanism [13]. Using 
the shock scattering mechanism, a shock front scatters from individual sparse bubbles formed 
from weak nuclei resulting in an inverted shockwave. This inverted shockwave combines with 
the incoming negative pressure phase to create very high negative pressures exceeding the 
cavitation threshold and generates a cavitation cloud. Because the shock scattering approach 
relies on the weak nuclei which often reside in the vessel wall, cavitation generated by this 
approach is usually less-confined and forms near the vessel wall.  This poor localization within 
the clot can result in vessel damage and hemolysis. 
Microtripsy is a new histotripsy approach that has recently been evaluated for its use in 
thrombolysis [14-16]. Microtripsy uses the intrinsic threshold mechanism where acoustic 
cavitation is generated via single-cycle ultrasound pulses with the negative pressure phase 
directly exceeding the cavitation threshold intrinsic to the media. The intrinsic threshold 
mechanism does not rely on pre-existing weak nuclei and is more reproducible and predictable 
than the shock scattering mechanism [17, 18]. Our in vitro microtripsy thrombolysis study 
showed that cavitation can be precisely generated and confined to the vessel lumen without 
contacting the vessel wall, which allows for creation of a precise flow channel within the clot 
while minimizing the risk of vessel damage [14]. 
This in vivo study investigated the safety and efficacy of microtripsy-mediated 
thrombolysis in a porcine DVT model. Thrombi were created in the femoral veins of juvenile 
pigs and then treated using an integrated, portable microtripsy thrombolysis system. Ultrasound 
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images were used to guide and monitor the treatment. Ultrasound cross-sectional scans of the 
femoral vein were acquired before and after each thrombolysis treatment for qualitative and 
quantitative assessments of treatment efficacy. To evaluate the treatment safety, vessel damage 
was examined by histology. Blood samples were collected to evaluate the degree of hemolysis 
induced during microtripsy thrombolysis. In addition to acute pigs, which were euthanized right 
after therapy, four pigs were survived for two weeks to assess the subacute extent of any vessel 
damage and/or hemolysis. 
7.2 Materials and Methods 
 
7.2.1 Animal Preparation and Thrombus Formation 
 
The protocols involved in this study have been approved by the University Committee on 
Use and Care of Animals at our university. A porcine DVT model, previously described by 
Maxwell et al. [11], was used in this study. Juvenile pigs (mixed breed) weighing approximately 
35 kg were selected as the subjects of the study. The animal was first sedated with 6 mg/kg 
tiletamine + zolazepam (Telazol, Fort Dodge Animal Health, Fort Dodge, Iowa, USA) and 2.2 
mg/kg xylazine (Lloyd Laboratories, Shenandoah, Iowa, USA). The animal was then 
endotracheally intubated and rotated to a supine position onto a medical grade, water-filled 
heating pad to maintain body temperature. 0.5%–3.5% isoflurane (Vet-One, Meridian, Idaho, 
USA) was administered through the endotracheal tube for anesthesia. The animal was attached to 
monitoring equipment for continuous monitoring of core body temperature, pulse, SpO2 levels, 
and respiratory rate throughout the procedure. A chemical depilatory (Nair, Church & Dwight 
Co, Princeton, New Jersey, USA) was applied on the legs and the lower quadrant for 10 minutes, 
followed by a surgical preparation consisting of three applications of betadine scrub followed by 
a sterile saline rinse and an application of iodine. The area was then draped with a sterile drape.  
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Two 5-Fr wedge occlusion balloon catheters (AI-07124, Arrow International, Reading, 
Pennsylvania, USA) were introduced percutaneously into the left femoral vein from the distal 
side of the desired location for thrombus formation [11]. The two balloons were positioned and 
inflated to occlude a 1.5-cm segment at the desired location in the vein. 0.5 mL thrombin (1000 
IU/mL) was then infused through the distal catheter into the occluded region in the vein to 
stimulate thrombus formation. Heparin (200 U/kg, IV) was administered systemically through an 
ear-vein catheter immediately after thrombin infusion to prevent blood coagulation outside the 
occluded region. The balloons remained inflated for two hours to allow the thrombus to become 
fully formed [19].  The balloons were then deflated and the catheters were removed from the 
vein. Blood pressure was continuously monitored from the carotid artery. Additional heparin 
(200 U/kg, IV) was administered every hour from the start of thrombus formation to the end of 
treatment to maintain an activated clotting time (ACT) of blood greater than 200 seconds. For the 
animals to be euthanized right after treatment, high dose pentobarbital (140-160 mg/kg, IV) was 
given. For the animals that were euthanized at two weeks after treatment, carprofen (2-4 mg/kg, 
SC) was given before treatment for pain relief, and protamine (0.5 mg/kg, IV) was given at the 
end of treatment to lower the ACT. The animals were continuously monitored until they were 
recovered from anesthesia and returned to the housing facility when they were fully mobile. 
Animals were observed twice daily for 48 hours for pain levels, activity levels, feeding activity, 
and any evidence of bleeding. Carprofen (2-4 mg/kg, PO) was given every 12-24 hours as 
needed until the animal returned to baseline activity levels.  
7.2.2 Microtripsy Thrombolysis System and Setup 
 
Thrombolysis treatments were performed with an integrated and portable microtripsy 
system, which was developed in-house for this specific application [14]. It consisted of three 
170 
 
subsystems: a microtripsy therapy system, an ultrasound imaging system, and a positioning 
system (Figure 7.1). Microtripsy pulses were generated by a 1-MHz, 18-element therapy 
transducer (Imasonic, Besancon, France) with an effective 10×8-cm aperture and a 7-cm focal 
length. A 7.5-MHz ultrasound imaging probe (Vermon, Tours, France) was embedded in the 
rectangular central hole of the therapy transducer to guide and monitor microtripsy thrombolysis 
treatment. The positioning system, including a compact motorized positioner and a multi-degree-
of-freedom mechanical arm, provided high-resolution and large-range mobility for the therapy 
transducer. Control software with a clinician-friendly interface was developed to manage 
treatments. 
 
Figure 7.1: The integrated microtripsy thrombolysis system. It consists of an ultrasound imaging system, a 
microtripsy therapy system, and a motorized positioning system. A linear imaging probe was embedded at the center 
of the therapy transducer. The therapy transducer is mounted on the top of the positioning system. Treatment is 
controlled using touch screen interface and physical buttons on the control panel. 
 
To enable direct ultrasound transmission between the therapy transducer and the subject, 
an Ioban
®
 sheet (3M, St Paul, Minnesota, USA) was first pasted onto a larger polyethylene sheet 
from which a 25-cm-diameter circular piece was previously removed. The Ioban
®
, exposed by 
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the central hole, was then pasted on to the subject’s skin. The Ioban® sheet was then cut away 
around the area of treatment. A bottomless bowl was placed around the combined sheet and was 
then filled with a water-based coupling medium developed in-house that was set to body-
temperature and degassed overnight. This provided a clear acoustic window while still 
maintaining a water-tight seal that prevented the coupling medium from leaking. The 
experimental setup is shown in Figure 7.2. 
 
Figure 7.2: Schematic experimental setup (Left) and a picture of the actual setup during one thrombolysis treatment 
(Right). 
 
7.2.3 Pre-treatment Planning 
 
The focus of the therapy transducer was first calibrated in the coupling bath. Cavitation 
was generated by firing microtripsy pulses in the coupling media, and the cavitational bubble 
cloud was shown as a bright (hyperechoic), dynamic region on the ultrasound image. The center 
of the cavitation region was then marked as the therapy focus on the ultrasound imaging window. 
The therapy transducer was re-positioned to align the therapy focus within the left femoral vein 
where the thrombus was formed. The therapy focus, aiming at the center of the vessel lumen, 
was moved from the distal end to the proximal end of the thrombus. The moving path was 





A dual-pass strategy, previously developed in our lab [16], was used for the thrombolysis 
treatments in this study. The thrombus was treated with microtripsy in two passes (Figure 7.3). 
In the first pass, the treatment zone was covered by one focus (the original therapy focus) at each 
treatment location and scanned through the thrombus following the preset treatment path. In the 
second pass, the treatment zone followed the preset treatment path and scanned through the 
thrombus again but was covered by two foci electronically steered to the lateral sides of the first-
pass focus. A pulse repetition frequency (PRF) of 100 Hz and a dose of 1000 pulses (10 seconds) 
at each focus was used for microtripsy treatments. The treatment time for each two-pass 
treatment was 16 min per cm length clot. With 1.5 to 2 cm overlying tissue and 0.5 dB/cm-MHz 
acoustic attenuation of the overlying tissue, the in situ peak negative pressure (P-) of the 
microtripsy pulses was estimated to be 34 to 35 MPa. In total, fourteen pigs were treated with 
microtripsy. Ten pigs were euthanized (Pentobarbital, 140-160 mg/kg, IV) within one hour after 
treatment (acute) and four pigs were recovered and euthanized two weeks later (subacute). 
  
 
Figure 7.3: Illustration of the dual-pass treatment. Each ellipse represents a focal zone with the number of the 






In 8 acute pigs, microtripsy treatment was also applied to the right femoral vein with no 
thrombi. Exposure of microtripsy in free blood flow in the femoral vein was considered to be the 
worst scenario test to evaluate the safety of microtripsy thrombolysis treatment, as it maximized 
the potential contact between cavitation and vessel wall (without the clot barrier between the 
two) and thus would lead to maximal vessel damage. In addition, the maximal volume blood 
would be exposed to cavitation that could induce increased hemolysis without the thrombus 
barrier [11, 12]. The same dual-pass strategy and microtripsy parameters used in the 
thrombolysis treatment in the left femoral vein were used in the free-flow treatments in the right 
femoral vein. An 18-mm segment of the right femoral vein was treated for each pig (30 minutes). 
7.2.5 Measurements and Evaluations 
 
To qualitatively evaluate the efficacy of the microtripsy thrombolysis treatments, 
ultrasound B-mode and color Doppler images of the left femoral vein were collected before, 
right after and two weeks after the treatments to compare the volumes of the thrombi and the 
blood flows in the veins. A 10-MHz linear imaging probe (L14-5, Ultrasonix, Vancouver, 
Canada) was placed directly on the skin to image the thrombi and the veins. For quantitative 
analysis, the thrombi were 3D-scanned before and right after the treatments. Before each 
treatment, the 10-MHz imaging probe was mounted to a positioning system and positioned in the 
coupling bath to image the cross sections of the thrombus. A path was set to scan the imaging 
probe through the thrombus, acquiring a scan image every 0.2 mm. There was no direct contact 
between the imaging probe and the skin to avoid tissue movements during the scanning. After 
treatment, the imaging probe was scanned through the thrombus using the exact same path. The 
contours of the thrombus and the vessel lumen on each scan image were depicted manually in 
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Matlab (The Mathworks, Natick, MA, USA). The diameter of the generated flow channel was 
quantified as the diameter of a circle with equivalent cross-sectional area on scan images.  
Blood samples were collected before and after the thrombolysis treatments, after the free-
flow treatments, and two weeks later for the subacute pigs. Serum laboratory studies and 
hemodynamic values were reported from each sample. Since the free-flow treatments always 
followed the thrombolysis treatments, the post-thrombolysis data were also used as the baseline 
data for the free-flow treatments. Carotid artery pressure was obtained at the start of each 
treatment and every 10 minutes during the treatment for all subjects. 
The left femoral bundles, where the thrombolysis treatments were conducted, were 
harvested together with surrounding tissue from the 4 subacute pigs. The right femoral bundles, 
where the free-flow treatments were conducted, were harvested with surrounding tissue from the 
8 acute pigs. Since the catheter and balloon procedures for thrombus formation caused 
significant vessel damage and would confound the data [11], the left femoral veins of all the 
acute pigs were not collected for evaluation of vessel damage. The harvested tissues were 
immersed in 10% buffered formalin for fixation. The cross sections of the femoral bundles were 
then embedded in paraffin, sectioned, stained with hematoxylin and eosin and examined with a 
light microscope for signs of damage. The lungs from one acute pig and one subacute pig were 
fixed with 10% formalin and grossly examined for emboli. 
7.2.5 Statistical Analysis 
 
All statistical comparisons in this study were performed using Student’s t-test. P-values < 







Thrombi were formed in the left femoral veins of the 14 subjects at a depth of 16 to 22 
mm from skin (Figure 7.4). The lengths of the thrombi ranged from 7.5 to 28.6 mm, with an 
average length of 16.0 mm. The diameters of the veins where the thrombi were formed had a 
mean of 6.7 mm and a standard deviation (SD) of 1.1 mm. Nine thrombi were completely 
occlusive and five were partially occlusive with an occlusion percentage of 81.9 ± 12.2 % (mean 
± SD). The morphological characteristics of the thrombi are summarized in Table 7.1. 
 




Table 7.1: Summary of Thrombus Formations and Treatment Outcomes 
* Vessel Occlusion = occluded cross-sectional area / total vessel lumen area × 100% 
**  cclusion Reduction (Area  )   (pre-treatment vessel occlusion    post-treatment vessel occlusion) / pre-
treatment vessel occlusion × 100% 
*** Channel Opening (Diameter %) = generated channel diameter / vessel diameter × 100% 
 
Partial Occlusive Total 
No. of Treatments 5 9 14 
Thrombus Length (mm) 15.3 ± 1.9 16.3 ± 6.9 16.0 ± 5.6 
Vessel Inner Diameter (mm) 7.5 ± 1.2 6.2 ± 0.8 6.7 ± 1.1 
Vessel Occlusion (Area %)* 81.9 ± 12.2 100 93.5 ± 11.3 
No. of Treatments with Flow Improved 5 8 13 
Increase in Channel Diameter (mm) 2.8 ± 1.2 3.6 ± 0.8 3.3 ± 1.0 
Occlusion Reduction (Area %)** 13.3 ± 4.7 32.6 ± 6.1 26.7 ± 10.8 





In all 14 subjects, during the thrombolysis treatments, cavitation bubble clouds were 
generated at the marked therapy focus without any spatial shift and were well confined within 
the target thrombi without contacting the femoral veins (Video). There was no pre-focal or post-
focal cavitation observed on the vessel walls or surrounding tissues. The cavitation bubble cloud 
remained at the therapy focus when it scanned through thrombus. During the free-flow 
treatments, cavitation behaved differently. Although the therapy focus was targeted at the center 
of the vessel lumen, the cavitation bubble clouds were only sporadically visible on the B-mode 




Figure 7.5: Representative US B-mode images (first row) and color Doppler images (second row) taken before and 
right after microtripsy thrombolysis treatment in an acute pig. (a)-(d): Longitudinal sections of the femoral vein. (e)-
(h): Cross sections of the femoral veins (indicated by the block arrows). 
 
 
As shown by color Doppler imaging, blood flow was restored or significantly improved 
by the microtripsy treatments in 13 of the 14 subjects (Figure 7.5 and 7.6). In the one treatment 
where no flow was restored, the thrombus could not be completely scanned through by 
microtripsy due to the extension of the thrombus to regions (deep into abdomen) with limited 
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acoustic access. Thrombus volume reductions, indicated by brightness decrease on B-mode 
imaging, were observed in all treatments. Figure 7.5 shows ultrasound images of the femoral 
vein taken before and right after one thrombolysis treatment in an acute pig. 
 
 
Figure 7.6: Representative US B-mode images (first row) and color Doppler images (second row) taken before, 
right after and two weeks after microtripsy thrombolysis treatment in a subacute pig. Blood flow was increased after 
two weeks of recovery compared to that right after the treatment. Since a relatively smaller velocity scale was 
chosen to be consistent throughout all the color Doppler images, velocity aliasing occurred on the two-week color 
Doppler image (g) with an increased blood flow. 
 
 
Figure 7.6 shows ultrasound images of the femoral vein taken before, right after and two 
weeks after one thrombolysis treatment in a subacute pig. For the subacute pigs, no remaining 
thrombus was observed in the femoral veins on ultrasound B-mode or color Doppler images after 
two weeks of recovery. The femoral veins appeared normal on the B-mode images. As shown on 
the color Doppler images of Figure 7.6(g) and (f), the blood flow after two weeks of recovery 
was further increased compared to the blood flow right after treatment, which was due to 
dissolution of both the remaining thrombus at the treatment site and the untreated thrombus 
outside the treatment site over two weeks.  
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Quantitative evaluation of the thrombolysis efficacy was conducted using the pre- and 
post-treatment scan images of the thrombi (Figure 7.7). Cross sections of the flow channels 
generated in thrombi were distinguished as regions with significant echogenicity reduction 
between the pre- and post-treatment scan images. The flow channels generated in the fully 
occlusive thrombi had a diameter of 3.6 ± 0.8 mm, in comparison to a mean vessel diameter of 
6.2 mm. The increase in channel diameter in the partially occlusive thrombi was 2.8 ± 1.2 mm. 
Occlusion (percent of cross-sectional area) was reduced by 32.6 ± 6.1% and 13.3 ± 4.7 % in the 
fully and partially occlusive thrombi, respectively. The vessels were opened by 56.2 ± 9.4 % and 
34.4 ± 12.8 % (generated channel diameter vs. vessel diameter) in the fully and partially 
occlusive thrombi, respectively. The average treatment time was 16 minutes per cm-long 
thrombus. The quantitative results are also presented in Table 7.1. 
 
 
Figure 7.7: Quantification of flow channel generated by microtripsy. On the left is the ultrasound image taken 
before treatment. On the right is the ultrasound image taken at the exact same location right after treatment. Green 














Table 7.2: Blood Contents Change. “*” indicates significant difference. 
 










Free Hgb (mg/dL) 3.8 ± 3.4 63.2± 21.6* 56.7 ± 25.1 78.1 ± 13.9 2.3 ± 0.8 2.1 ± 1.0 
LDH (U/L) 404.4 ± 104.3 524.6 ± 130.1* 554.1 ± 132.0 608.4 ± 164.5 355.0 ± 78.0 334.5 ± 67.0 
K (mmol/L) 4.1 ± 0.2 4.9 ± 0.5* 4.7 ± 0.4 4.9 ± 0.5 4.0 ± 0.3 3.6 ± 0.2 
Serum Hematocrit 
(%PCV) 
26.6 ± 2.5 27.1 ± 3.2 27.3 ± 3.9 27.3 ± 3.1 28.3 ± 1.0 25.3 ± 3.6 
pH 7.3 ± 0.1 7.3 ± 0.1 7.4 ± 0.1 7.4 ± 0.1 7.3 ± 0.1 7.4 ± 0.03 
SBP (mmHg) 81.4 ± 11.2 86.6 ± 10.8 84.5 ± 9.2 86.0 ± 11.3 NA NA 
HR (BPM) 79.8 ± 11.2 79.9 ± 12.5 76.6 ± 13.6 78.4 ± 14.5 NA NA 
1 The baselines are the measurements before any treatments and calculated using all 14 samples. 
2 The baselines are the measurements after the thrombolysis treatments and before the free-flow treatments and calculated only 
using the corresponding 8 samples. 
3 The baselines are the measurements before any treatments and calculated only using the corresponding 4 samples. 
 
Hemodynamic and hematological effects of the microtripsy treatments are shown in 
Table 7.2. Over the 14 thrombolysis treatments, there were significant increases in free 
hemoglobin (3.8 ± 3.4 mg/dL baseline vs 63.2 ± 21.6 mg/dL after treatment, P < 0.0001) and 
lactate dehydrogenase (LDH) (404.4 ± 104.3 U/L baseline vs 524.6 ± 130.1 U/L after treatment, 
P < 0.01). There was a small but statistically significant increase (P <0.0001) in serum potassium 
(4.1 ± 0.2 mmol/L baseline vs 4.9 ± 0.5 mmol/L after treatment). No significant difference was 
shown in serum hematocrit (P = 0.32) between the baseline (26.6 ± 2.5%) and post-treatment 
(27.1 ± 3.2%). With regard to hemodynamic responses, there were no significant changes in 
system systolic blood pressure (81.4 ± 11.2 mmHg vs 86.6 ± 10.8 mmHg, P = 0.11) or heart rate 
(79.8 ± 11.2 BPM vs 79.9 ± 12.5 BPM, P = 0.49).  
After two weeks of recovery for the 4 subacute pigs, all the parameters returned back to 
the pre-treatment baseline. Free hemoglobin decreased back to 2.1 ± 1.0 mg/dL, which showed 
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no significant difference from its baseline (P = 0.41). LDH decreased to 334.5 ± 67.0 U/L and 
showed no difference from its baseline (P = 0.35). There was also no significant difference in 
serum potassium (P = 0.035) and serum hematocrit (P = 0.08) between the recoveries and their 
baselines.  
For the 8 free-flow treatments, there was no significant change in all variables compared 
to the pre-free-flow treatment baselines: free hemoglobin (P = 0.027), LDH (P = 0.24), serum 
potassium (P = 0.18), system systolic blood pressure (P = 0.39), hear rate (P = 0.40) and serum 
hematocrit (P = 0.50). 
7.3.5 Gross and Histology Evaluation 
 
The hematoxylin and eosin stained sections of the femoral bundles were examined to 
assess vessel damage caused by microtripsy. Acute vessel damage was evaluated on the right 
femoral veins harvested right after the free-flow treatments, and subacute vessel damage was 
evaluated on the left femoral veins recovered after two weeks from the thrombolysis treatments. 
In the acute vessel samples, there was focal venular wall thickening with corresponding 
hemorrhage in the tunica adventitia and thickening of the tunica media distal to the ultrasound 
source, as shown in Figure 7.8(a)-(d). Most of the tunica intima of the femoral veins was intact, 
with no evidence of perforation through vessel walls. In rare cases, there was tunica intima and 
media injury with hemorrhage into the tunica adventitia. No thrombus was noted in the lumen. 
No injury was found in or around the femoral arteries. In the subacute vessel samples, there was 
a mild thickening of the tunica media with granulation tissue composed of small vascular 
channels and inflammatory cells, presumably secondary to the microtripsy injury, otherwise 
there was no other significant abnormalities (Figure 7.8(e)-(h)). There was no hemorrhage or 
evidence of tunica intima injury. No injury to the femoral arteries and surrounding tissues as 
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well. Valves in the femoral veins were preserved from the thrombolysis treatments as shown in 
Figure 7.8(f)-(g). Grossly, there is no pulmonary embolus or infarct in the lung parenchyma. 
 




7.3.5 Animal Behavior and Symptom Monitoring 
  
During anesthesia, none of the animals showed clinical signs of distress due to the clot 
formation or the thrombolysis treatment. All recovery animals showed no significant pain levels 
post-treatment and returned to normal activity levels and feeding activity upon full recovery 
from anesthesia. No evidence of abnormal bleeding was observed in any of the recovered 
animals. No change in general behavior was observed during the course of two weeks.  
7.4 Discussion 
 
This study demonstrated the efficacy and safety of microtripsy-mediated thrombolysis in 
a porcine DVT model. Microtripsy reliably generated well-controlled acoustic cavitation in the 
pig femoral vein to perform thrombolysis treatments. In 13 out of the 14 thrombolysis treatments 
conducted in this study, a flow channel was generated through the completely occlusive or 
partially occlusive clot by microtripsy and blood flows were successfully restored or 
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significantly improved. The flow channel diameters generated were increased by an average of 
3.3 ± 1.0 mm, in comparison to an average vessel diameter of 6.7 mm. The average treatment 
time was 16.6 minutes per cm-long thrombus. Only mild intravascular hemolysis was induced 
during microtripsy thrombolysis. No damage was observed on vessel walls after two weeks of 
recovery, venous valves were preserved, and there was no sign of pulmonary embolism. 
The efficacy of microtripsy-mediated thrombolysis was shown to be significantly 
improved from the previous histotripsy-mediated thrombolysis using the shock scattering 
mechanism. Using a similar porcine DVT model, microtripsy achieved 13 successful 
recanalizations in the total 14 treatments, whereas the shock-scattering histotripsy only achieved 
successful recanalizations in 7 out of 12 treatments [11]. Only one microtripsy treatment in this 
study was unable to restore flow, due to the unintentional extension of the thrombus to 
ultrasound-inaccessible regions. The difference in treatment efficacy is likely related to the 
different mechanisms that the two approaches use to generate cavitation. Microtripsy uses the 
intrinsic threshold mechanism where acoustic cavitation is generated when the negative pressure 
phase of a single-cycle ultrasound pulse directly exceeds a cavitation threshold intrinsic to the 
media, and shock-scattering histotripsy uses multi-cycle ultrasound pulses and relies on pre-
existing weak nuclei to reflect and invert positive pressure phases to combine with the incident 
negative pressure phases to generate acoustic cavitation. Weak nuclei often reside on tissue 
interfaces, such as vessel walls, so cavitation generated by shock-scattering histotripsy is easily 
formed on vessel walls instead of at target thrombus inside the vessels. In contrast, cavitation 
generated by microtripsy is more confined at its desired focus and less affected by surrounding 
tissue interfaces than shock-scattering histotripsy, resulting in more reliable and continuous 
fractionations in target thrombi.  
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The safety of microtripsy thrombolysis was also shown to be improved from the previous 
shock-scattering histotripsy. Hemolysis and vessel damage were both greatly reduced using 
microtripsy. Only minor hemolysis was observed during microtripsy thrombolysis treatments in 
this study. In the free-flow treatments, hemolysis induced by microtripsy was about 15 times less 
than that induced by shock-scattering histotripsy [12]. The lower PRF used in microtripsy 
thrombolysis is expected to play an important role in reducing hemolysis. In microtripsy 
thrombolysis, a higher pressure (~30 MPa P-) and a lower PRF (100 Hz) was used in comparison 
to the previous shock-scattering histotripsy study (~17 MPa P- and 500 Hz PRF). With relatively 
slow blood flow, the same volume of blood is exposed to cavitation more times using a higher 
PRF, resulting in the rupturing of more erythrocytes using the shock-scatter approach. The 
natures of the two cavitation mechanisms may also make a difference in hemolysis. The less-
confined, larger cavitation bubble clouds generated by shock-scattering histotripsy may affect a 
larger volume of blood in the flow than the better-confined, smaller cavitation generated by 
microtripsy. In addition, no vessel damage was observed after two weeks of recovery from the 
microtripsy-mediated thrombolysis treatments. There was no damage observed in the endothelial 
cells of the targeted femoral veins or adjacent femoral arteries. Focal hemorrhage observed in the 
tunica adventitia disappeared completely after two weeks of recovery. This improvement was 
attributed to the better-confined cavitation in the vessel lumen generated by microtripsy, as 
shock-scattering histotripsy tends to generate cavitation on vessel walls where weak nuclei reside 
and therefore cause damage. Microtripsy generates more reproducible and predictable cavitation 
at the desired target without contacting the vessel walls so that vessel damage can be minimized. 
In addition, the new design of the therapy transducer also contributed to the reduced vessel 
damage. The therapy transducer used in this study was designed for DVT treatment to have the 
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focal zone smaller than the lumen of the femoral vein, while the therapy transducer used in the 
previous study had a focal zone larger than the femoral vein.  
Exposure of microtripsy in free blood flow in the femoral vein was considered to be the 
worst case test to further evaluate the safety of microtripsy-mediated thrombolysis treatment, as 
it maximized the potential contact between cavitation and vessel wall without a thrombus barrier, 
thus resulting in maximal vessel damage. In addition, without the thrombus barrier, a higher 
volume of free blood was expected to be exposed to cavitation in the flow, leading to a greater 
risk of hemolysis. The histological results showed no vessel perforation or major endothelial 
damage in any samples treated in free blood flow, and there was only microscopic hemorrhage 
located in the tunica adventitia of the target femoral veins. The hematological results also 
showed no statistically significant increase in free Hgb, LDH, potassium, or serum hematocrit in 
blood before and after the free flow treatments, suggesting that only slight hemolysis was 
induced during the free-flow treatments. All of these results from the free-flow scenario provide 
further evidence to support the safety of microtripsy thrombolysis treatment. A surprising result 
was that a lesser degree of hemolysis was observed in the free-flow treatments than that induced 
during the thrombolysis treatments with clots. One explanation is that in the thrombolysis 
treatment, cavitation was reliably and robustly generated in the targeted clots, and dissolving the 
targeted clots mostly consisting of red blood cells would lead to an increase in free hemoglobin. 
Another reason is associated with the different behavior of acoustic cavitation generated in free 
blood flow than in static tissue. Although the therapy system was consistently targeted at the 
center of vessel lumen, the cavitation tended to form at the bottom of the vessel wall in the 
flowing environment. Therefore, blood cells passing though the target may not get full cavitation 
exposure to be fractionated. Cavitation also appeared smaller and sparser in the free flow 
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environment than in the thrombus on the ultrasound images, which could further reduce the 
blood cell lysis. In the flow environment, residual bubble nuclei from cavitational bubble 
collapse are immediately flushed away with blood flow and cannot serve as “seeds” to enhance 
the following cavitation generation. Therefore the cavitation observed in the free-flow veins was 
smaller and sparser and lyzed less blood cells.  
There are notable differences between this porcine DVT model and a human DVT: 
available acoustic access, thrombi age, thrombi length and localization of thrombi. There is 
better acoustic access to DVT sites in human legs than in pig legs. Pig legs are short and the 
femoral veins are very close to the abdomen, leaving us with a limited acoustic window for 
ultrasound to transmit to the target in the veins. Human legs are longer, and DVT sites are 
usually accessible from more angles and locations. Therefore, thrombolysis treatments in human 
legs could potentially be more effective with a therapy transducer with a larger aperture and 
more transmitting area than the transducer used in this study. Another consideration about this 
study is that the age of thrombi in human femoral veins varies from several days to weeks, but 
we were only able to form and treat very acute thrombi using this porcine model in this study. 
We are currently working on developing a new porcine model to form chronic thrombi inside 
femoral veins. We are also developing a real-time thrombolysis monitoring algorithm to 
adaptively adjust therapy doses and strategies for thrombi with different ages [16, 20]. In some 
cases, the thrombi formed in human legs can be extended to over 10 cm long, whereas the 
thrombi formed in our study were less than 3 cm. Treating a long thrombus may be challenging 
because re-clotting may occur before complete recanalization is achieved. Localization of 
thrombi in humans may also be a challenge. In some cases, the thrombi (especially in the chronic 
phase) are not easily visualized on ultrasound images due to the lack of red blood cells inside the 
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thrombi. Pre-treatment planning based on other thrombus localization methods, such as 
angiography or magnetic resonance imaging, may be needed. We believe the potential issues 
from these differences are solvable, and the application of microtripsy-mediated thrombolysis for 
human DVT therapy is promising. 
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 This dissertation demonstrates the efficacy and safety of microtripsy for thrombolysis 
application through a series of in vitro and in vivo studies. The work follows a step-by-step 
approach that first develops a system platform, then researches new therapy and monitoring 
methods, and finally validates in a large animal model. More specifically, an integrated, portable, 
and image-guided histotripsy thrombolysis system is first designed and developed for both 
research and clinical uses. Two technical innovations, microtripsy and bubble-induced color 
Doppler feedback, are then investigated in vitro to augment histotripsy thrombolysis. Finally, the 
histotripsy thrombolysis system with the new technical enhancements is validated by a 
comprehensive pre-clinical study in an in vivo porcine DVT model. It is our hope that this work 
will provide enough scientific and engineering bases for clinical translation of histotripsy 
thrombolysis technology. 
1) Development: The histotripsy thrombolysis system was designed and developed for 
both research and clinical use, and incorporated all the necessary hardware and software 
components for potential technology implementations. It served as a platform where microtripsy 
parameters and bubble-induced color Doppler feedback could be implemented and investigated, 
and also served as an integrated therapy device for pre-clinical validations. This prototype 
system can also provide design and engineering guidance for future product commercialization. 
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Such a clinically designed integrated system is an important milestone to advance the research 
and clinical translation of the histotripsy thrombolysis technology. 
2) Research: Technical innovations for both therapy and therapy monitoring were 
systematically investigated in vitro for thrombolysis application. A new histotripsy approach, 
microtripsy, was first investigated for therapy enhancements. Microtripsy approach was 
demonstrated to improve both the safety and efficacy of histotripsy thrombolysis [1]. Cavitation 
was reliably generated by microtripsy and consistently confined within targeted vessel lumen, 
resulting in precise, effective recanalization and significantly lowered risk of collateral vessel 
damage. Flow channels could be quickly and precisely established by microtripsy treatments, 
followed by significant flow improvements. The debris particles generated by microtripsy were 
measured with over 99.9% smaller than 10 µm and the largest particle was less than 200 µm. 
Under the microtripsy approach, acoustic parameters and treatment strategy were then further 
optimized in an in vitro setting. The different pulse repetition frequencies (PRF) of microtripsy 
were explored and evaluated, and an optimal PRF under current technical limits was identified 
[2]. Different treatment strategies were also investigated on different blood clot types. It was 
found that treatment efficacy differed under different treatment strategies and electronically 
focal-steering and multiple treatment passes can significantly improve the thrombolysis efficacy 
[3]. Bubble-induced color Doppler was also developed and investigated to enable advanced 
therapy monitoring [4, 5]. It was verified that BCD can monitor the tissue motion induced by 
histotripsy pulses. It was further demonstrated that BCD feedback can be used to quantitatively 
monitor clot fractionation during histotripsy thrombolysis and accurately predict the completion 
of clot fractionation in real-time. These in vitro research studies demonstrated the capabilities of 
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microtripsy and bubble-induced color Doppler to improve histotripsy thrombolysis and provided 
optimized solutions for later large animal validation studies. 
3) Validation: The safety and efficacy of the histotripsy thrombolysis system 
incorporated with the newly-developed technical enhancements was demonstrated in an in vivo 
porcine DVT model. Comprehensive evaluations were conducted during this study to assess the 
thrombolysis performance. Microtripsy reliably generated well-controlled acoustic cavitation in 
the pigs’ femoral veins to perform thrombolysis treatments. In 13 out of the 14 thrombolysis 
treatments conducted in this study, a flow channel was generated through the completely 
occlusive or partially occlusive clot by microtripsy and blood flows were successfully restored or 
significantly improved. In the one treatment where no flow was restored, the thrombus could not 
be completely scanned through by microtripsy due to the extension of the thrombus to regions 
(deep into abdomen) with limited acoustic access. The flow channel diameters generated were 
increased by an average of 3.3 ± 1.0 mm, in comparison to an average vessel diameter of 6.7 
mm. The average treatment time was 16.6 minutes per cm-long thrombus. Only mild 
intravascular hemolysis was induced during microtripsy thrombolysis. No damage was observed 
on vessel walls after two weeks of recovery, and there was no sign of any pulmonary embolism.  
While this dissertation demonstrated the improved safety and efficacy of microtripsy 
thrombolysis and provided a real-time therapy monitoring method using BCD, much work 
remains to facilitate the successful clinical translation of this assembly of the technologies and 
designs. The remainder of this chapter details the key components of our future work that will 
permit the continued development of the therapy and the monitoring technologies for histotripsy 
thrombolysis.   




8.2.1 Further Investigation of Bubble-induced Color Doppler Feedback 
 
The feasibility of using BCD for real-time quantitative therapy monitoring was 
demonstrated in Chapter 6 of this dissertation. Most of the work involved verifying the BCD 
feedback in vitro, where the accuracy of BCD to detect tissue motion was established by high-
speed optical images in transparent fibrin clots. The strong correlation of the BCD feedback with 
clot fractionation was verified in three-layer fibrin clots and in in vitro clots in vessel 
environment. However, limited work was done to directly use BCD feedback to guide histotripsy 
thrombolysis treatments and validate the treatment outcomes. 
In order to further demonstrate the capability of BCD feedback and to apply it directly 
during histotripsy thrombolysis treatments, a software development project and two sets of 
studies should be conducted. For the development project, the BCD feedback pathway and 
algorithms should be integrated into the control software of the histotripsy thrombolysis system 
(see details in Chapter 2). The BCD feedback was previously realized in Matlab (The 
Mathworks, Natick, MA, USA) based on Verasonics
®
 system (Kirkland, WA, USA), which was 
completely separate from positioning and therapy systems and could not implement BCD-guided 
thrombolysis treatments. In order to increase the processing speed of the real-time BCD feedback 
and directly control treatment according to the feedback, the histotripsy thrombolysis system 
with a better Ultrasonix
®
 (Vancouver, Canada) imaging core should be used. The control 
software will be able to use the BCD feedback to real-time monitor clot fractionation, detect the 
completion at each treatment location and automatically manage the positioning and therapy 
systems to move to the next treatment location and start fractionation. 
An in vitro study should be conducted first with the BCD-embedded histotripsy 
thrombolysis system to validate its efficacy and tune the BCD parameters. The flow model setup 
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described in Chapter 3, 4, and 5 should be used to mimic the clinical thrombosis environment. 
BCD-guided thrombolysis treatments should be performed on blood clots formed in the flow 
model. Treatment outcomes should be compared to over-dosed treatments to support our 
hypothesis that BCD-guided treatment can achieve the same recanalization outcomes as over-
dosed treatments with less treatment time. Different BCD parameters, such as delay for velocity 
detection and Doppler ensemble length, should be also tested to identify the optimal values. 
Blood clots with different ages and stiffness should be treated using BCD-guided thrombolysis to 
show the capability of adaptive dosing of BCD feedback. 
An in vivo study should be also conducted to validate the BCD feedback in the porcine 
DVT model described in Chapter 7. With the fully optimized settings, BCD-guided thrombolysis 
treatments should be performed on blood clots formed in pigs’ femoral veins. Comprehensive 
evaluations of the safety and efficacy of the BCD-guided treatments should be included in this 
study, such as recanalization time, recanalized channel size, degree of hemolysis and collateral 
damage. The results from this study should conclude the investigation of BCD feedback for 
thrombolysis application.     
8.2.2 Microtripsy PRF Study 
 
 The parameter space of microtripsy PRF was explored for thrombolysis treatments in 
Chapter 4 of this dissertation. But with the technical limitation, the tested PRF did not exceed 
100 Hz. It was found that within this tested range (≤ 100 Hz) higher PRF could achieve a better 
treatment outcome with less time. This led us to think about the potential of even higher PRF. A 
follow-up study should be conducted to investigate higher microtripsy PRF (> 100 Hz). 
Hardware should be first updated to allow output of higher microtripsy PRF. A new therapy 
transducer and the corresponding amplifier should be developed. The limits of the hardware 
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should be carefully tested and verified. An extended range of output PRF from 100 Hz to 500 Hz 
should be feasible according to the current-available technical improvements. An in vitro study, 
the same to the study described in Chapter 4, should be conducted using the microtripsy PRFs 
higher than 100 Hz. Our hypothesis is that as PRF increases, the benefit from the cavitation 
memory effects on clot fractionation will be reduced or canceled by the pre-focal cavitation on 
vessel walls induced by high PRF. In addition to verify our hypothesis, finding the optimal PRF 
which can maximize the clot fractionation with no or minimal pre-focal cavitation should be 
another primary goal of this study.    
8.2.3 Retracted Clots in the Porcine DVT Model 
 
 Microtripsy thrombolysis treatments were conducted and validated in an in vivo porcine 
DVT model, as described in Chapter 7 of this dissertation. In that porcine DVT model, blood 
clots were freshly formed and matured for only two hours inside the femoral veins. The blood 
clots treated in that study were only considered as acute clots in clinical circumstances. There are 
still a large portion of patients with subacute (retracted) blood clots need to be treated. In order to 
investigate the efficacy of microtripsy on subacute retracted clots, additional work should be 
conducted to develop a new porcine DVT model with the capability to form subacute retracted 
clots inside of femoral veins. Preliminary experiments have been done to form a blood clot inside 
the vein and wait for several days for the clot to retract. But the clots usually dissolved or 
detached after the period. One possible alternative approach is to pre-form retracted clots ex vivo 
and then inject back into femoral veins. Studies have shown that retracted clots can be prepared 
in an in vitro environment [6]. It may be possible to inject the pre-formed retracted clots into the 
femoral vein using a big catheter and let it re-form inside of the vein for several hours before 
treatment. If it works, microtripsy thrombolysis treatments should be performed and evaluated in 
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a similar manner as described in Chapter 7. These results should be used to provide additional 
data to back up the clinical translation of histotripsy thrombolysis.    
8.2.4 Further Investigation of Multi-pass Treatment Strategy 
 
 Different treatment strategies were explored in Chapter 6 of this dissertation. It was found 
that electronically focal-steering and multiple treatment passes could significantly improve the 
microtripsy thrombolysis efficacy. In that study, dual-pass strategy was investigated. One of the 
hypotheses for this dual-pass enhancement is that cavitation at different lateral locations were 
more separated both temporally and spatially. Therefore, more treatment passes may have the 
potential to further improve the thrombolysis efficacy. An in vitro study using the same setup as 
in Chapter 6 should be conducted and microtripsy treatments should be performed with different 
number of treatment passes. The thrombolysis efficacy of different passes on the same treatment 
path should be compared to that of single pass with the same accumulated dose. The treatment 
efficacy of different passes on different laterally-shifted treatment paths should be compared to 
that of single pass with therapy focus electronically steered at different lateral locations. The 
influence of different number of passes on thrombolysis efficacy should be also investigated. 
With the series of experiments, a better idea about the mechanism of multi-pass enhancement 
may be obtained and the optimal treatment solution can be identified for histotripsy 
thrombolysis.   
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